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Abstract: 53 
Introduction: The ESPEN guideline presents a multidisciplinary focus on clinical nutrition in 54 
inflammatory bowel disease (IBD).   55 
Methodology: The guideline is based on extensive systematic review of the literature, but 56 
relies on expert opinion when objective data were lacking or inconclusive.  The conclusions 57 
and 64 recommendations have been subject to full peer review and a Delphi process in 58 
which uniformly positive responses (agree or strongly agree) were required. 59 
Results: IBD is increasingly common and potential dietary factors in its aetiology are briefly 60 
reviewed.  Malnutrition is highly prevalent in IBD – especially in Crohn's disease.  Increased 61 
energy and protein requirements are observed in some patients. The management of malnu-62 
trition in IBD is considered within the general context of support for malnourished patients.  63 
Treatment of iron deficiency (parenterally if necessary) is strongly recommended.  Routine 64 
provision of a special diet in IBD is not however supported.  Parenteral nutrition is indicated 65 
only when enteral nutrition has failed or is impossible. The recommended perioperative man-66 
agement of patients with IBD undergoing surgery accords with general ESPEN guidance for 67 
patients having abdominal surgery. Probiotics may be helpful in UC but not Crohn's disease. 68 
Primary therapy using nutrition to treat IBD is not supported in ulcerative colitis, but is mod-69 
erately well supported in Crohn's disease, especially in children where the adverse conse-70 
quences of steroid therapy are proportionally greater. However, exclusion diets are generally 71 
not recommended and there is little evidence to support any particular formula feed when 72 
nutritional regimens are constructed.   73 
Conclusions: Available objective data to guide nutritional support and primary nutritional 74 
therapy in IBD are presented as 64 recommendations, of which 9 are very strong recom-75 
mendations (grade A), 22 are strong recommendations (grade B) and 12 are based only on 76 
sparse evidence (grade 0); 21 recommendations are good practice points (GPP).  77 
 78 
Keywords: Crohn’s disease, ulcerative colitis, enteral nutrition, parenteral nutrition, inflam-79 
matory bowel disease, nutritional therapy 80 
81 
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Introduction 82 
Inflammatory bowel disease (IBD), predominantly ulcerative colitis (UC) and Crohn's disease 83 
(CD), is now common in the entire developed world.  A systematic review conducted in 2012 84 
demonstrated a range of prevalence rates for UC from 0.6 to 505 per 100,000, and for CD 85 
the estimates range from 0.6 to 322 per 100,000 (1,2). IBD affects children as well as adults, 86 
with 15–20% of patients being diagnosed during childhood (3).  A study from Scotland sug-87 
gests that as much as 50% of IBD may now present during childhood and adolescence (4).  88 
The involvement of the gastrointestinal tract has encouraged the investigation of the relation-89 
ship between nutrition and IBD, both for ways to prevent IBD and to support IBD treatment.  90 
Malnutrition can occur as well in UC and CD, but is a considerably greater problem in CD 91 
given its capacity to affect any part of the gastrointestinal tract, unlike UC, which is restricted 92 
to the colon and has few direct malabsorptive effects (5).  As in adults, malnutrition is preva-93 
lent in paediatric IBD, mainly in active disease and more in CD than in UC. 94 
In both UC and CD malnutrition may be the result of reduced oral intake, increased nutrient 95 
requirements, increased gastrointestinal losses of nutrients, and occasionally from drug–96 
nutrient interactions (5). The severity of malnutrition in IBD is influenced by the activity, dura-97 
tion and extent of the disease, and particularly to the magnitude of the inflammatory re-98 
sponse which drives catabolism and is anorexigenic.  Patients with CD remain at risk even 99 
when their disease appears quiescent, whereas patients with UC generally develop problems 100 
only when the disease is active (6).  Although patients with IBD thus constitute a high-risk 101 
population for malnutrition, the principles of screening for malnutrition, with its subsequent 102 
assessment and management, are in common with those for other chronic conditions.   103 
Nutritional care is clearly important in the treatment of patients with IBD and includes preven-104 
tion of the treatment of malnutrition and micronutrient deficiencies, prevention of osteoporo-105 
sis, and, in children promotion of optimal growth and development (7-11).  106 
107 
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Methodology 108 
The present ESPEN guideline for Clinical Nutrition in IBD began with updated methodology 109 
dating from 2011, which has since (2015) been replaced by new standard operating proce-110 
dures for ESPEN guidelines and consensus papers (Bischoff et al., 2015). These new and 111 
more rigorous methodologies for ESPEN guidelines both have a focus on disease rather 112 
than the historical technique-based approach (enteral vs parenteral). The multidisciplinary, 113 
multinational approach remains, but the guidelines are more structured and depend on sys-114 
tematic review, relying on expert opinion only when the systematic approach is not possible 115 
or yields inconclusive results.  In the specific case of guidelines for Clinical Nutrition in IBD 116 
there were previous ESPEN guidelines for enteral and parenteral nutrition in gastrointestinal 117 
disease (Lochs et al. 2006; Van Gossum et al. 2009).  118 
For the present guideline an expert writing panel was sought, both to retain some of the key 119 
contributors from 2006 and 2009 (by mutual consent) and to introduce new faces. An intend-120 
ed fully integrated approach for joint guidelines with the European Crohn’s and Colitis Organ-121 
isation (ECCO) and the European Society for Paediatric Gastroenterology Hepatology and 122 
Nutrition (ESPGHAN) was explored, but although there were positive discussions practical 123 
obstacles prevented this. The following guidelines are therefore informed by discussion with 124 
representatives from ECCO and ESPGHAN, but are not joint guidelines and form the rec-125 
ommendations of ESPEN alone. The expert panel was accredited by the ESPEN Guidelines 126 
Group, by the ESPEN Education and Clinical Practice Committee, and by the ESPEN Execu-127 
tive. All members of the working group had declared their individual conflicts of interest ac-128 
cording to the rules of the International Committee of Medical Journal Editors (ICMJE). 129 
Following the previous methodology, the expert panel created a series of clinical questions 130 
for adult and paediatric practice, presented according to the PICO formulation, which stands 131 
for Population, Intervention, Comparison and Outcome.  PICO questions accordingly include 132 
short but exact definitions of the population of interest, the intervention, comparators, and 133 
outcome. It was anticipated that the data would not permit satisfactory analyses in all cases 134 
and that for some questions data would be differently robust for adult and child patients. It 135 
was nonetheless felt appropriate to try to present the data for all age groups in a comparable 136 
format. The interpretation of the data from the literature was to be based on the panel’s deci-137 
sion as to the outcomes that matter most to patients, and not necessarily the outcomes pre-138 
sented in the original studies. It was recognised from the outset that some aspects of nutri-139 
tion in IBD would not be susceptible to fruitful systematic review, and it was initially intended 140 
that the guidelines would be constructed in two parts: a first section with the elements which 141 
would necessarily be opinion-based, and a second section considering those elements sus-142 
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ceptible to systematic review. The Cochrane team of Prof Leonard Leibovici in Israel was 143 
commissioned by ESPEN to conduct the systematic review according to questions devised 144 
by the expert panel for this second section. The Cochrane Centre assessed 1299 papers in 145 
the systematic review.  The data were almost uniformly poor or absent, with studies which 146 
were typically small and underpowered.  Few strong recommendations were possible and a 147 
major need for new and better research was identified. Only three Grade A recommenda-148 
tions were possible, and two of these were negative.  Grade B evidence supported four fur-149 
ther recommendations, but most of the questions for which clinical answers were sought re-150 
main unanswered (Table 1).    151 
Faced with the poor, but not entirely unexpected, outcome of the systematic review, the de-152 
sign and methodology of the present guideline were modified substantially according to the 153 
current ESPEN methodology (Bischoff et al., 2015).  In conjunction with the ESPEN Guide-154 
lines Group the expert panel expanded the PICO-style questions to include the areas inten-155 
tionally omitted from the original commission to the Cochrane Centre, and reformulated those 156 
originally selected so as to permit a more comprehensive framework to enable constructive 157 
and practical recommendations.  A final list of 40 PICO-style questions was created, which 158 
ultimately generated 64 recommendations.   159 
The time interval inherent in this process meant that it was necessary to redraft the commen-160 
taries intended to accompany the questions and recommendations, and in some cases to 161 
create these de novo. The opportunity was taken to perform an additional literature search 162 
based on PubMed terms relevant to each question (Appendix A). This process obviously falls 163 
short of a second systematic review, but its results are felt by the ESPEN Guidelines Group 164 
to represent sufficiently high levels of robustness and authority in combination with the earlier 165 
analysis. The combined result of these approaches means that the guidelines now form a 166 
single Results section based around 40 questions, and there is no longer a distinction be-167 
tween areas with and without expectations of strong objective data. 168 
The recommendations were graded according to the Scottish Intercollegiate Guidelines Net-169 
work (SIGN) grading system (Table 2). Grading is based on the systematic determination of 170 
the level of evidence for the literature, on which the recommendation is based. In total, 36 171 
references have been graded as listed in the evidence table (Appendix B) 172 
All recommendations were drafted by the working group were made available to interested 173 
ESPEN members via an internet platform for comments and online voting (DELPHI round, 174 
March/April 2016). Five voting options (agree, rather agree, indecisive, rather agree, disa-175 
gree) and the possibility to place individual comments were offered. A total of 29 experts par-176 
ticipated in the Delphi process prior to the final consensus conference on April 18th, 2016. If 177 
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the recommendations received more than 75% agreement in the DELPHI, they were 178 
usually finalized without further discussion. All other recommendations were revised by 179 
the working group and the revised versions underwent a second voting round during the 180 
final consensus conference. The voting results are indicated for each recommendation ac-181 
cording to the current ESPEN classification (Table 3).  182 
Table 1:  Recommendations from the systematic review 183 
Grade A Omega-3 supplementation in maintenance of UC not supported 
High fibre diet in maintenance of Crohn’s not supported 
Treatment of iron deficiency anaemia in IBD is valuable (oral or iv) 
Grade B Probiotics are ineffective in maintenance of CD 
Elemental diet is ineffective in inducing remission in CD in adults 
Probiotics are effective in maintenance of UC 
Probiotics are effective in inducing remission in acute UC 
 184 
Table 2: Grades of recommendations 185 
Grade Level of 
evidence 
Explanation 
A 1++ or 1+  At least one metaanalysis, systematic review, or RCT rated 
as 1++, and directly applicable to the target poulation; or  
A body of evidence consisting principally of studies rated 
as 1+, directly applicable to the target poulation, and 
demonstrating overall consistency of results    
B 2++ or 2+  A body of evidence including studies rated as 2++, directly 
applicable to the target population;  or a body of evidence 
including studies rated as 2+, directly applicable to the 
target population and demonstrating overall consistency of 
results: or extrapolated evidence from studies rated as 1++ 
or 1+.  
O 3 or 4  Evidence level 3 or 4; or  extrapolated evidence from 
studies rated as 2++ or 2+ 
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GPP  Good practice points. Recommended best practice based 
on the clinical experience of the guideline development 
group  
 186 
Table 3: Classification of the strength of consensus 187 
Strong consensus Agreement of > 90% of the participants 
Consensus Agreement of > 75 - 90% of the participants 
Majority agreement Agreement of > 50 - 75 % of the participants 
No consensus Agreement of < 50 % of the participants 
188 
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Results 189 
I. Nutrition in aetiology and its potential to prevent inflammatory bowel disease   190 
Can diet affect the incidence of IBD? 191 
Recommendation 1: 192 
A diet rich in fruit and vegetables, rich in n-3 fatty acids, and low in n-6 fatty acids is 193 
associated with a decreased risk of developing Crohn's disease or ulcerative colitis 194 
and is therefore recommended.  195 
Grade of recommendation 0 – strong consensus (90 % agreement) 196 
Commentary: 197 
The rising incidence of IBD in Western countries has generally predated that in developing 198 
nations, supporting the hypothesis that 'Westernization' of our lifestyle has led to the in-199 
creased incidence of IBD. Smoking, antibiotic use, and diet are potentially reversible risk 200 
factors for IBD. Multiple dietary components may impact on the resident flora, generating 201 
dysbiosis diminishing or damaging the mucus layer, may increase intestinal permeability or 202 
increase the ability of pathological microbiota to adhere to epithelial cells or translocate 203 
across the epithelial barrier. For example, in a recent study it has been shown that western 204 
diet induces changes in the composition of gut microbiota, alters host homeostasis and pro-205 
motes an unfavourable gut colonisation in genetically susceptible mice (12).   206 
Many studies have evaluated the effect of diet on the risk of developing IBD. However most 207 
of them are retrospective case-control studies. In 2011 Hou and al. published the first sys-208 
tematic review entitled “Dietary Intake and Risk of Developing IBD” (13). They used guide-209 
line-recommended methodology to evaluate the association between pre-illness intake of 210 
nutrients (fats, carbohydrates, protein) and food groups (fruits, vegetables, meats) and the 211 
risk of subsequent IBD diagnosis. Nineteen studies were included, encompassing 2,609 IBD 212 
patients (1,269 with CD and 1,340 with UC), and over 4,000 controls. The main results of this 213 
systemic review are the following:  214 
 There is an increased risk of developing UC with high intake of total fat, PUFAs, 215 
omega-6 fatty acids, and meats, 216 
 There is an increased risk of CD with high intake of PUFAs, omega-6 fatty acids, sat-217 
urated fats, and meat.  218 
 There is a decreased risk of CD, but not UC, with high intake of dietary fibre and 219 
fruits. A consistent association was shown between high dietary fibre and decreased 220 
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risk of CD, with the protective effect observed to be statistically significant in those 221 
consuming more than 22.1 g/d. The review also observed that a high intake of fruit is 222 
associated with a 73–80% decreased risk of CD. This association was confounded by 223 
dietary fibre intake and the fact that a diet high in fruits may conversely be low in fats 224 
and meats.  225 
 There is no consistent association between total carbohydrate intake and IBD risk, 226 
even in studies reporting intake greater than double the recommended daily intake.  227 
Some important studies from established prospective cohorts [the Investigation into Cancer 228 
and Nutrition (EPIC) cohort and the Nurses’ Health Study I and II cohorts], have been recent-229 
ly published and bring additional and important new insights.  230 
Fibre, fruit and vegetables: In a large prospective cohort study including 170,776 female 231 
registered nurses followed over 26 years, 269 incident cases of CD and 338 cases of UC 232 
were identified (14). Compared to women with the lowest energy-adjusted fibre intake, intake 233 
of fibre in the highest quintile (median 24 grams per day) was associated with a significant 234 
reduction in risk of CD [hazard ratio (HR) 0.59, 95% confidence interval (CI) 0.39 – 0.90] but 235 
not UC. Interestingly, this association seemed specific for fibre from fruits in particular, and 236 
only to a lesser degree from vegetables and cruciferous vegetables. No association was 237 
identified between intake of fibre from other sources such as cereals, whole grains, or leg-238 
umes. This association was also slightly stronger with respect to small bowel as opposed to 239 
colonic CD. 240 
In a recent meta-analysis including a total of 14 case-control studies (15), consumption of 241 
vegetables was negatively associated with the risk of UC (OR=0.71, 95% CI 0.58-0.88, n=9 242 
studies), but not with CD (OR=0.66, 95% CI 0.40-1.09, n=8 studies). Higher consumption of 243 
fruit was negatively associated with the risk of UC (OR=0.69, 95% CI 0.49-0.96, n=8 studies) 244 
and CD (OR=0.57, 95% CI 0.44-0.74, n=10 studies). On subgroup analysis the intake of 245 
vegetables was negatively associated with the risk of CD in studies carried out in Europe 246 
(OR=0.36, 95% CI 0.23-0.57), but not in Asia (OR=1.00, 95% CI 0.50-2.03). 247 
Dietary fat: Among the 170,805 women enrolled in the Nurses’ Health Study the effect of 248 
energy-adjusted cumulative average total fat intake, as well as specific types of fat and fatty 249 
acids, on the risk of CD and UC was examined using Cox proportional hazards models ad-250 
justing for potential confounders (16). Cumulative energy-adjusted intake of total fat, saturat-251 
ed fats, unsaturated fats, n-6 and n-3 polyunsaturated fatty acids (PUFA) were not associat-252 
ed with risk of CD or UC. However, greater intake of long-chain n-3 PUFA was associated 253 
with a trend towards lower risk of UC (Hazard ratio (HR) 0.72; 95% CI 0.51 – 1.01). In con-254 
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trast, high long-term intake of trans-unsaturated fatty acids was associated with a trend to-255 
wards an increased incidence of UC (HR 1.34, 95% CI 0.94 – 1.92). 256 
In the EPIC study, 229 702 participants were recruited from nine European centres between 257 
1991 and 1998 (17). At recruitment, dietary intakes of DHA and fatty acids were measured 258 
using validated food frequency questionnaires. In a nested case–control analysis, each par-259 
ticipant who developed incident UC (n=126) was matched with four controls. The highest 260 
quartile of intake of linoleic acid was associated with an increased risk of UC (odds ratio 261 
(OR): 2.49; 95% CI: 1.23 to 5.07, p=0.01) with a significant trend across quartiles (OR 1.32 262 
per quartile increase (95% CI: 1.04 to 1.66; p=0.02 for trend). In another nested case–control 263 
analysis of the EPIC study (18), each participant who developed incident CD (n=79) was 264 
matched with four controls. All higher quintiles of DHA intake were inversely associated with 265 
development of CD; the highest quintile had the greatest effect size (OR 0.07; 95% CI 0.02–266 
0.81). The OR trend across quintiles of DHA was 0.54 (95% CI 0.30–0.99). Including BMI in 267 
the multivariate analysis, due to its correlation with dietary fat showed similar associations. 268 
There were no associations with the other dietary fatty acids studied. 269 
Looked at from an alternative perspective in nearly 200 children with a new diagnosis of CD, 270 
Costea et al again concluded that a high omega-6:omega-3 ratio in the diet predisposes to 271 
the condition (odds ratio of up to 3), but that this is the case only for those with specific poly-272 
morphisms of the CYP4F3 and FADS2 genes (19). The two genes code for a leukotriene B4 273 
inhibitor and for enzymes in PUFA metabolism respectively and further support an interaction 274 
between nature and nurture in IBD. 275 
It is also possible (and of relevance to nutrition when it is used therapeutically) that it is not 276 
only the fats themselves that are important, but additional agents employed to keep them in 277 
forms that are aesthetically acceptable.  The emulsifiers used in commercially prepared 278 
foods may be implicated in this regard, with at least one (polysorbate 80) having a proposed 279 
specific mechanism as it increases bacterial translocation across the intestinal epithelium 280 
(20). 281 
Vitamin D: Khalili et al, using the Nurses’ Health Study cohort, demonstrated a lower risk for 282 
both CD (HR 0.48, 95% CI 0.30 – 0.77) and UC (HR 0.62, 95% CI 0.42 – 0.90) in women 283 
who were residing in southern latitudes at age 30, compared to those residing in northern 284 
latitudes (21). In a prospective cohort study of 72,719 women (age, 40–73 y) enrolled in the 285 
Nurses’ Health Study, women completed an assessment of diet and lifestyle, from which a 286 
25-hydroxy vitamin D [25(OH)D] prediction score was developed and validated against di-287 
rectly measured levels of plasma 25(OH)D (22).  During 1,492,811 person-years of follow-up 288 
122 incident cases of CD and 123 new cases of UC were documented. The median predict-289 
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ed 25(OH)D level was 22.3 ng/mL in the lowest, and 32.2 ng/mL in the highest quartiles. 290 
Compared with the lowest quartile for vitamin D levels, the multivariate-adjusted HR for CD 291 
was 0.54 (95% CI: 0.30–0.99) in the highest quartile for vitamin D, and 0.65 (95% CI, 0.34–292 
1.25) for UC. Compared with women with a predicted 25(OH)D level less than 20 ng/mL, the 293 
multivariate-adjusted HR for UC was 0.38 (95% CI, 0.15–0.97) and a non-significant 0.57 for 294 
CD (95% CI, 0.19–1.70) for women with a predicted 25(OH)D level greater than 30 ng/mL. 295 
There was a significant inverse association between dietary and supplementary vitamin D 296 
and UC, and a non-significant reduction in CD risk. 297 
Zinc: There has been limited examination of the role of micronutrients in IBD pathogenesis. 298 
Dietary zinc is promising as a risk factor and may influence risk of IBD through effects on 299 
autophagy, innate and adaptive immune response and maintenance of the intestinal barrier. 300 
In a recent study concerning zinc intake and incidence of IBD, data from 170,776 women 301 
from the Nurses Health Study I and Nurses Health (using semi-quantitative food question-302 
naire) were presented. There were 269 incident cases of CD and 338 of UC (23). Zinc intake 303 
ranged from a median of 9 mg/day in the lowest quintile to 27 mg/day in the highest quintile. 304 
Compared to women with the lowest quintile of intake, the multivariate hazard ratios (HR) for 305 
CD were 0.92 (95% CI, 0.65 - 1.29) for the second quintile of intake, 0.60 (95% CI, 0.40 - 306 
0.89) for the third quintile, 0.57 (95% CI, 0.38 - 0.86) for the fourth quintile, and 0.74 (95% CI, 307 
0.50 - 1.10) for the highest quintile (p for trend = 0.003). Compared to individuals with intake 308 
of zinc less than the recommended daily allowance (8 mg/day), those with an intake of 8-309 
16mg/day (HR 0.69, 0.44 - 1.08) and >16mg/day (HR 0.52, 0.32 - 0.86) had a reduced risk of 310 
CD. The association was stronger for dietary zinc (HR 0.63, 95% CI: 0.43-0.93), comparing 311 
extreme quintiles, than for zinc intake from supplements. In conclusion, in two large prospec-312 
tive cohorts of women, intake of zinc was inversely associated with risk of CD but not UC. 313 
Dietary pattern: Within the prospective EPIC programme, a nested matched case-control 314 
study was performed among 366,351 participants with IBD data, which included 256 incident 315 
cases of UC and 117 of CD, and 4 matched controls per case (24). Dietary intake was rec-316 
orded at baseline from validated food frequency questionnaires. Incidence rate ratios for the 317 
development of UC and CD were calculated for quintiles of the Mediterranean diet score, and 318 
a posteriori dietary patterns were produced from factor analysis. No dietary pattern was as-319 
sociated with either UC or CD.  Specifically there were no associations with a Mediterranean 320 
diet and either condition. However, when excluding cases occurring within the first 2 years 321 
after dietary assessment, there was a positive association between a "high sugar and soft 322 
drinks" pattern and UC risk (incidence rate ratios for the 5th versus the 1st quintile: 1.68 (1.00-323 
2.82). When considering the foods most associated with the pattern, high consumers of sug-324 
ar and soft drinks were at higher UC risk only if they had low vegetable intakes. 325 
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Other micronutrients, microparticles and the unintentional inclusion of trace metals in the 326 
diet, such as by the swallowing of toothpaste, have been explored and there are no robust 327 
data to indicate important effects on IBD pathogenesis (reviewed by Andersen et al (25)). 328 
In conclusion, the external environment offers particular promise as a modifiable risk factor 329 
for both incident disease and for outcomes in those with established disease (26). Many con-330 
cordant results suggest that a diet rich in fruits and vegetables in n-3 fatty acids and low in n-331 
6 fatty acids is associated with a decreased risk of developing CD or UC. Interesting new 332 
data suggest that a diet rich in vitamin D and zinc may also protect against CD but not UC. 333 
Rigorous randomized controlled trials examining the effect of dietary factors are required to 334 
establish or refute the role of these factors in achieving and maintaining disease remission. 335 
 336 
Does breastfeeding protect against IBD?    337 
Recommendation 2: 338 
Breastfeeding can be recommended, because it is the optimal food for infants and it 339 
reduces the risk of IBD. 340 
Grade of recommendation B – strong consensus (93 % agreement) 341 
Commentary: 342 
An early case control study conducted in in 9 countries included 499 patients to investigate 343 
childhood factors predicting IBD yielded no significant differences between patients and con-344 
trols in the frequency of breast feeding, cereal consumption, sugar added to milk in infancy, 345 
and other dietetic factors (27). This finding was confirmed in a German study (28). In con-346 
trast, an Italian study indicated that lack of breastfeeding is associated with an increased risk 347 
of UC (OR = 1.5; 95% CI: 1.1-2.1) and CD (OR = 1.9; 95% CI: 1.1-3.3) (29). Systematic re-348 
views from 2004 and 2009 concluded strongly in favour of breastfeeding (29a, 29b) and sub-349 
sequent studies have reinforced this interpretation.  A case-control study from New Zealand 350 
reported that breastfeeding was protective against IBD (CD OR 0.55 [0.41-0.74], UC OR 351 
0.71 [0.52-0.96]) with a duration-response effect (30). Comparable data were reported from a 352 
Danish cohort study, in which breastfeeding for >6 months decreased the odds of IBD (OR, 353 
0.50; 95% CI, 0.23-1.11) (31).  More recently still, 2 further publications confirmed this rela-354 
tionship, one from the US and another from Asia-Pacific. The US study was a single centre 355 
study in which the relation between breastfeeding and requirement for disease-related sur-356 
gery in 333 CD and 270 UC patients was examined. Among those with CD, being breastfed 357 
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was associated with reduced risk of CD-related surgery (34% vs. 55%), while none of the 358 
early life variables influenced disease phenotype or outcome in UC (32). The Asia-Pacific 359 
study included 442 incident IBD cases from eight countries in Asia and Australia and 940 360 
controls. In a multivariate model, being breastfed for >12 months decreased the odds for CD 361 
(aOR 0.10; 95% CI 0.04 to 0.30) and UC (aOR 0.16; 0.08 to 0.31) in Asians (33).  362 
Breastfeeding for around six months is desirable in all infants (34). Regarding longer periods 363 
of breastfeeding, current European recommendations suggest that breastfeeding is contin-364 
ued as long as mutually desired by both mother and infant (34). In summary, the majority of 365 
the literature (and in particular the more recent publications) supports the importance of 366 
breastfeeding as a protective factor in early childhood regarding the development of IBD.  367 
 368 
What is the risk of malnutrition in IBD; what are the consequences? 369 
Recommendation 3 A: 370 
Patients with IBD are at risk and therefore should be screened for malnutrition at the 371 
time of diagnosis and thereafter on a regular basis.  372 
Grade of recommendation GPP – strong consensus (96 % agreement)   373 
Recommendation 3 B: 374 
Documented malnutrition in patients with IBD should be treated appropriately, be-375 
cause it worsens the prognosis, complication rates, mortality and quality of life.  376 
Grade of recommendation GPP – strong consensus (96 % agreement) 377 
Commentary: 378 
Adults with IBD are at increased risk of malnutrition, with deficits more common in patients 379 
with CD than UC (35).   Obese patients may have covert deficits in lean mass which may be 380 
unmasked by tools such as skinfold thickness measurement. Patients with active IBD, partic-381 
ularly those whose disease is poorly responsive to medical therapy, are at highest risk of 382 
poor nutrition. In adults, risk of malnutrition can be assessed with validated screening tools 383 
(36). 384 
Malnourished patients with IBD are more likely to be hospitalised following emergency de-385 
partment attendance (37) and are more likely to be admitted to hospital due to infection (38). 386 
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In hospitalised patients malnutrition is an independent risk factor for venous thromboembo-387 
lism (39), non-elective surgery (40), longer admission (35,40) and increased mortality (35).  388 
Pragmatically optimising nutrition status may improve outcomes for patients with IBD there-389 
fore it is logical to screen for, and manage, undernutrition using an appropriately trained mul-390 
tidisciplinary team. 391 
Malnutrition in children: Malnutrition in childhood Crohn's is common at diagnosis and may 392 
persist despite disease treatment (41). Children with UC are also at risk of poor nutrition but 393 
nutritional deficits may not be immediately obvious on assessment of just height and weight 394 
(42). Although a variety of screening tools exists, the tools have poor ability to discern differ-395 
ent levels of nutrition risk for children with IBD (43). Poor nutrition in childhood IBD contrib-396 
utes to disrupted pubertal development and impaired growth velocity which may lead to short 397 
stature in adulthood. 398 
Malnutrition plays a role in the pathogenesis of IBD, in its clinical presentation and in disease 399 
treatment and outcome. As in adults, the mechanisms involved include limited food intake, 400 
malabsorption of nutrients, and increased nutrient losses. With specific drugs (sulfasalazine, 401 
methotrexate, steroids) it can include interactions between these drugs and nutrients.  402 
Of particularly importance in paediatric IBD is growth failure, which is the result of a combina-403 
tion of inflammation and chronic malnutrition (44). Growth failure is seen in 15-40% of chil-404 
dren with IBD (44,45). Both growth failure and delay of puberty are more common in Crohn’s 405 
than in UC. Despite greater disease awareness, growth failure is still found to precede the 406 
diagnosis of Crohn's by many years in a high proportion of patients. This may have an ad-407 
verse effect on the final height of these patients, who commonly fail to reach their final pre-408 
dicted height: short stature (final height below 5th percentile) is present in up to 30% of 409 
Crohn's patients (46).   410 
Iron deficiency is particularly common in paediatric IBD, while other deficiencies include folic 411 
acid, zinc, magnesium, calcium, vitamins A, B12, D, E, and K (47). A detailed discussion of 412 
nutritional assessment is beyond the scope of these guidelines, however, a careful account 413 
of nutrition intake, anthropometric measurements, including history of growth with plotting of 414 
previous measurements of weight and height and assessment of growth rate are essential. 415 
Laboratory work up to identify and treat nutrient deficiencies is also essential.    416 
 417 
Do patients with IBD have altered energy requirements? 418 
  15 
Recommendation 4: 419 
In general, the energy requirements of patients with IBD are similar to those of the 420 
healthy population; provision should be in line with this.  421 
Grade of recommendation GPP – strong consensus (93 % agreement) 422 
Commentary: 423 
For clarity this question can be formulated in two ways; firstly do patients with IBD have an 424 
altered energy requirement compared to healthy individuals, and secondly do energy re-425 
quirements vary with disease activity. It is also worth noting that an individual patient’s daily 426 
energy requirement includes their resting energy expenditure (REE), which includes the en-427 
ergy cost of depositing tissue/growth, energy expended in physical activity, and dietary in-428 
duced thermogenesis.  An important consideration highlighted in paediatric data is how to 429 
adjust for differences in energy expenditure attributable to body size: patients with greater 430 
mass have greater REE. This effect may not be fully negated by expressing REE per unit of 431 
mass or lean mass, and alternative analyses have been proposed (48-50). 432 
There are relatively few studies examining energy expenditure in patients with UC and all 433 
studies are of only small numbers of patients. There may be an increase in metabolic activity 434 
at times of acute severe colitis compared to remission in adults (51,52) which is understand-435 
able considering that systemic disturbance (fever and tachycardia) is common. However, an 436 
increase in REE is likely to be offset by reduction of physical activity. Significant reduction in 437 
dietary intake is common in acute colitis and may result in negative energy balance (53). 438 
Inconsistent results about changes in resting energy expenditure are found for milder dis-439 
ease activity and for children.  440 
One single study has measured total energy expenditure in adults with CD and recorded 441 
normal values (54). Comparison between other studies of resting energy is hampered by 442 
differing presentation of data. However, measured REE has consistently been found to be 443 
similar to predictive equations based on weight in adults (55, 56) or children (57-60). Meas-444 
ured REE/kg in adult patients  has been found to be higher than (61) or the same as (62) that 445 
measured in healthy controls. However, this could be due to inadequate consideration of 446 
body size and the relative proportions of tissues of differing metabolic activity.  REE does not 447 
appear to be raised in patients with weight loss, but decreased nutrient intake  and malab-448 
sorption has been shown in these patients (63,64). No consistent  association between CD 449 
activity and REE in adults has been demonstrated. In children with Crohn's, measured REE 450 
has not been demonstrated to be significantly different in children before and after infliximab 451 
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(anti-TNF) (65-67) and no consistent association has been found between REE/kg FFM and 452 
markers of disease activity (68). 453 
In summary, patients with IBD do not have an increased energy expenditure as a direct re-454 
sult of their disease  and predictive equations are suitable for estimating requirements. Die-455 
tary intake may be inadequate to meet even normal requirements particularly during periods 456 
of disease activity which may lead to weight loss.  Measurement of REE by indirect calorime-457 
try could be used in troublesome cases. 458 
 459 
Do patients with IBD have altered protein requirements? 460 
Recommendation 5 A: 461 
Protein requirement are increased in active IBD, and intake should be increased (to 462 
1.2-1.5 g/kg/d in adults) relative to that recommended in the general population.   463 
Grade of recommendation GPP – strong consensus (96 % agreement) 464 
Recommendation 5 B: 465 
The protein requirements in remission are generally not elevated and provision should 466 
be similar (about 1g/kg/d in adults) to that recommended for the general population.  467 
Grade of recommendation GPP – strong consensus (96 % agreement) 468 
Commentary: 469 
Patients with IBD develop a relative reduction in lean mass and increase in adiposity over 470 
time. This may occur due to chronically poor dietary intake, increased rates of protein turno-471 
ver and gut loss of nutrients during phases of active disease or from the effect of disease 472 
treatments. Corticosteroids increase net loss of protein in children (69) and adults (70) with 473 
Crohn's. In contrast administration of elemental or polymeric feed as treatment of Crohn's or 474 
as adjunctive nutrition support results in reduction of proteolysis and acquisition of lean tis-475 
sue in children and adults (1,71,72). In children with active CD one study examined the re-476 
duction in protein turnover resulting from treatment with Infliximab and demonstrated im-477 
proved protein metabolism in patients receiving parenteral nutrition both before and after 478 
infliximab treatment (67).  479 
Monitoring of anthropometry provides insight into which patients develop relative deficits in 480 
lean mass and therefore would benefit from nutritional supplementation. There is no good 481 
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evidence that the daily protein needs of IBD patients differ from those of healthy controls, but 482 
as discussed elsewhere poor appetite and restricted dietary intake is commonplace. In pa-483 
tients receiving steroids and gut rest, enteral tube feeding may provide beneficial effects on 484 
protein turnover without deleterious consequences on disease activity. 485 
There is no good evidence that the daily protein needs of IBD patients in remission differ 486 
from those of healthy controls. Provision of 1g protein for each kilogram of body weight is 487 
therefore reasonable.  However in active inflammation the proteolytic, catabolic response 488 
justifies an increase in provision to 1.2 to 1.5 g/kg bodyweight (73,74). 489 
 490 
Do patients with IBD have an altered micronutrient requirement? 491 
Recommendation 6: 492 
Patients with IBD should be checked for micronutrient deficiencies on a regular basis 493 
and specific deficits should be appropriately corrected.  494 
Grade of recommendation GPP – strong consensus (100 % agreement) 495 
Commentary: 496 
Patients with IBD are vulnerable to micronutrient deficits due to gut loss from diarrhoea and 497 
inadequate dietary intake from anorexia accompanying disease activity. At times when nutri-498 
tion support is offered then multivitamin and micronutrient supplements should also be of-499 
fered to ensure an appropriately balanced nutritional intake. 500 
When interpreting blood results of micronutrients and trace elements it is important to con-501 
sider that many serum values, or markers of status, are positive or negative acute phase 502 
reactants; Serum levels rise or fall, as part of the inflammatory response; for example ferritin, 503 
and copper increase but folate, selenium and zinc decrease in inflammation (75) . In light of 504 
this some authors have examined micronutrient status in patients in clinical disease remis-505 
sion and found deficits of a variety of micronutrients (76,77). Furthermore, deficits may be 506 
present even in apparently well nourished individuals (78). These observations highlight the 507 
need for routine monitoring (perhaps annually) to  screen for deficiency. A daily multivitamin 508 
supplement may correct most deficiencies but is no guarantee of adequacy, even over the 509 
long term; iron, zinc and Vitamin D are likely to require specific replacement regimens (79). 510 
Poor compliance, particularly in adolescents, is common with multivitamin supplements and 511 
patient education about the rationale behind their use is important (80). 512 
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Consequences of deranged micronutrient status include anaemia, impaired linear growth and 513 
poor bone health. Recent research has focused on Vitamin D; it and its receptor may have 514 
some immunomodulatory properties, which further highlights the need for specific attention to 515 
micronutrient status in patients with IBD. 516 
 517 
Is iron supplementation needed in IBD? 518 
Recommendation 7 A: 519 
Iron supplementation is recommended in all IBD patients when iron deficiency anae-520 
mia is present. The goal of iron supplementation is to normalize haemoglobin levels 521 
and iron stores. 522 
Grade of recommendation A – strong consensus (100 % agreement) 523 
Recommendation 7 B: 524 
Oral iron should be considered as first-line treatment in patients with mild anaemia, 525 
whose disease is clinically inactive, and who have not been previously intolerant to 526 
oral iron.  527 
Grade of recommendation A – strong consensus (100 % agreement)  528 
Recommendation 7 C: 529 
Intravenous iron should be considered as first-line treatment in patients with clinically 530 
active IBD, those with previous intolerance to oral iron, those with haemoglobin below 531 
100 g/L, and in patients who need erythropoiesis-stimulating agents.  532 
Grade of recommendation A – strong consensus (93 % agreement) 533 
Commentary: 534 
Anaemia is considered the most frequent extraintestinal manifestation of IBD, usually com-535 
plicating the course both in UC and Crohn disease (CD). Prevalence rates of anaemia in IBD 536 
vary widely from 6 to 74% (81). Anaemia is reported more frequently in hospitalized patients 537 
with IBD and occurs more frequently in CD than in UC (82). In IBD patients anaemia in-538 
creases, morbidity, rate of hospitalization, medical costs and deaths (81,83). In the majority 539 
of cases, IBD-associated anaemia represents a combination of chronic iron deficiency and 540 
anaemia of chronic disease (81). The currently used WHO definition of anaemia (Table 4) 541 
applies also to patients with IBD (84).  542 
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Table 4: Haemoglobin concentrations (in g/L) for diagnosis of anaemia, by population 543 
 Healthy Mild anae-
mia 
Moderate 
anaemia 
Severe 
anaemia 
Boys and girls (0.5-4 years) ≥110 100-109 70-99 <70 
Boys and girls (5-11 years) ≥115 110-114 80-109 <80 
Boys and girls (12-14 years) ≥110 110-119 80-109 <80 
Non-pregnant women and girls 
(≥ 15 years) 
≥120 110-119 80-109 <80 
Pregnant women and girls (≥ 15 
years) 
≥120 100-109 70-99 <70 
Men and boys (≥15 years) ≥130 110-129 80-109 <80 
 544 
All patients with IBD regardless of their age should be assessed for the presence of anaemia 545 
(85). The major forms of anaemia in IBD are iron deficiency anaemia (IDA), anaemia of 546 
chronic disease (ACD) and anaemia of mixed origin [ECCO Anaemia Statement 1A]. Diag-547 
nostic criteria for iron deficiency depend on the level of inflammation. For laboratory screen-548 
ing, complete blood count, serum ferritin, and C-reactive protein [CRP] should be used [EC-549 
CO Anaemia Statement 1B]. For patients in remission or mild disease, measurements should 550 
be performed every 6 to 12 months. In outpatients with active disease such measurements 551 
should be performed at least every 3 months [ECCO Anaemia Statement 1B]. In patients 552 
without clinical, endoscopic, or biochemical evidence of active disease, serum ferritin <30 553 
μg/L is an appropriate criterion for the diagnosis of IDA. In the presence of inflammation, a 554 
serum ferritin up to 100 μg/L may still be consistent with iron deficiency  [ECCO Anaemia 555 
Statement 1D]. In the presence of biochemical or clinical evidence of inflammation, the diag-556 
nostic criteria for ACD are a serum ferritin >100 μg/L and transferrin saturation <20%. If the 557 
serum ferritin level is between 30 and 100 μg/L, a combination of true iron deficiency and 558 
ACD is likely  [ECCO Anaemia Statement 1E]. 559 
Iron supplementation is recommended in all IBD patients, whatever their age, when iron-560 
deficiency anaemia is present [ECCO Anaemia Statement 2A]. Quality of life improves with 561 
correction of anaemia, and this improvement is independent of clinical activity (86). The deci-562 
sion to supplement iron in patients without anaemia is more controversial and will depend on 563 
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the patients’ history, symptoms and individual preferences. Although there is evidence of 564 
benefit in treating iron deficiency without anaemia in other conditions such as chronic fatigue 565 
and heart failure, such evidence is not yet available in the context of IBD (85). In a recent 566 
meta-analysis of randomized controlled trials comparing intravenous versus oral iron for the 567 
treatment on anaemia in IBD, five eligible studies, including 694 IBD patients, were identified 568 
(87). IV iron demonstrated a higher efficacy in achieving a haemoglobin rise of ≥ 2.0 g/dL as 569 
compared to oral iron (OR: 1.57, 95% CI: 1.13, 2.18). Treatment discontinuation rates, due to 570 
adverse events or intolerance, were lower in the IV iron groups (OR: 0.27, 95% CI: 0.13, 571 
0.59). Similarly, the occurrence of gastrointestinal adverse events was consistently lower in 572 
the IV iron groups. On the contrary, serious adverse events (SAEs) were more frequently 573 
reported among patients receiving IV iron preparations (OR: 4.57, 95% CI: 1.11, 18.8); how-574 
ever, the majority of the reported SAEs were judged as unrelated or unlikely to be related to 575 
the study medication. The recent European Crohn’s and Colitis Organization (ECCO) guide-576 
lines (85) conclude that ‘‘IV iron is more effective, shows a faster response, and is better tol-577 
erated than oral iron’’ and state that ‘‘IV iron should be considered as first line treatment in 578 
patients with clinically active IBD, with previous intolerance to oral iron, with haemoglobin 579 
below 100 g/L, and in patients who need erythropoiesis-stimulating agents; while oral iron 580 
may be used in patients with mild anaemia, whose disease is clinically inactive, and who 581 
have not been previously intolerant to oral iron (85). The estimation of iron need is usually 582 
based on baseline haemoglobin and body weight (Table 5) (88).  583 
Table 5: Simple scheme for estimation of total iron need (88) 584 
Haemoglobin g/L Body weight <70 kg Body weight ≥70 kg 
100-120 (women) 1000 mg 1500 mg 
100-130 (men) 1000 mg 1500 mg 
70-100 1500 mg 2000 mg 
 585 
Anaemia seems to recur frequently and fast after intravenous iron therapy (89).  After suc-586 
cessful treatment of iron deficiency anaemia with intravenous iron, re-treatment with intrave-587 
nous iron should be initiated as soon as serum ferritin drops below 100 μg/L or haemoglobin 588 
below 12 or 13 g/dL according to gender [ECCO Anaemia Statement 3E] 589 
590 
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II. Dietetic recommendations in active disease 591 
Should IBD patients with active disease adhere to a specific diet?  592 
Recommendation 8: 593 
There is no “IBD diet” that can be generally recommended to promote remission in 594 
IBD patients with active disease.  595 
Grade of recommendation GPP – strong consensus (96 % agreement)   596 
Commentary: 597 
Lately, there is interest in specific carbohydrate, paleolithic, gluten-free, low FODMAP, ω-3 598 
PUFA enriched and other diets in active IBD. However RCT data regarding the effects of 599 
experimental diets on intestinal inflammation or on inducing remission are still lacking at this 600 
time. An adequately powered RCT of fructo-oligosaccharides (FOS) showed no clinical bene-601 
fit in patients with active CD (90). Therefore, no “oral IBD diet” can be generally recommend-602 
ed to promote remission in IBD patients with active disease. This recommendation does not 603 
prelude the needs of all IBD patients to receive an individual (nutritional) approach based on 604 
their specific personal situation, preferably with the active input of a dedicated dietician or 605 
nutritionist as part of the multidisciplinary approach. It is important that each IBD patient with 606 
active disease should undergo malnutrition screening and diet counselling in the case of 607 
malnutrition. It is recorded that approximately 75% of hospitalised CD patients suffer from 608 
malnutrition and 33% have a BMI <20 kg/m2 (91). Screening for nutritional deficiencies in 609 
chronic disease patients is warranted 610 
Enteral nutrition (EN), as an exclusive form of nutrition (EEN), has generated interest over 30 611 
years as a treatment modality for active IBD since it is hypothesized to promote mucosal 612 
healing in the gastrointestinal tract by altering favourably the intestinal microbiota, reducing 613 
intestinal permeability, enhancing barrier defence and adaptation, and promoting a reduction 614 
of pro-inflammatory cytokines. In an open-label-trial in 37 CD children it was demonstrated 615 
that mucosa healing was significantly higher in the polymeric (74%; 95% CI 51%-89%) than 616 
the corticosteroid group (33%; 95% CI 16%-57%, P<0.05) (92). In these cases, polymeric EN 617 
seems more effective that elemental ones (93,94). EN in a supplemental form as partial en-618 
teral nutrition (PEN) therapy induced remission in 47 children and young adults (95), where-619 
as this effect was not found in a former RCT in 50 CD children (96). Due to strong concerns 620 
over corticosteroid use and aiming for optimal growth in children, EN is often first-line therapy 621 
for paediatric patients with active CD (97). Although EEN as primary therapy in adults with 622 
CD has also repeatedly been considered to be effective the data are not robust.  Opposite 623 
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results have appeared regarding the amount and nature of fat in the enteral formulas and on 624 
the question of polymeric versus elemental EN in RCTs of adults with active CD (98-100). 625 
Meta-analyses do not support the use of EN as primary treatment for acute exacerbations of 626 
CD in adults (97,101). Patchy clinical conviction and the data, which appear better than might 627 
be expected with placebo, ensure continuing controversy over its role in adults. 628 
Is there specific dietetic advice for IBD patients with a stoma or severe diarrhoea?  629 
Recommendation 9 A: 630 
IBD patients with severe diarrhoea or a high output jejunostomy or ileostomy should 631 
have fluid output and urine sodium monitored, and fluid input adapted accordingly 632 
(decrease hypotonic fluid and increase saline solutions), with consideration of food 633 
intolerances that may enhance fluid output.  634 
Grade of recommendation 0 – strong consensus (93 % agreement) 635 
Recommendation 9 B: 636 
Parenteral infusions (fluid and electrolytes) can be needed in the case of on-going 637 
high output stomas.  638 
Grade of recommendation 0 – strong consensus (96 % agreement) 639 
Commentary: 640 
In the case of extraordinary amount of faecal production, diarrhoea or increased/high output 641 
stoma (HOS), a systematic diagnostic approach is advised in which screening for clostridium, 642 
antibiotic associated diarrhoea, pouchitis in the case of IPAA, bile acid diar-643 
rhoea/steatorrhoea after distal ileal resection, (distal) colonic inflammation, lactase deficiency 644 
in the case of proximal small intestinal inflammation, and coeliac disease should be incorpo-645 
rated. Depending on the underlying cause of diarrhoea in IBD, medication can be considered 646 
as well as a supportive diet regime in some cases (eg lactose restricted diet). 647 
Ongoing and severe diarrhoea or HOS can result in intestinal insufficiency (102) with malab-648 
sorption, unintentional weight loss, malnutrition, nutritional deficiencies and/or dehydration. 649 
Malabsorption is an important contributing factor to malnutrition in IBD (64). The retrospec-650 
tive study of Baker in 687 stoma patients (103), showed that early high output (within 3 651 
weeks) from an ileostomy is common and although 49% resolved spontaneously, 51% need-652 
ed ongoing medical treatment, usually because of a short small-bowel remnant. 71% patients 653 
were treated with oral hypotonic fluid restriction, glucose-saline solution and anti-diarrhoeal 654 
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medication to wean from parenteral infusions and 8% had to continue parenteral or subcuta-655 
neous saline in home-setting. Satisfactory home management with oral fluid restriction and 656 
monitoring of urine sodium content was demonstrated more than 35 years ago (104). In a 657 
study in 13 adult (ileal) HOS patients, oral rehydration solutions containing rice maltodextrins 658 
(R-ORS) supplementation improved the sodium and potassium balance. The association of 659 
increased body weight with decreased serum renin concentrations suggests that a positive 660 
water balance also occurred (105). In another study, 3 different saline and/or glucose solu-661 
tions were tested in 6 patients with jejunostomies. Based on this small group, a sipped glu-662 
cose electrolyte solution seemed to be the optimal mode of sodium replacement in patients 663 
with HOS (106). No RCTs are available on nutritional treatment of IBD related diarrhoea or 664 
HOS. Only case studies on treatment of Crohn with HOS have been published, which show 665 
successful treatment with restriction of hypotonic fluids, sodium enriched diets, fully enteral 666 
nutrition and/or parenteral sodium-containing infusions. 667 
 668 
What are the dietetic recommendations for CD patients with strictures? 669 
Recommendation 10: 670 
In CD patients with intestinal strictures or stenosis in combination with obstructive 671 
symptoms, a diet with adapted texture, or distal (post-stenosis) enteral nutrition can 672 
be recommended.  673 
Grade of recommendation GPP – strong consensus (95 % agreement) 674 
Commentary: 675 
Some patients with CD develop clinically significant intestinal strictures.  Depending on their 676 
severity (degree of obstruction) and site, nutritional support may become necessary while the 677 
effects of treatment are awaited.  Such treatment may be medical (with drugs) where the 678 
narrowing is mainly the result of inflammation, or mechanical (by balloon dilatation or sur-679 
gery) when there is fibrotic scarring.  In patients with radiologically identified but asymptomat-680 
ic stenosis of the intestine it is conventional to recommend a modified diet which is low in 681 
insoluble fibre, but there are no robust data to support this apparently logical approach.  682 
When symptoms are present it may be necessary to adapt the diet to one of soft consisten-683 
cy, perhaps predominantly of nutritious fluids.  684 
Intestinal fibrosis is a common feature of CD and may appear as a stricture, stenosis, or in-685 
testinal obstruction. Stenosing CD leads to a significantly impaired quality of life in affected 686 
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patients and constitutes a challenging treatment situation. Different treatment approaches 687 
with potentially harmful side effects are frequently used: medical options (drugs) where the 688 
narrowing is mainly the result of inflammation, endoscopic (by balloon dilatation) or surgical 689 
approaches when there is fibrotic scarring. Depending on their severity (degree of obstruc-690 
tion) and site, nutritional support may become necessary while the effects of treatment are 691 
awaited at least in case of (risk of) malnutrition. 692 
A recent Chinese prospective observational study in 59 adult CD patients with inflammatory 693 
bowel strictures showed that 12-weeks exclusive enteral nutrition (EEN) can effectively re-694 
lieve inflammatory bowel strictures; (81.4%) achieved symptomatic remission, 35 patients 695 
(53.8%) achieved radiologic remission, and 42 patients (64.6%) achieved clinical remission 696 
(107). A small study of 7 patients showed no clinical effect of TPN on colonic strictures (108). 697 
No RCTs are available on nutritional management in IBD strictures. Some case studies re-698 
port on occasional effectiveness of TPN or semi-elementary enteral nutrition. 699 
Although it is common practice to recommend a modified diet with adapted consistency per-700 
haps predominantly of nutritious fluids, at least in patients with radiologically identified steno-701 
sis of the (proximal) intestine and obstructive symptoms, or to feed distally by enteral nutri-702 
tion whenever this is possible, there are no robust data to support these apparently logical 703 
approaches.  704 
 705 
What are the dietetic recommendations for IBD patients with respect to bone mineral density 706 
(including those on steroid therapy)? 707 
Recommendation 11: 708 
In IBD patients (adults and children) with active disease and those who are steroid-709 
treated, serum calcium and 25(OH) vitamin D should be monitored and supplemented 710 
if required to help prevent low bone mineral density.  Osteopenia and osteoporosis 711 
should be managed according to current osteoporosis guidelines. 712 
Grade of recommendation B – strong consensus (96 % agreement) 713 
Commentary: 714 
Osteoporosis (low bone mineral density BMD) and fractures are frequently encountered in 715 
patients with CD. The prevalence of osteoporosis in paediatric patients with IBD is approxi-716 
mately the same as in adult patients. Osteoporosis may already be present before steroid 717 
treatment (109). In order to prevent fractures, treatment with bone protecting drugs appears 718 
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warranted early in the course of bone disease when bone loss is not yet prominent. Signifi-719 
cant risk factors for low BMD studied in adult IBD populations (n=116 and n=205) prove to be 720 
low serum vitamin D, male gender, Asian ethnicity, CD, low BMI and corticosteroid use, 721 
whereas no consensus on role of age, or age at diagnosis was found (110,111). In children 722 
and adolescents with IBD risk factors associated with low BMD are cumulative corticosteroid 723 
dose, height-for-age Z-score, and BMI Z-score (112).  724 
It should however be remembered also that prednisone treatment in CD can stimulate food 725 
intake, promoting an overall positive energy balance despite large faecal nutrient losses 726 
(113).  727 
There is no overall consensus on the vitamin D status and necessary actions in children and 728 
adolescents with IBD. In Veit’s study there is no difference in mean serum 25(OH)D concen-729 
tration between children and adolescents with IBD and controls (n=58 child vs n=116 HC) 730 
(114). Vitamin D deficiency is common (55%) among adult patients with active UC, particu-731 
larly those requiring corticosteroids (n=34) (115). Vitamin D deficiency should be treated 732 
since low plasma 25(OH)D is associated with an increased risk of surgery and hospitaliza-733 
tions in both CD and UC, and normalization of 25(OH)D status is associated with a reduction 734 
in the risk of CD-related surgery (n=3217 adults with IBD) (7). Next, a higher plasma 735 
25(OH)D is associated with reduced risk of Clostridium difficile infection in patients with IBD 736 
(n=3188 adults with IBD) (8). Vitamin D supplementation seemed effective in increasing se-737 
rum 25(OH)D levels in 83 children with quiescent CD (116). 738 
A RCT of 132 osteopenic CD patients, showed improved BMD at lumbar spine after 2 years 739 
of once weekly treatment course with risedronate 35 mg, concomitant with calcium and vita-740 
min D supplementation (117). An earlier RCT showed no significant benefit of calcium sup-741 
plementation (1 g/day) alone on the BMD at 1 year in corticosteroid-using IBD patients with 742 
osteoporosis (117). 743 
Evaluation for vitamin D deficiency is recommended in IBD, and ensuring always an ade-744 
quate supply of calcium and vitamin D, especially in steroid-treated IBD patients.  Limitation 745 
of corticosteroid use helps to prevent low BMD. 746 
 747 
 748 
Are there subgroups of patients with Crohn's disease who are at particular risk of fat malab-749 
sorption?  750 
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Recommendation 12 A: 751 
CD patients treated with sequestrants such as colestyramine have minimal additional 752 
risk of fat malabsorption, and therefore do not need differences in nutrition therapy 753 
compared to other patients with Crohn's.  754 
Grade of recommendation GPP – consensus (86 % agreement) 755 
Recommendation 12 B: 756 
IBD patients with hyperoxaluria often also have fat malabsorption and these patients 757 
should be counselled regarding fat malabsorption. 758 
Grade of recommendation GPP – consensus (88 % agreement) 759 
Commentary: 760 
The common causes of bile acid malabsorption are ileal resection and inflammation of the 761 
terminal ileum, common in CD. Decreased reabsorption of conjugated gall bile acids leads to 762 
excess transmission to the colon, where deconjugation by bacteria occurs. Osmotic diar-763 
rhoea and (in severe bile acid malabsorption) fat malabsorption might be a consequence 764 
(91).  If mild, bile acid diarrhoea can be controlled by a sequestrant such as cholestyramine 765 
(119,120). In a double-blind cross-over study in 14 CD patients who had undergone ileal re-766 
section, no negative effect of colestyramine treatment on jejunal fat absorption was reported. 767 
In severe cases of bile acid malabsorption however, steatorrhoea may worsen as a result of 768 
colestyramine treatment (121).  769 
Enteric (secondary) hyperoxaluria (with increased risk of kidney stones) occurs in severe 770 
small bowel CD associated with fat malabsorption and a consecutive elevation of intestinal 771 
oxalate absorption.  Enteric hyperoxaluria may occur after ileal resection. Presence of the 772 
colon is an important factor, as oxalate remains available for colonic absorption because of 773 
concomitant fat malabsorption and its binding of calcium (122).  Urinary oxalate excretion 774 
correlates with fat excretion, as was shown in one study in CD patients undergoing intestinal 775 
resection. Increasing the dietary fat intake in these patients further increased urinary oxalate 776 
excretion (123). Significantly lower mean values of urinary oxalate excretion were found in 777 
paediatric than in adult Crohn’s patients (124). A reason for this may be the shorter history of 778 
CD, which usually also implies fewer bowel resections.  This implies that a diet low in fat and 779 
oxalate and high in calcium should be recommended in patients with hyperoxaluria.  Re-780 
striction of dietary oxalate (teas and fruits mainly) seems warranted only in those with recur-781 
ring urinary tract stones.   782 
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 783 
Are exclusion diets effective in achieving remission in active CD?  784 
Recommendation 13: 785 
Exclusion diets cannot be recommended to achieve remission in active CD, even if the 786 
patient suffers from individual intolerances.  787 
Grade of recommendation GPP – strong consensus (96 % agreement) 788 
Commentary: 789 
The systematic enquiry revealed insufficient evidence to make firm recommendations for 790 
exclusion diets as induction therapy. Exclusion diets have been described to alleviate symp-791 
toms (125), but only few studies reports induction of remission (95,126). In the open label 792 
study by Sigall-Boneh et al, 47 paediatric and adult CD patients received polymeric formula 793 
feed (50% of caloric intake) combined with an exclusion diet (no gluten, dairy products, glu-794 
ten-free baked goods and breads, animal fat, processed meats, products containing emulsi-795 
fiers, canned goods, and no packaged products). After 6 weeks, remission was obtained in 796 
70% of children and 69% of adults (95). Another uncontrolled study in only 6 paediatric pa-797 
tients with moderate-severe CD, using an elimination diet (free of dairy products, certain 798 
grains and carrageenan containing foods) together with nutraceuticals (consisting of fish pep-799 
tides, bovine colostrum, boswellia serrata, curcumin and a multivitamin) as well as Lactoba-800 
cillus GG, and also growth hormone (administered daily) showed induction of remission in all 801 
patients (126).   802 
In a randomised controlled trial, longer maintenance of remission (after successful induction 803 
of remission using elemental formula) was seen in patients using a stepwise dietary introduc-804 
tion programme excluding foods that worsened symptoms, compared to patients receiving 805 
corticosteroids on a tapering schedule while eating a normal diet (127). Similar results on 806 
maintenance of remission were reported in an open label study by the same group using a 807 
personal food exclusion diet (128). Another study reported maintenance of clinical remission 808 
using a IgG4 guided exclusion diet in adult CD patients (129).  809 
Exclusion diets are labour-intensive for staff, and complex, challenging and often unpleasant 810 
for patients. The systematic enquiry revealed no evidence that exclusion diets are hazardous 811 
when applied under medical supervision.  Evidence was not forthcoming to indicate that they 812 
contribute to nutritional deficiencies.  Nonetheless it is good practice to monitor carefully for 813 
deficiencies that might be predicted from any particular set of exclusions. 814 
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 815 
Is there evidence for a useful effect of probiotics in active IBD?  816 
Recommendation 14 A: 817 
Probiotic therapy using E. coli Nissle 1917 or VSL#3, but not necessarily other probi-818 
otics, can be considered for use in patients with mild to moderate UC for the induction 819 
of remission.  820 
Grade of recommendation 0 – strong consensus (92 % agreement) 821 
Recommendation 14 B: 822 
Probiotics should not be used for treatment of active CD.  823 
Grade of recommendation B – strong consensus (95 % agreement) 824 
Commentary: 825 
Two clinical trials in paediatric UC patients show a moderate effect of rectal enemas contain-826 
ing Lactobacillus reuteri in mild distal colitis (130) and of an oral preparation of VSL#3 in ac-827 
tive colitis (131). There are no specific data confirming harm, but lack of efficacy and the 828 
possible enhanced risks of and from bacteraemia in acute severe colitis lead the panel to 829 
advise against their use. 830 
The systematic enquiry indicated that probiotics were, in general, ineffective in active CD. 831 
Not a single RCT has been performed using probiotics as induction treatment in paediatric 832 
CD. As stated in the recent ECCO/ESPGHAN guidelines on paediatric CD, probiotics are 833 
also not recommended for maintenance of remission (132).  It is possible that probiotics oth-834 
er than those studied or optimised doses and periods of treatment might have more useful 835 
effects, but the panel recommended that they should not be used.  There are some positive 836 
data in respect of the use of Lactobacillus GG in maintenance in children with CD (133). 837 
838 
  29 
III. Artificial nutrition in active IBD 839 
Is supportive nutritional therapy (ONS, EN or PN) indicated in patients with IBD?    840 
Recommendation 15 A: 841 
Oral Nutrition Supplements (ONS) are the first step when artificial nutrition is indicat-842 
ed in IBD, but generally are a minor supportive therapy used in addition to normal 843 
food.   844 
Grade of recommendation 0 – strong consensus (92 % agreement) 845 
Recommendation 15 B: 846 
If oral feeding is not sufficient then tube feeding should be considered as supportive 847 
therapy. Enteral feeding using formulas or liquids should always take preference over 848 
parenteral feeding, unless it is completely contraindicated.  849 
Grade of recommendation A – strong consensus (100 % agreement) 850 
Recommendation 15 C: 851 
PN is indicated in IBD (i) when oral or tube feeding is not sufficiently possible, (e.g. 852 
when the GI tract is dysfunctional or in CD patients with short bowel), (ii) when there 853 
is an obstructed bowel where there is no possibility of placement of a feeding tube 854 
beyond the obstruction or where this has failed, or (iii) when other complications oc-855 
cur such as an anastomotic leak or a high output intestinal fistula. 856 
Grade of recommendation B – strong consensus (96 % agreement) 857 
Commentary: 858 
The decision on the optimal route of artificial nutrition in IBD can be complex and involve 859 
several aspects, including the ability of the patient to eat, the absorptive capacity of the GI 860 
tract, the nutritional status of the patient, and the therapeutic goals (supportive care, treat-861 
ment of malnutrition, induction of remission, maintenance of remission).  The decision will 862 
also be influenced by the type of formula used in prior studies, and the dietary modulation of 863 
the intestinal immune response in IBD and its potential clinical implications. 864 
Oral Nutrition Supplements (ONS) are the first step but generally are but a minor supportive 865 
therapy used in addition to normal food.  By using ONS, a supplementary intake of up to 600 866 
kcal/day can be achieved without compromising normal food intake in adults.  Enteral feed-867 
ing using formulas or liquids should always take preference over parenteral feeding, unless it 868 
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is completely contraindicated. If oral feeding is not possible, feeding the patient through a 869 
nasogastric or nasoenteric tube should be considered. 870 
Enteral nutrition should be considered in patients with a functional gastrointestinal tract but 871 
who are unable to swallow safely (134,135).  In situations when the gut cannot absorb all 872 
nutritional needs, enteral nutrition should nonetheless be attempted with supplementary PN 873 
(78,136,137). 874 
PN is indicated when there is an obstructed bowel where there is no possibility of placement 875 
of a feeding tube beyond the obstruction or where this has failed.  It is required in patients 876 
with short bowel resulting in severe malabsorption of nutrients and/or fluid and electrolyte 877 
loss which cannot be managed enterally.  PN is also indicated in surgical cases as above, 878 
and in any patient who is intolerant of enteral nutrition or in whom nutrition cannot be main-879 
tained by the enteral route (138). However, it must be recognized that these patients in need 880 
of PN are those with the most complicated disease (139).  881 
 882 
Is primary nutritional therapy (EN or PN) effective in active CD?   883 
Recommendation 16: 884 
Exclusive EN is effective and is recommended as the first line of treatment to induce 885 
remission in children and adolescents with acute active CD.  886 
Grade of recommendation B – strong consensus (92 % agreement) 887 
Commentary: 888 
There are strong clinical impressions supported by trials deemed to be of poor quality that 889 
primary nutritional therapy is effective in the induction of remission and that the remission 890 
rates are reproducibly better than might be expected from a placebo response.  It is therefore 891 
recommended that primary nutritional therapy in the form of exclusive enteral nutrition (EEN) 892 
is considered in all patients with acute active CD and that this is a first choice in patients at 893 
high risk from alternative therapy such as steroids.  Old meta-analyses demonstrated that 894 
corticosteroids are better than EEN in induction of remission in adults.  The argument in fa-895 
vour of EEN is stronger in paediatric practice and will normally be the first choice in many 896 
centres.  Firstly, this is because of the deleterious effects of undernutrition on growth (45).  897 
Secondly, since growth is so essential in children, this increases the possibility of avoiding 898 
the use of steroids or delaying their introduction (140) which is of paramount importance.  899 
Third, and most importantly, is the observed effect on induction of remission in paediatric 900 
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studies demonstrating similar efficacy of steroids and EEN (141), and that in some settings 901 
(i.e. concomitant  immuno-modulatory treatment) EEN might even be superior to corticoster-902 
oids in children (142). However, these studies suffer from major methodological limitations 903 
including lack of proper randomization and retrospective analysis. Furthermore, most of the 904 
data relate to mild to moderate disease activity. 905 
Recommendations in children are made only for EEN as limited data suggest that partial 906 
enteral nutrition may be less effective than exclusive enteral nutrition (96), though one RCT 907 
showed similar efficacy (93). 908 
Commentary: 909 
The data are weaker for adult practice (143), and most centres will continue to use steroids 910 
(or biologicals) as first-line therapy unless these agents are actively contra-indicated.  How-911 
ever patient and disease characteristics also contribute to therapeutic management deci-912 
sions and these may make enteral nutritional therapy a first-line option also in selected cases 913 
of adults with acute CD (144). 914 
EN is preferred, because PN has not been shown to offer any advantage in CD, and should 915 
be used only to improve nutritional status for surgery and when other modes of nutrition are 916 
not possible (143). 917 
 918 
When EN is indicated in IBD what special technical steps are needed?  919 
Recommendation 17 A: 920 
For tube feeding in IBD, nasal tubes or percutaneous access can be used.  921 
Grade of recommendation B – strong consensus (96 % agreement) 922 
Recommendation 17 B: 923 
Tube feeding in CD should be administered via an enteral feeding pump. 924 
Grade of recommendation B – strong consensus (92 % agreement) 925 
Commentary: 926 
There are few reliable data on special steps or complications peculiar to patients with IBD.  927 
Reference can be made to general guidelines for nutrition support in severely malnourished 928 
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patients, in respect of both EN and PN.  Some features specific to IBD can nonetheless be 929 
summarised.   930 
Tube feeding can be safely delivered by nasogastric tube, or percutaneous endoscopic gas-931 
trostomy (145-147). Continuous tube feeding administered via an enteral feeding pump and 932 
increased slowly to the full prescribed volume appears to have lower complication rates than 933 
bolus delivery (145-148). The most frequent complications of EN are mechanical (tube-934 
related), then metabolic and infectious, but these are not notably different from those seen in 935 
other chronic conditions [148,149].   936 
Few patients with UC will need artificial feeding other than during the most severe exacerba-937 
tions and in the peri-operative phase.  Enteral nutrition is most appropriate and associated 938 
with significantly fewer complications than parenteral nutrition in acute colitis.  Bowel rest 939 
through intravenous nutrition does not alter the outcome, but nonetheless, there are no spe-940 
cific contraindications for the use of parenteral nutrition in UC.  941 
In CD nutritional support is more often needed. Specific micronutrient deficiency states are 942 
relatively common in CD; these should be sought (perhaps annually) and corrected as ap-943 
propriate – a need for supplementary iron (oral or intravenous) and for parenteral vitamin 944 
B12 being the most common.  945 
There is no specific contraindication to the use of parenteral nutrition in patients with CD in 946 
comparison to other diseases, and a central or peripheral route may be selected according to 947 
its expected duration.  There are not enough data to dictate the use of specific substrates in 948 
the composition of PN in CD.  PN must however be adjusted to fulfil the needs of the individ-949 
ual patient. This will reflect the extent of malabsorption, and enteric losses, and will influence 950 
the prescription of energy and amino acids, and especially of water, electrolytes and miner-951 
als.  Each PN cycle (usually nocturnal) should be complete and adjusted according to pro-952 
gress (eg through the number of cycles per week). PN, especially at home, should be viewed 953 
as complementary non-exclusive nutrition, which can be tapered to a minimal level when 954 
body composition has been sufficiently restored.  The most frequent complications of PN in 955 
IBD are infectious (catheter sepsis), metabolic and mechanical.  Specific attention should be 956 
paid to electrolyte supplementation (especially sodium and magnesium) in short bowel pa-957 
tients.  Again, these risks and precautions are not notably different from those seen in other 958 
chronic conditions.   959 
 960 
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Is there any advantage to particular formulations (eg polymeric vs oligomeric, fat content, 961 
nutraceuticals)?  962 
Recommendation 18 A: 963 
Standard EN (polymeric, moderate fat content, no particular supplements) can be em-964 
ployed for primary and supportive nutritional therapy in active IBD. 965 
Grade of recommendation 0 – strong consensus (96 % agreement) 966 
Recommendation 18 B: 967 
Specific formulations or substrates (e.g. glutamine, omega-3-fatty acids) are not rec-968 
ommended in use of EN or PN in IBD patients.  969 
Grade of recommendation B – strong consensus (96 % agreement) 970 
Commentary: 971 
Several studies have compared the efficacies of different types (elemental, semi-elemental, 972 
oligomeric or polymeric diets) of enteral formulas in the management of active CD. A 973 
Cochrane meta-analysis of ten trials showed no statistically significant difference between 974 
patients treated with elemental (n=188), and non-elemental diet (semi-elemental or polymeric 975 
diet; n=146) (150).  The protein composition did not appear to influence the therapeutic po-976 
tential of EN.  The present systematic enquiry reveals insufficient evidence to make firm rec-977 
ommendations [150,151].  It is therefore advised that standard feeds are employed if primary 978 
nutritional therapy is being employed.  There are hypothetical advantages from some 979 
amended formulations.  980 
Comparing one form of enteral nutrition to another has not shown any difference in effective-981 
ness for treating active CD, but a non-significant trend favouring low fat formulations has 982 
emerged [152-154).  Some centres may therefore wish to consider the use of feeds with low-983 
er fat content.   984 
The use of feeds supplemented with growth factors, ones with lower levels of emulsifying 985 
data, or oligomeric feeds, as alternatives to standard feeds, is not supported by reliable data 986 
(151,155,156). Equally there is no evidence that any of these alternatives is inferior to the 987 
use of standard polymeric feeds (97,157). 988 
There are not enough data to dictate the use of specific substrates in the composition of PN 989 
in CD.  PN must however be adjusted to fulfil the needs of the individual patient. This will 990 
reflect the extent of malabsorption, and enteric losses, and will influence the prescription of 991 
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energy and amino acids, and especially of water, electrolytes and minerals.  Each PN cycle 992 
(usually nocturnal) should be complete and adjusted according to progress (eg through the 993 
number of cycles per week). PN, especially at home, should be viewed as complementary 994 
non-exclusive nutrition, which can be tapered to a minimal level when body composition has 995 
been sufficiently restored (158-160).  The most frequent complications of PN in IBD are in-996 
fectious (catheter sepsis), metabolic and mechanical (161).  Specific attention should be paid 997 
to electrolyte supplementation (especially sodium and magnesium) in short bowel patients 998 
(159,160).  Again, these risks and precautions are not notably different from those seen in 999 
other chronic conditions.  1000 
 1001 
What nutritional recommendations exist for CD patients at risk of thromboembolism?  1002 
Recommendation 19: 1003 
In CD patients every effort should be made to avoid dehydration to minimize the risk 1004 
of thromboembolism.  1005 
Grade of recommendation GPP – strong consensus (100 % agreement) 1006 
Commentary: 1007 
Patients with IBD are at increased risk of venous thromboembolism. Thrombosis is a specific 1008 
feature of IBD that can be involved in both the occurrence of thromboembolic events and the 1009 
pathogenesis of the disease itself (162,163). The precise aetiology for the higher rates of 1010 
thromboembolism in IBD and the specific association is as yet unknown, but multiple ac-1011 
quired and inherited factors are implicated. The impact of inflammation on coagulation has 1012 
been confirmed by several experimental studies showing that inflammatory mechanisms shift 1013 
the haemostatic balance to favour the activation of coagulation which, in turn, can also sus-1014 
tain inflammation promoting a vicious circle between chronic inflammation and thrombosis. 1015 
Although there are insufficient data to mandate routine anticoagulation, this should be con-1016 
sidered in all IBD patients and especially those on PN, with every effort made to avoid dehy-1017 
dration (162-166).  1018 
 1019 
What nutritional recommendations exist for CD patients with fistulae?  1020 
Recommendation 20 A: 1021 
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CD patients with a distal (low ileal or colonic) fistula and low output can usually re-1022 
ceive all nutritional support via the enteral route (generally as food).   1023 
Grade of recommendation 0 – strong consensus (100 % agreement) 1024 
Recommendation 20 B: 1025 
CD patients with a proximal fistula and/or a very high output should receive nutritional 1026 
support by partial of exclusive PN.  1027 
Grade of recommendation B – strong consensus (96 % agreement) 1028 
Commentary: 1029 
Patients with CD are prone to fistulae formation between 2 intestinal sites or from intestine to 1030 
another organ (especially skin, bladder and vagina).  Most occur post-operatively.  It is 1031 
demonstrated that in surgical patients, early nutritional support, independently of the route of 1032 
administration, decreases the occurrence and severity of fistulae (144,167,168).  Malnutrition 1033 
with BMI <20 appears as an independent risk factor that should be confirmed in further stud-1034 
ies (169).  1035 
Treatment of intestinal fistulae is usually complex, depending on the location, scale and the 1036 
nature of the symptoms, and warrants the input of a multidisciplinary team including gastro-1037 
enterologist, surgeon and dietician (168). Treatment will often need to be surgical but some 1038 
patients clearly benefit from drug treatment with immunomodulators or/and biologics 1039 
(170,171).  Once a fistula is mature and there is no longer any possibility of a free communi-1040 
cation with the peritoneal space, there ceases to be any contraindication to enteral nutrition.  1041 
Indeed in the patient with a distal (low ileal or colonic) fistula it may be possible to provide all 1042 
necessary nutritional support via the enteral route (170,172,173).  In the patient with a proxi-1043 
mal fistula and/or a very high output it may be preferable to manage the situation with a rest-1044 
ed gut and full PN (174,175), but even then the psychological benefit of eating may warrant 1045 
its inclusion in the nutritional regimen despite minimal expectations of useful nutrient absorp-1046 
tion (172).  Surgical correction is more likely to be successful if nutritional status has been 1047 
optimised pre-operatively (176). 1048 
 1049 
What are the nutritional recommendations for CD patients at risk for refeeding syndrome? 1050 
Recommendation 21: 1051 
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In CD patients in whom nutritional deprivation has extended over many days, standard 1052 
precautions and interventions to prevent refeeding syndrome are mandatory, particu-1053 
larly with respect to phosphate and thiamine.  1054 
Grade of recommendation B – strong consensus (100 % agreement) 1055 
Commentary: 1056 
Refeeding syndrome should not be a problem in the well-managed patient with IBD but 1057 
nonetheless it is not unusual to encounter patients in whom nutritional deprivation has ex-1058 
tended over many days and in whom this hot issue is pertinent.  Standard precautions and 1059 
interventions are mandatory in these high-risk patients particularly in respect of phosphate 1060 
and thiamine (177-179). 1061 
 1062 
Are there special indications for artificial nutrition in UC? 1063 
Recommendation 22 A: 1064 
EN appears safe and can be recommended as supportive therapy according to stand-1065 
ard nutritional practice in patients with severe UC. 1066 
Grade of recommendation GPP – strong consensus (100 % agreement) 1067 
Recommendation 22 B: 1068 
PN should not be used in UC unless intestinal failure occurs.  1069 
Grade of recommendation 0 – consensus (88 % agreement) 1070 
Commentary: 1071 
The systematic enquiry demonstrated evidence in favour of the use of probiotics in induction 1072 
of remission and in maintenance of UC – see elsewhere in this document. 1073 
Despite early indications that omega-3 fatty acid supplementation contributed beneficially in 1074 
induction and maintenance the systematic enquiry documented an absence of effect from a 1075 
diet supplemented by omega-3 fats in patients with UC in the maintenance of remission 1076 
(180-185).  This is therefore not advised. 1077 
The above data were obtained in adults.  It appears reasonable and safe to extrapolate the 1078 
conclusions and suggested actions on omega-3 fats into paediatric practice. 1079 
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Literature analysis otherwise yielded insufficient evidence to make firm recommendations.  1080 
There are few aspects in which the presence of UC alters conventional management in any 1081 
important way (186).  It is therefore advised that standard nutritional practice is followed in 1082 
patients with UC, giving due attention to nutrition screening and to generic nutritional support 1083 
where needed. 1084 
Enteral nutrition has not been adequately evaluated in active UC.  However it appears safe 1085 
and can be nutritionally adequate in patients with severe disease [186].  Its efficacy needs to 1086 
be tested by additional studies in larger cohorts of patients.   1087 
PN is recommended in malnourished patients with UC and in those with severe disease, only 1088 
when they not able to tolerate enteral feeding, or cannot be fed effectively by either mouth or 1089 
enteric tube [139,186-188). 1090 
1091 
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IV. Surgical aspects of nutrition in IBD 1092 
ESPEN has produced guidance on nutrition in the surgical patient and most of the principles 1093 
apply equally to the IBD patient undergoing surgical intervention. Briefly, the following guid-1094 
ance should be followed during the perioperative period. 1095 
How should nutritional support be performed in the preoperative phase?  1096 
Recommendation 23 A: 1097 
In most elective surgery cases, pre-operative fasting from midnight should not be per-1098 
formed – instead, an enhanced recovery (ERAS) protocol can be used.  1099 
Grade of recommendation B, see Surgery guidelines – strong consensus (100 % 1100 
agreement) 1101 
Commentary: 1102 
It is inappropriate to replicate detailed analysis of ESPEN’s Surgery Guidelines but brief 1103 
comments are offered here to help in the specific case of patients having surgery for IBD. 1104 
Protocols for enhanced recovery after surgery (ERAS) aim to accelerate rehabilitation includ-1105 
ing a desirable reduction of length of hospital stay. Functional recovery is considered the 1106 
most important target (189-193).  From a metabolic and nutritional point of view, therefore, 1107 
the key aspects of perioperative care include:  1108 
 avoidance of long periods of pre- operative fasting  1109 
 re-establishment of oral feeding as early as possible after surgery  1110 
 integration of nutrition into the overall management of the patient  1111 
 metabolic control eg of blood glucose  1112 
 Reduction of factors which exacerbate stress related catabolism or impair GI function  1113 
 Early mobilisation to facilitate protein synthesis and muscle function. 1114 
 1115 
 1116 
 1117 
Recommendation 23 B: 1118 
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In emergency surgery patients artificial nutrition (EN, PN) should be initiated if the 1119 
patient is malnourished at the time of surgery or if oral diet cannot be recommenced 1120 
within 7 days after surgery.  1121 
Grade of recommendation B, see Surgery guidelines – consensus (88 % agreement)  1122 
Commentary: 1123 
Nutritional support is indicated in patients with malnutrition and even in patients with-1124 
out significant malnutrition, if it is anticipated that the patient will be unable to eat for more 1125 
than seven days perioperatively. It is also indicated in patients who cannot maintain oral in-1126 
take above 60-75% of recommended intake for more than ten days. In these situations, it is 1127 
recommended to initiate nutritional support (preferably by the enteral route) without delay.  1128 
The influence of nutritional status on postoperative morbidity and mortality has been well 1129 
documented in both retrospective (194-198) and prospective studies (199-206). It is clear 1130 
that inadequate oral intake for more than 14 days is associated with a higher mortality (207).  1131 
The general indications for nutritional support in surgery are in the prevention and treatment 1132 
of undernutrition, ie the correction of undernutrition before surgery and the maintenance of 1133 
nutritional status after surgery, when periods of prolonged fasting and/or severe catabolism 1134 
are expected.[ESPEN Guidelines for Surgery] 1135 
 1136 
Which nutritional strategies need to be considered in the perioperative phase?  1137 
Recommendation 24 A: 1138 
Patients who do not meet their energy and/or protein needs from normal food should 1139 
be encouraged to take oral nutritional supplements (ONS) during the perioperative 1140 
period.  1141 
Grade of recommendation B – strong consensus (100 % agreement) 1142 
Recommendation 24 B: 1143 
Patients who do not meet their energy and/or protein needs from normal food plus 1144 
ONS should receive EN during the perioperative period.   1145 
Grade of recommendation B – strong consensus (100 % agreement) 1146 
Recommendation 24 C: 1147 
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If malnutrition is diagnosed, then IBD surgery should be delayed for 7–14 days when-1148 
ever possible, and that time should be used for intensive artificial feeding.  1149 
Grade of recommendation A, see Surgery guideline – strong consensus (96 % agree-1150 
ment) 1151 
Commentary: 1152 
A: Insufficient preoperative intake is an indication for dietary counselling or ONS, because as 1153 
Kuppinger et al (208) showed for patients undergoing abdominal surgery, lower food intake 1154 
before hospital admission is an independent risk factor for postoperative complications. 1155 
Twenty-four trials on the use of ONS and tube feeding (TF) have reported significant ad-1156 
vantages from EN with particular regard to the reduction of infectious complications, length of 1157 
hospital stay and costs.  1158 
In six randomised controlled trials postoperative and post-hospital administration of ONS has 1159 
been investigated (209-213). The available data do not show with certainty that routine ad-1160 
ministration improves outcome, but they do show benefit in terms of nutritional status, rate of 1161 
minor complications, well-being and quality of life in patients who cannot meet their nutrition-1162 
al requirements at home from normal food. 1163 
B: As stated above, insufficient preoperative intake affects complication rates. Therefore, if 1164 
the oral intake is inadequate, regardless of the intervention (dietary counselling and/or ONS), 1165 
tube feeding (TF) should be initiated (ESPEN Guidelines: Surgery).  Postoperatively, TF 1166 
should be continued/started as many studies have shown the benefits and feasibility of feed-1167 
ing via a tube either inserted distal to the anastomosis, eg needle catheter jejunostomy, or 1168 
inserted via the nose with its tip passed distally at the time of operation (nasojejunal tube) 1169 
(214-219). 1170 
C: Undernutrition has a negative impact on the clinical course, the rate of postoperative 1171 
complications and on mortality (196,220-224). Therefore patients with severe nutritional risk 1172 
will benefit from nutritional therapy prior to major surgery even if surgery has to be delayed. 1173 
“Severe” nutritional risk has been defined by an ESPEN working group (2006) as the pres-1174 
ence of at least one of the following criteria: 1175 
 Weight loss > 10-15% within 6 months  1176 
 BMI < 18.5 kg/m2 1177 
 Serum albumin < 30g/l (with no evidence of hepatic or renal dysfunction)  1178 
These parameters reflect undernutrition as well as disease-associated catabolism. 1179 
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Enteral nutrition with either ONS or TF is always preferred in such situations. Only if the GI 1180 
tract is dysfunctional should PN be used.  1181 
In the case of an emergency, such as a completely obstructing lesion, uncontrolled bleeding, 1182 
toxic megacolon or an acute abdomen, surgery should not be postponed. In those cases EN 1183 
or PN starts postoperatively.  1184 
 1185 
When should parenteral nutrition be used in the perioperative phase? 1186 
Recommendation 25 A: 1187 
EN should always be preferred over the parenteral route, but combinations of EN and 1188 
PN should be considered in patients in whom there is an indication for nutritional 1189 
support and in whom >60% of energy needs cannot be met via the enteral route.   1190 
Grade of recommendation A, see ESPEN Surgery Guideline – strong consensus (100 1191 
% agreement) 1192 
Recommendation 25 B: 1193 
PN in the perioperative period in IBD patients should be usually used as supplemen-1194 
tary to EN 1195 
Grade of recommendation B – strong  consensus (96 % agreement) 1196 
Recommendation 25 C: 1197 
PN shall be used as the only intervention if EN is impossible (absence of access, se-1198 
vere vomiting or diarrhoea) or contraindicated (intestinal obstructions or ileus, severe 1199 
shock, intestinal ischaemia).  1200 
Grade of recommendation A – strong consensus (96 % agreement) 1201 
Commentary: 1202 
The enteral route should always be preferred except when one or more of the following con-1203 
traindications exists [ESPEN Guidelines for Surgery 2016, manuscript in preparation]: 1204 
 Intestinal obstructions or ileus,  1205 
 Severe shock  1206 
 Intestinal ischaemia 1207 
 High output fistula 1208 
  42 
 Severe intestinal haemorrhage 1209 
In those cases parenteral nutrition may be needed for a period of days or weeks until the 1210 
function of gastrointestinal tract returns. 1211 
As in other vulnerable surgical patients, nutritional support (by the enteral route if possible) 1212 
should be instituted without delay even in patients without obvious undernutrition if it is antic-1213 
ipated that the patient will be unable to eat for more than 7 days peri-operatively and in pa-1214 
tients who cannot maintain oral intake above 60% of their recommended intake for more than 1215 
10 days.  1216 
The enteral route should always be preferred over parenteral nutrition, but combinations of 1217 
enteral and parenteral nutrition (PN) should be considered in patients in whom there is an 1218 
indication for nutritional support and in whom >60% of energy needs cannot be met via the 1219 
enteral route.   1220 
Combined enteral/parenteral nutrition has not yet been evaluated in prospectively controlled 1221 
clinical trials with patients undergoing elective surgery. The only studies available are those 1222 
of Heyland et al. and Dhaliwal et al., which analysed the studies carried out on critically ill 1223 
patients (225,226). Unfortunately, those studies come from the same authors and contain 1224 
those same patients to approximately 80%. Nonetheless, as inadequate oral intake for more 1225 
than 14 days is associated with a higher mortality (207) the proper provision of nutrients must 1226 
be ensured.  1227 
 1228 
Are particular nutritional strategies required in CD patients during the perioperative phase?  1229 
Recommendation 26 A: 1230 
Surgical patients with CD should obtain early nutritional support, because, inde-1231 
pendently of the route of administration, it decreases the risk of postoperative compli-1232 
cations.  1233 
Grade of recommendation B – strong consensus (100 % agreement) 1234 
Commentary: 1235 
The advantages of early enteral nutrition within 24 hours of surgery versus later commence-1236 
ment have been shown in two meta-analyses (one Cochrane systematic review)  (226,227). 1237 
Recommendation 26 B: 1238 
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In CD patients with prolonged gastrointestinal failure (such as patients in whom resec-1239 
tion has created a short bowel) PN is mandatory and life-saving at least in the early 1240 
stages of intestinal failure.  1241 
Grade of recommendation B, see Surgery guidelines – strong consensus (92 % 1242 
agreement) 1243 
Commentary: 1244 
Intestinal failure (IF) has been defined from reduction in gut function below the minimum 1245 
necessary for the absorption of macronutrients and/or water and electrolytes, such that intra-1246 
venous supplementation is required to maintain health and/or growth (102). 1247 
Although enteral nutrition has proven to be the most beneficial in almost all patient popula-1248 
tions, it is relatively rare that it is sufficient in AIF/ ECF individuals because of the compro-1249 
mised integrity of the gastrointestinal tract. Therefore, parenteral nutrition often represents 1250 
the main option, alone or in association with EN (supplemental PN) (228). 1251 
Moreover, many authors have pointed out the possible advantages of PN when there is a 1252 
limited tolerance of enteral nutrition due to intestinal dysfunction especially in the early post-1253 
operative phase, which is associated with a lower energy intake (229). 1254 
 1255 
How should nutritional support be performed in the postoperative phase?  1256 
Recommendation 27A: 1257 
Normal food intake or EN can be commenced early after surgery in most IBD patients 1258 
in the postoperative phase.  1259 
Grade of recommendation 0, see Surgery guideline – strong consensus (100 % 1260 
agreement) 1261 
Recommendation 27 B: 1262 
In the early phase after proctocolectomy or colectomy, water and electrolytes shall be 1263 
administered to assure haemodynamic stability.  1264 
Grade of recommendation A, see Surgery guideline – strong consensus (96 % agree-1265 
ment) 1266 
Commentary: 1267 
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As stated in the Surgical Guidelines, early normal food or EN, including clear liquids on the 1268 
first or second postoperative day, does not cause impairment of healing of anastomoses in 1269 
the colon or rectum (230-233) and leads to significantly shortened hospital length of stay 1270 
(234). This has been emphasized by a Cochrane Systematic Review (226).  Recent meta-1271 
analyses (227,235,236) showed significant benefits with regard to postoperative recovery 1272 
and infection rate.  Early postoperative nutrition is associated with significant reductions in 1273 
total complications compared with traditional postoperative feeding practices and does not 1274 
negatively affect outcome such as mortality: anastomotic dehiscence, resumption of bowel 1275 
function, or hospital length of stay (236).  1276 
 1277 
1278 
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V. Dietetic recommendations during remission 1279 
What is the role of dieticians for IBD patients?  1280 
Recommendation 28: 1281 
All IBD patients in remission should undergo counselling by a dietician as part of the 1282 
multidisciplinary approach to improve nutritional therapy and to avoid malnutrition 1283 
and nutrition-related disorders. 1284 
Grade of recommendation GPP – strong consensus (100 % agreement) 1285 
Commentary: 1286 
There are very limited original data in this area, but at least 9 papers include statements indi-1287 
cating that the input of a dietician is likely to be helpful in IBD management in adults and 1288 
children; the evidence base is poor.  Nutritional deficiencies are self-evidently more likely in 1289 
patients with CD affecting the small bowel than in those with isolated colonic disease or UC, 1290 
but the latter groups are not immune (172).  Nutritional screening has been adopted as a 1291 
mandatory component of gastrointestinal management in many European countries, and it is 1292 
further recommended that all IBD patients have access to a dietician with a specialist interest 1293 
in IBD.  In gastrointestinal cancer studies it appears that the input of a dietician and specific 1294 
dietary counselling is at least as valuable as nutrient supplement prescription (237) and a 1295 
single incompletely controlled study in CD (238) supports the extrapolation of this finding to 1296 
IBD practice.  We therefore recommend specialist dietary counselling for all IBD patients in 1297 
remission in order to improve any nutritional therapy offered and to help to avoid malnutrition 1298 
and nutrition-related disorders. 1299 
In general, no specific diet needs to be followed during remission phases. None of the alter-1300 
native diets or semi-exclusive diets seems effective in obtaining remission. However, individ-1301 
ual food intolerances are frequently seen in IBD patients, lactose and dairy products, spices, 1302 
herbs, fried, gas-generating and fibre rich products are often poorly tolerated (239-242).  Ac-1303 
quired lactase deficiency (usually in patients with proximal Crohn's) will also warrant a lac-1304 
tose-restricted diet.   1305 
 1306 
Are exclusion diets effective in maintaining remission in IBD?  1307 
Recommendation 29: 1308 
No specific diet needs to be followed during remission phases of IBD.  1309 
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Grade of recommendation 0 – strong consensus (96 % agreement) 1310 
Commentary: 1311 
There is now a substantial but mostly low quality literature which addresses diet in IBD.  1312 
Patients with CD typically select a diet low in fibre and vegetables, and often one which is 1313 
hypocaloric and associated with multiple micronutrient deficiencies (77).  Acquired lactase 1314 
deficiency is particularly prevalent in patients with proximal Crohn's and will warrant a lac-1315 
tose-restricted diet.  Specific exclusion diets have been considered to have good effects by 1316 
their protagonists, but for best results it is proposed that the diets should be customised to 1317 
avoid the patients’ individual food intolerances.  This strategy then makes it difficult to gener-1318 
alise and there are no recent trials of exclusion diets.  Limited controlled data support the 1319 
elimination of lactose, dairy products in general, spices, herbs, fried foods, gas-generating 1320 
and fibre-rich products, but only when they are poorly tolerated. Their removal is then proba-1321 
bly helpful in prolonging remission (243).  Other studies of reasonable quality have also in-1322 
cluded dietary manipulations, but alongside the use of nutritional supplements; these studies 1323 
are addressed in later sections.  The use of an exclusive enteral nutritional regimen is clearly 1324 
an extreme form of dietary exclusion.  1325 
Manipulation of the food in the diet has arguably been better studied in UC, but still in studies 1326 
of relatively low quality.  In UC there is a general and statistically significant tendency for pa-1327 
tients in remission to eat less dietary fibre, fewer vegetables and more fat than control popu-1328 
lations (244,245).  Cohort studies suggest that those who habitually consume more meat and 1329 
alcohol have a higher relapse rate (246).  Elimination of cows’ milk protein in unselected chil-1330 
dren with colitis is ineffective (247).  Conventional advice on healthy eating is therefore ap-1331 
propriate for patients with UC. 1332 
In summary, no specific diet needs to be routinely followed during remission phases of IBD. 1333 
None of the alternative diets or semi-exclusive diets seems uniformly effective in maintaining 1334 
remission.  General advice on healthy eating can be given to patients with UC and Crohn’s, 1335 
probably aiming for a Mediterranean-style diet rich in fruit and vegetable fibre unless there 1336 
are known strictures; even small amounts of red wine may be permitted (248)! 1337 
There is some evidence that enteral nutrition may reduce the relapse rate of patients with CD 1338 
in remission but not sufficient to warrant a recommendation.  1339 
Enteral feeding has been thought to have a role in preventing relapse in children with inactive 1340 
CD (136,150,152,249) but the effect has also been observed in a Japanese study of adult 1341 
Crohn's patient (153,154,250).  Esaki et al (251) considered from their trial of 145 patients 1342 
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with Crohn's (mostly induced into remission with TPN) that, under maintenance with ele-1343 
mental/polymeric nutrition, the risk of recurrence was lower in those with small bowel rather 1344 
than large bowel involvement.  However the present systematic enquiry has indicated that 1345 
overall the use of elemental enteral feeding is ineffective in maintaining remission in CD.  1346 
This is therefore due for a verdict of not recommended.  The panel considers this a contro-1347 
versial conclusion, especially in view of a previous Cochrane evaluation which considered 1348 
that ongoing EN may help maintenance of remission and reduce use of corticosteroids in CD 1349 
(145,251).  No recommendation is therefore made.  1350 
Enteral nutrition may be used as an adjunct to other treatments. Tanaka et al and Yamamoto 1351 
et al in their prospective studies showed that there appeared to be a higher rate of remission 1352 
with infliximab in those patients receiving concurrent enteral nutrition, and that relapse rates 1353 
were lower in those groups (153,154).  This conclusion could not be supported by the sys-1354 
tematic review and should be considered unproven.  No recommendation is therefore given. 1355 
 1356 
Do omega-3 fatty acids prevent relapse in IBD?  1357 
Recommendation 30: 1358 
Supplementation with omega-3 fatty acids should not be advised to support mainte-1359 
nance of remission in patients with IBD.   1360 
Grade of recommendation B – strong consensus (100 % agreement) 1361 
Commentary: 1362 
Once laboratory-based studies, case reports and informal reviews are excluded there are 19 1363 
papers for consideration.  Strikingly there are more systematic reviews than original papers 1364 
on the clinical effects of omega-3 fatty acids.  1365 
In UC in remission the actuarial relapse-free survival was significantly improved by n-3 fatty 1366 
acids in the 2nd and 3rd months of a 2 year study, but the effect was then lost and the cumula-1367 
tive relapse rate at 2 years was not different from those taking placebo (184).  Similar nega-1368 
tive results came from a 12 month study of a cocktail of gamma-linolenic acid, eicosapentae-1369 
noic acid and docosahexaenoic acid, in which there were numerically more relapses in the 1370 
actively treated group (185).  Systematic reviews have reached the conclusion that supple-1371 
menting the diet with omega-3 fats is ineffective in the maintenance of remission of patients 1372 
with UC (252,253).  This is therefore not advised.   1373 
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The above data were obtained in adults.  It appears reasonable to extrapolate the conclu-1374 
sions into paediatric practice. 1375 
In an early Italian double-blind, placebo-controlled study of fish-oil in the maintenance of re-1376 
mission in CD there was a statistically significant advantage to the actively treated group with 1377 
sustained remission at 1 year of 59% against 26% in the controls (254).  No effect was how-1378 
ever seen in a contemporary study performed in Germany in which the relapse rate was 70% 1379 
in both groups (255).  EPIC-1 and EPIC-2, the most substantial studies to date compared 4 1380 
g/d of omega-3 free fatty acids to placebo for a year (256).  The relapse rates were 32% (EP-1381 
IC-1) and 48% (EPIC-2) in patients who received omega-3 free fatty acids, and 36% and 1382 
49% respectively in those who received placebo; these differences were distant from statisti-1383 
cal significance.    1384 
In children a 12 month study of eicosapentaenoic acid and docosahexaenoic acid used olive 1385 
oil as a placebo (257).  There was a significant advantage in relapse rate in the fish oil-1386 
treated group, but this has not been thought of sufficient weight to influence general paediat-1387 
ric practice (252,253). 1388 
The latest Cochrane review (258) has concluded that omega 3 fatty acids are probably inef-1389 
fective for maintenance of remission in CD.   1390 
In summary, at present there is insufficient evidence to justify the prescription of omega-3 1391 
fatty acids in the remission phase of CD either in adults or children and this is accordingly not 1392 
recommended. 1393 
 1394 
Is there evidence for fibre in preventing relapse of active IBD?  1395 
Recommendation 31: 1396 
Non-specific high fibre diets should not normally be recommended for maintenance of 1397 
remission in IBD.  1398 
Grade of recommendation 0 – strong consensus (96 % agreement) 1399 
Commentary: 1400 
The use of a non-specific high fibre diet in CD was found to be ineffective.  This is therefore 1401 
not generally recommended.  Much of the recent literature however relates to the effects of 1402 
specific agents chosen as prebiotics and these are not considered here, but it is recognised 1403 
that many forms of fibre will have an important effect on the gut microbiota and thus possibly 1404 
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on the maintenance of remission in IBD.  It is generally agreed that dietary fibre is unwise in 1405 
patients known to have intestinal structuring (GPP), but the evolving literature suggests that 1406 
prebiotic fibres may be useful in maintenance of remission in some patients with UC.    1407 
Several small controlled studies have shown apparent benefit from the addition of fibre to the 1408 
diet of patients with UC (259-261).  Given that the effects in maintaining remission were simi-1409 
lar for germinated barley, ispaghula husk and Plantago ovata seeds it may be reasonable to 1410 
conclude that this is a generic effect of increased dietary fibre.  The studies are not sufficient-1411 
ly robust to warrant general changes in practice, but increased amounts of fibre appear safe 1412 
in UC and allow a consistent message about healthy eating to be delivered to patients (see 1413 
section below).   1414 
Fibre is more often relatively contra-indicated in CD because of the presence of strictures, 1415 
and fibre in the form of the prebiotic fructo-oligosaccharide is apparently ineffective in CD 1416 
(90).  However, in a loosely controlled study of wheat fibre supplementation the supplement-1417 
ed patients did better in respect of quality of life and had no apparent adverse events (262).  1418 
There is another recent study of fibre supplementation that also claims benefit, and this was 1419 
through the uncontrolled use of an ovo-vegetarian diet with over 30g of fibre for every 1420 
2000kcal.  Maintenance of remission to 1 year was a remarkable 92% (263).  On balance, 1421 
additional fibre will not be offered to patients with CD on this evidence, but it seems that veg-1422 
etable fibre need not be discouraged in the majority of patients. 1423 
 1424 
Is there evidence for probiotics in preventing relapse in IBD? 1425 
Recommendation 32 A: 1426 
Probiotic therapy should be considered for the maintenance of remission in ulcerative 1427 
colitis.   1428 
Grade of recommendation B - strong consensus (96 % agreement) 1429 
Recommendation 32 B: 1430 
Probiotic therapy should not be used for maintenance of remission in CD. 1431 
Grade of recommendation 0 - strong consensus (100 % agreement) 1432 
Commentary: 1433 
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This question explores the role of probiotics to maintain remission and therefore prevent re-1434 
lapse in patients who have quiescent disease. See above (QUESTION 14) for the role of 1435 
probiotics in inducing remission. There is considerable heterogeneity in probiotics studied 1436 
which hinders analysis however some more frequently studied preparations have demon-1437 
strated consistent results.  1438 
E. coli Nissle 1917 and VSL#3 have benefit, supported by meta-analysis (264) in the main-1439 
tainance of remission in patients – including children - with mild to moderate UC, in compari-1440 
son to 5-aminosalicylate compounds (131,265,266). Other probiotic preparations have been 1441 
studied but although they have usually been well tolerated with trends toward benefit, signifi-1442 
cant effectiveness has not been demonstrated (267,268).  A cautionary note exists for Lacto-1443 
bacillus rhamnosus GG; case reports in both children and adults describe bacteraemia with 1444 
the administered probiotic in patients with acute severe colitis (269,270).  1445 
Probiotics are probably ineffective in preventing disease recurrence for patients with CD 1446 
(266).  Although some positive claims are made no unequivocal benefit can be discerned 1447 
(271-276). Probiotics are not currently recommended. 1448 
 1449 
Which probiotic/nutritional concept should be followed in pouch patients?  1450 
Recommendation 33 A: 1451 
Colectomized patient with a pouch and pouchitis should be treated with probiotics 1452 
such as VSL#3, if antibiotic treatment has failed.  1453 
Grade of recommendation B – strong consensus (96 % agreement) 1454 
Recommendation 33 B: 1455 
The probiotic mixture VSL#3 may be used for primary and secondary prevention of 1456 
pouchitis in patients with ulcerative colitis who have undergone colectomy and 1457 
pouch-anal anastomosis. 1458 
Grade of recommendation B – strong consensus (100 % agreement) 1459 
Commentary: 1460 
Some patients with UC have their colon and rectum removed with construction of a pouch 1461 
(made from a loop of small intestine) to serve in place of the rectum. This is known as ileal 1462 
pouch-anal anastomosis (IPAA) surgery. Pouchitis is inﬂammation of the surgically con-1463 
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structed pouch. Symptoms of active pouchitis include diarrhoea, increased stool frequency, 1464 
abdominal cramping, faecal urgency, tenesmus (feeling of constantly needing to pass 1465 
stools), and incontinence. Pouchitis occurs in approximately 50% of patients following IPAA 1466 
for chronic UC.  1467 
Food intolerance is a common, albeit mild, problem after ileal pouch-anal anastomosis (277). 1468 
Comparisons of the food consumption of patients without (n = 23) and with pouchitis (n = 45) 1469 
showed that the former consumed twice as many fruit servings as the latter (3.6 ± 4.1 serv-1470 
ings/d vs. 1.8 ± 1.7 servings/d, respectively, P < 0.05). In addition, the pouchitis patients 1471 
consumed significantly fewer liposoluble antioxidants, such as cryptoxanthin and lycopene, 1472 
and less vitamin A and vitamin C than the patients without pouchitis. Decreased consumption 1473 
of antioxidants by patients with pouchitis may expose them to the effects of inflammatory and 1474 
oxidative stress and contribute to the development of pouchitis (278). Inflammation is a con-1475 
stant finding in the ileal reservoir of patients with an ileal pouch-anal anastomosis and is as-1476 
sociated with decreased faecal concentrations of the short chain fatty acid butyrate, in-1477 
creased faecal pH, changes in faecal flora, and increased concentrations of secondary bile 1478 
acids.  A study has evaluated the effect of enteral supplementation of inulin on inflammation 1479 
of the ileal reservoir. Twenty patients received 24 g of inulin or placebo daily during three 1480 
weeks in a randomized, double blind, crossover design. Stools were analysed after each test 1481 
period for pH, short chain fatty acids, microflora, and bile acids. Inflammation was assessed 1482 
endoscopically, histologically, and clinically. Compared with placebo, three weeks of dietary 1483 
supplementation with 24 g of inulin increased butyrate concentrations, lowered pH, de-1484 
creased numbers of Bacteroides fragilis, and diminished concentrations of secondary bile 1485 
acids in faeces. This was endoscopically and histologically accompanied by a reduction of 1486 
inflammation of the mucosa of the ileal reservoir (279). 1487 
Antibiotics (ciprofloxacin, metronidazole) are the treatment of reference of acute pouchitis 1488 
(280). As faecal stasis with immunologic reactivity seems to be important in the pathogenesis 1489 
of pouchitis, several studies evaluated the effect of probiotics in chronic pouchitis and pre-1490 
vention of pouchitis (281).  1491 
Treatment of chronic pouchitis: Two double-blind placebo-controlled trials performed in 1492 
adults showed effectiveness of the probiotic mixture VSL#3 (the probiotic mixture VSL#3TM 1493 
contains 450 billion colony forming units of 8 lactic acid bacteria: B. breve, B. longum, B. in-1494 
fantis, L. acidophilus, L. casei, L. delbrueckii, L. plantarum and Streptococcus salivarius 1495 
subsp. thermophilus) in maintaining remission in patients with chronic pouchitis (282,283). A 1496 
pooled analysis of these two studies (76 participants) suggests that VSL#3 may be more 1497 
effective than placebo for maintenance of remission. Eighty-ﬁve per cent (34/40) of VLS#3 1498 
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patients maintained remission at 9 to 12 months compared to 3% (1/36) of placebo patients 1499 
(RR 20.24, 95% CI 4.28 to 95.81). A GRADE analysis indicated that the quality of evidence 1500 
supporting this outcome was low due to very sparse data (35 events) (280). In another study 1501 
(284) effects of VSL#3 were evaluated as an adjunctive to a standard therapy. A total of 144 1502 
consecutive patients were randomly treated for 8 weeks with VSL#3 at a dose of 3,600 billion 1503 
CFU/day (71 patients) or with placebo (73 patients). The decrease in UC disease activity 1504 
index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo 1505 
group (63.1 vs. 40.8; per protocol (PP) P=0.010, confidence interval (CI: 95%: 0.51-0.74; 1506 
intention to treat (ITT) P=0.031, CI: 0.47-0.69). Remission was higher in the VSL#3 group 1507 
than in the placebo group (47.7% vs. 32.4%; PP P=0.069, CI: 0.36-0.60; ITT P=0.132, CI: 1508 
0.33-0.56).  1509 
Prevention of pouchitis: The results of a small study (40 participants) suggest that VSL#3 1510 
may be more effective than placebo for prevention of pouchitis (285). Ninety per cent (18/20) 1511 
of VSL#3 patients had no episode of acute pouchitis during the 12 month study compared to 1512 
60% (12/20) of placebo patients (RR 1.50, 95% CI 1.02 to 2.21). A GRADE analysis indicat-1513 
ed that the quality of evidence supporting this outcome was low due to very sparse data (30 1514 
events). In contrast, in a 3-month double blind, placebo-controlled trial Lactobacillus rhamno-1515 
sus strain GG (two gelatine capsules/day of 0.5-1 x 1010 CFU/capsule) in patients with a 1516 
previous history of pouchitis showed that this probiotic was not effective in preventing relaps-1517 
es (286). 1518 
ECCO guidelines suggest the use of VSL#3 both for maintenance of antibiotic-induced re-1519 
mission and for prevention of pouchitis in adults (287) and in paediatric UC (288).  1520 
 1521 
Is artificial nutrition (ONS, EN, PN) effective in preventing relapse in IBD?  1522 
Recommendation 34 A: 1523 
Neither EN nor PN is recommended as primary therapy for maintaining remission in 1524 
IBD.    1525 
Grade of recommendation GPP – strong consensus (100 % agreement) 1526 
Recommendation 34 B: 1527 
ONS or EN can be recommended in patients with CD in remission, if undernutrition 1528 
cannot be treated sufficiently by dietary counselling. 1529 
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Grade of recommendation GPP – strong consensus (100 % agreement) 1530 
Commentary: 1531 
Nutritional support hasn’t been assessed as a maintenance therapy in UC, neither has PN in 1532 
CD. A recent systematic review of twelve randomized controlled trials and non-randomized 1533 
cohort studies (289) (1169 patients, including 95 children), most of good quality, showed that 1534 
maintenance EN was as or more effective than the comparator (standard diet, 5-ASA or aza-1535 
thioprine) in preventing CD relapses over periods of 6 months to 4 years. The study with the 1536 
lowest risk of bias compared supplemental (50%) EN with a regular diet in 51 adult CD pa-1537 
tients (155). Patients in each arm of the study were on similar medications (5-ASA or azathi-1538 
oprine). The study showed that in the EN group, 9 of 26 patients (34%) had a relapse during 1539 
a mean follow-up of 11.9 months, as compared with 16 of 25 patients (64%) in the non-EN 1540 
group (HR = 0.40; 95% CI: 0.16–0.98; P < .01). Hanai et al. (290) compared the effect of 6-1541 
mercaptopurine (6-MP), an elemental diet and no therapy in CD patients in remission. After 2 1542 
years, the clinical remission rates were 60, 47 and 27% for 6-MP, elemental diet and the con-1543 
trol group, respectively. The remission rates in the 6-MP and elemental diet groups were 1544 
significantly higher than in the control group, with no significant difference between the 6-MP 1545 
and the elemental diet group. A study from the UK found that supplemental elemental nutri-1546 
tion may only be useful in children not commencing azathioprine (291). Esaki et al (156) con-1547 
sidered from their trial of 145 patients with Crohn's (mostly induced into remission with TPN) 1548 
that, under maintenance with elemental/polymeric nutrition, the risk of recurrence was lower 1549 
in those with small bowel rather than large bowel involvement. Along with a lower risk of clin-1550 
ical relapse, studies have showed a negative effect of EN on endoscopic inflammation 1551 
scores and levels of pro-inflammatory cytokine (292). 1552 
The study of maintenance EN as an adjuvant to infliximab therapy has yielded conflicting 1553 
results, with one negative (154) and two positive (293,294) studies published so far. 1554 
Elemental formulae have been the most studied. A systematic review was unable to show 1555 
any significant difference in remission rate between elemental and polymeric formulae (295). 1556 
However, it found a lower adherence rate for elemental EN compared to an unrestricted diet, 1557 
as well as compared to a polymeric EN (RR = 0.68, 95% CI 0.50-0.92) (100). A low palatabil-1558 
ity (when EN is taken orally rather than via a NG tube) and higher cost may be responsible. 1559 
The European organizations for IBD and for paediatric gastroenterology and nutrition, ECCO 1560 
and ESPGHAN, have advised on the possible use of partial maintenance EN in patients with 1561 
very mild disease or a low risk of relapse, preferring polymeric feeds, with elemental feeds 1562 
being advised only in the case of allergy to cow’s milk proteins (132). 1563 
  54 
Due to the heterogeneity of published studies (children vs. adults, elemental vs. polymeric, 1564 
supplemental vs. exclusive, duration, outcome criteria), to the fact that most studies come 1565 
from a single country (Japan), and especially to the fact that most studies pre-date new 1566 
maintenance treatment modalities (dosage of azathioprine metabolites and circulating biolog-1567 
icals), the panel considers that EN should not be a first line maintenance therapy. However, 1568 
EN/ONS can be of interest for nutritional reasons, in the frequent cases of malnutrition or risk 1569 
of malnutrition in CD patients in remission. 1570 
 1571 
Is there any advantage to particular formulations (eg. polymeric vs oligomeric, or regarding 1572 
fat content or supplementation with nutriceuticals) in IBD patients in remission?  1573 
Recommendation 35: 1574 
Standard diet or ONS should be followed in patients with IBD in remission, giving at-1575 
tention to nutrition screening and generic nutritional support where needed. 1576 
Grade of recommendation: GPP – strong consensus (95 % agreement) 1577 
Commentary: 1578 
Few dietary supplementations have been tested in maintenance of remission in IBD patients 1579 
with clinical endpoints. An open label, parallel-group, multicentre, randomized clinical trial 1580 
demonstrated in 105 UC patients in remission that plantago ovata seeds (10 g twice daily) 1581 
were as efficient as mesalamine (500 mg thrice daily) in maintaining remission to 1 year 1582 
(260). A Cochrane systematic review has analysed 6 studies (1039 patients) of omega-3 1583 
fatty acid supplementation (258): there was a marginal significant benefit of n-3 therapy on 1584 
maintenance of remission. Thirty-nine per cent of patients in the n-3 group had relapsed by 1585 
12 months compared to 47% of placebo patients (6 studies, 1039 patients; RR 0.77, 95% CI 1586 
0.61 to 0.98). However, when the two largest studies at low risk of bias were considered 1587 
alone, the benefit was no longer statistically significant (2 studies, 738 patients; RR 0.88, 1588 
95% CI 0.74 to 1.05).  1589 
Elemental EN formulae have been the most studied in CD patients in remission. A systemat-1590 
ic review was unable to show any significant difference in remission rate between elemental 1591 
and polymeric formulae (295). However, it found a lower adherence rate for elemental EN 1592 
compared to an unrestricted diet, as well as compared to polymeric EN (RR = 0.68, 95% CI 1593 
0.50-0.92) (100). Lower palatability (when EN is taken orally rather than via a NG tube) and 1594 
higher cost to the patient may be responsible. 1595 
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Overall, the panel did not find enough evidence to make firm recommendations over and 1596 
above previous European recommendations (132,145). It is therefore advised that standard 1597 
practice is followed in patients with CD in remission. 1598 
 1599 
What are the indications for vitamin B12 therapy in CD?  1600 
Recommendation 36: 1601 
When more than 20 cm of distal ileum, whether or not in combination with the ileo-1602 
caecal valve, is resected, vitamin B12 shall be administered to patients with CD.  1603 
Grade of recommendation A – strong consensus (100 % agreement) 1604 
Commentary: 1605 
Vitamin B12 (cobalamin) is selectively absorbed in the distal ileum, bound with gastric-1606 
derived intrinsic factor. A recent systematic review has assessed the literature for preva-1607 
lence, risk factors, evaluation and management of vitamin B12 deficiency in IBD (296). Unre-1608 
sected UC does not predispose to low B12 levels or B12 deficiency. 1609 
The prevalence of B12 deficiency in CD ranges from 5.6 to 38%. Resection of more than 30 1610 
cm of distal ileum, whether or not in combination with the ileo-caecal valve, will put the pa-1611 
tient at risk for B12 deficiency. Resection of less than 20 cm does not normally cause defi-1612 
ciency (296a). 1613 
Ileal CD is not inevitably associated with B12 deficiency (297,298), but it is difficult to rule out 1614 
its responsibility when more than 30-60 cm are involved (296).  1615 
The diagnosis of biochemical B12 deficiency is based on the association between low serum 1616 
cobalamin levels (< 148 pM) and a functional biomarker such as homocysteine (> 15 µM) or 1617 
methylmalonic acid (> 270 µM). The diagnosis of clinical B12 deficiency further requires mac-1618 
rocytosis and/or neurological symptoms (296). 1619 
CD patients with ileal involvement and/or resection and/or clinical deficiency features should 1620 
be screened yearly for B12 deficiency (296). 1621 
Patients with clinical deficiency should receive 1000 µg of vitamin B12 by intramuscular in-1622 
jection every other day for a week and then every month for life (299). Patients with more 1623 
than 20 cm of ileum resected should receive 1000 µg of vitamin B12 prophylactically also 1624 
every month and indefinitely (299).  It is recognized that this is more frequently than the 3-1625 
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monthly injections typically advised in the past, but appears necessary to be sure to prevent 1626 
clinical manifestations of deficiency. 1627 
Oral therapy may be as effective, but is poorly explored in CD. A retrospective open-label 1628 
non-randomized study of 36 CD patients has showed the oral route (1200 µg per day for 33, 1629 
2400 µg per day for 3) to be effective in treating vitamin B12 deficiency (300). For now, par-1630 
enteral supplementation remains the reference, but oral supplementation may become 1631 
standard in the coming years. 1632 
 1633 
What are the indications for oral vitamin B9 / folic acid therapy in IBD?  1634 
Recommendation 37: 1635 
Selected IBD patients, e.g. those treated with sulphasalazine and methotrexate, should 1636 
be supplemented with vitamin B9 / folic acid.  1637 
Grade of recommendation B – strong consensus (100 % agreement) 1638 
Commentary: 1639 
A 2-year prospective Spanish study of 180 consecutive CD patient and 70 UC patients found 1640 
a prevalence of folate deficiency of 22.3% in CD patients, compared to 4.3% in UC (301). In 1641 
contrast, the systematic assessment of 37 children with newly-diagnosed IBD by teams in 1642 
the USA did not show any folate deficiency compared to controls (302). 1643 
There are several causes for folate deficiency in IBD: low intake, malabsorption, excess fo-1644 
late utilization due to mucosal inflammation and medications. A combination of these factors 1645 
may be responsible for the deficiency of this vitamin.  Distinction between North American 1646 
and European populations may also be explained by the supplementation of wheat with fo-1647 
late in the USA in attempts to prevent neural tube defects in unborn children. 1648 
Drugs are responsible for folate deficiency by inhibition of dihydrofolate reductase, an en-1649 
zyme that catalyses reduction of dihydrofolic acid to tetrahydrofolic acid (methotrexate) (303) 1650 
or folate malabsorption (sulphasalazine) (304). Azathioprine and 6-mercaptopurine also in-1651 
duce macrocytosis but through myelosuppressive activity. 1652 
A systematic review and meta-analysis of 10 studies reporting on 4517 patients found an 1653 
overall protective effect for folic acid supplementation on the development of colo-rectal can-1654 
cer (pooled HR = 0.58; 95% CI: 0.37-0.80) (305). 1655 
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An Italian study compared 1 month of supplementation with 15 mg of either folic or folinic 1656 
acid in 30 IBD patients treated with sulphasalazine (306). Both were able to restore the body 1657 
stores of folate, but folinic acid was more efficient. 1658 
The ECCO-ESPGHAN guidelines on the medical management of paediatric CD advise oral 1659 
administration of folate in patients on methotrexate, 5 mg once weekly 24–72 hours after the 1660 
methotrexate, or 1 mg daily for 5 days per week (132).   1661 
This panel recommends the same practice in adults. Furthermore, in patients with active dis-1662 
ease, the few who take sulphasalazine and those who develop macrocytosis should always 1663 
be tested for folate deficiency (serum and red blood cell concentrations). 1664 
 1665 
Are there special dietetic recommendations for pregnant and breastfeeding IBD patients?  1666 
Recommendation 38 A: 1667 
In IBD patients who are pregnant, iron status and folate levels should be monitored 1668 
regularly and in the case of deficiencies, iron and/or vitamin B9/folic acid should be 1669 
additionally supplemented.  1670 
Grade of recommendation: GPP – strong consensus (95 % agreement) 1671 
Recommendation 38 B: 1672 
In IBD patients who are breastfeeding, nutritional status should be monitored regular-1673 
ly and in case of deficiencies, they should be supplemented  1674 
Grade of recommendation: GPP – strong consensus (100 % agreement) 1675 
Commentary: 1676 
A US team collected national data from 4.21 million deliveries in 2005, including 2372 in CD 1677 
patients and 1368 in UC patients (307). Blood transfusions occurred more frequently in 1678 
women with CD (aOR, 2.82; 95% CI, 1.51–5.26), whereas protein-calorie malnutrition oc-1679 
curred more frequently both in women with CD (aOR, 20.0; 95% CI, 8.8–45.4) and with UC 1680 
(aOR, 60.8; 95% CI, 28.2–131.0). A further review has more recently been published which 1681 
also underlines the increased risks of nutritional deficiencies during pregnancy in IBD pa-1682 
tients (308). 1683 
The consequences of anaemia and those of neural tube defects (309), along with the fre-1684 
quent deficiencies in IBD patients warrant regular screening for iron and folate deficiencies, 1685 
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respectively, during pregnancy, along with nutritional follow-up.  Given the prior contact with 1686 
the patient and the likelihood that pregnancy will already have been discussed because of its 1687 
impact on the IBD, the opportunity should already have been taken to advise preconception 1688 
or very early post-conception supplementation with folate. 1689 
The panel agrees on the fact that any proven deficiency requires supplementation. 1690 
There is little information available that is specific to the situation of the woman with IBD who 1691 
is considering breastfeeding.  However there is no evidence of harm from the use of any nu-1692 
tritional intervention that is thought otherwise appropriate as part of the management of the 1693 
new mother.  The most important element from the infant’s point of view is that the milk do-1694 
nor is as healthy as possible (nugyen 2016).  No nutritional measures different from standard 1695 
practice are therefore recommended.  1696 
 1697 
What are the indications for physical activity in IBD?  1698 
Recommendation 39: 1699 
In all IBD patients, endurance training should be encouraged. In IBD patients with de-1700 
creased muscle mass and/or muscle performance, appropriate physical activity 1701 
should be recommended.  1702 
Grade of recommendation: GPP – strong consensus (95 % agreement) 1703 
Commentary: 1704 
The systematic review of 19 body composition studies reporting on 926 IBD patients (631 CD 1705 
and 295 UC) revealed a low fat-free mass in 28% of CD patients and in 13% of UC patients 1706 
(310). Low muscle mass (311,312), strength (135,311,313) and performance (313) have 1707 
been reported in adult IBD cohorts, but similar findings have also been made in children 1708 
(314). Sarcopenia was reported in 12% of 137 Australian IBD patients of mean age 31 years, 1709 
associated with osteopenia (311).  1710 
A US survey among 250 IBD patients reported that 16.4% never exercised, 32.8% exercised 1711 
1-2 times per week, 23.6% exercised 3-4 times per week, and 18.0% exercised more than 1712 
four times per week. Ninety-nine patients (44%) reported that their IBD limited their exercise 1713 
for reasons including fatigue (n = 81), joint pain (n = 37), embarrassment (n = 23), and 1714 
weakness (n = 21) (315). 1715 
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In a German study, 30 patients, aged 41 ± 14 years, with mild to moderate IBD were ran-1716 
domized to either supervised moderate-intensity running thrice a week for 10 weeks or to a 1717 
control group with no exercise. Health-related quality of life, reported as IBDQ total score, 1718 
improved by 19% in the intervention group and 8% in the control group, with significant dif-1719 
ferences for the IBDQ social sub-scale that was significantly improved in the intervention 1720 
group compared with controls (ΔIBDQsocial = 6.27 ± 5.46 vs. 1.87 ± 4.76, p = 0.023) (316). 1721 
Other studies were conducted in patients with a quiescent or moderately active disease and 1722 
mostly showed positive effects on quality of life, not on disease activity (317). Therefore, the 1723 
panel recommends endurance training (for a minimum of 30 minutes three times a week) in 1724 
all IBD patients. 1725 
The reference treatment for sarcopenia, along with maintaining an adequate protein intake, is 1726 
resistance training. This is what is advised in age-related sarcopenia (318). However, this 1727 
hasn’t been assessed in IBD patients. Still, the panel recommends prescribing resistance 1728 
training (weight-bearing exercises) in IBD patients with sarcopenia or features of sarcopenia 1729 
(reduced muscle mass, strength and/or performance). 1730 
 1731 
Are there special dietetic recommendations for obese IBD patients?  1732 
Recommendation 40: 1733 
Obese IBD patients should be advised to reduce weight only in phases of stable re-1734 
mission and then according to current obesity guidelines.  1735 
Grade of recommendation: GPP – strong consensus (100 % agreement) 1736 
Commentary: 1737 
Overweight and obesity are nowadays the most frequent nutritional disorder in IBD patients. 1738 
Their prevalence varies between countries, affecting 32.7% of 581 US adult IBD patients 1739 
(30.3% in CD patients and 35.2 in UC patients) (319) and 17% of 100 Irish adult CD patients 1740 
(320). A Polish retrospective study of 675 new paediatric IBD cases (368 CD, 307 UC) re-1741 
vealed higher BMI values in UC patients than in CD patients. The prevalence of overweight 1742 
and obesity was significantly higher in UC than in CD patients (4.89% CI95 2.76-7.93 vs. 1743 
2.45% CI95 1.12-4.59 and 8.47% CI95 5.61-12.16 vs. 1.9% CI95 0.77-3.88, respectively) 1744 
(321) 1745 
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The US study of 1494 IBD patients (31.5% obese) found an association between obesity and 1746 
its usual comorbidities, a poor quality of life and high CRP levels (322). However, obesity 1747 
was not associated with increased health care utilization or IBD-related surgery. 1748 
No intervention study has addressed the treatment of obesity in IBD patients. However, the 1749 
high prevalence of both micronutrient deficiencies (76) and sarcopenia (312), here indicating 1750 
sarcopenic obesity, indicates that the patient on a restrictive diet is at risk of further deficien-1751 
cies and muscle mass loss, especially in catabolic states such as those associated with IBD 1752 
flares. Therefore, the panel recommends against low-calorie diets in patients with active dis-1753 
ease, and recommends endurance training as the first step in any effort to lose weight. 1754 
1755 
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Discussion 1756 
The review panel and the other discussants do not hide their collective disappointment in the 1757 
results of the initial systematic review.  It has proved remarkably difficult to provide evidence-1758 
based and clinically useful conclusions.  Best evidence is gained from methodologically 1759 
sound, randomized controlled trials (RCTs).  It is more difficult to do such a trial of a nutri-1760 
tional intervention - where blinding is very challenging and placebo controls are impossible – 1761 
than with a new drug.  It is also difficult to make unique alterations in the dietary regimen 1762 
(reducing the proportion of one macronutrient will almost inevitably lead to an increase in 1763 
another).  The situation is further complicated by the rapid recent changes in the medical 1764 
management of IBD which might negate nutritional conclusions based on their effects on 1765 
patients managed in other respects in now-outdated fashion.  Moreover the decision to per-1766 
form an RCT may not follow the burden of disease, but be prompted by the evaluation of a 1767 
new product or mechanistic concept.  In nutrition this frequently leads to the situation that 1768 
relevant trials for important, clinical questions are missing partly because no sponsor can be 1769 
found.   1770 
One may interpret non-superiority as ineffectiveness, as was many times the conclusion of 1771 
the initial systematic review (for example the conclusion that elemental diet was ineffective in 1772 
inducing remission in CD).  This has made it difficult to provide clinically relevant recommen-1773 
dations.  An admitedly less rigorous approach permits the conclusion that there was no dif-1774 
ference between the use of polymeric and elemental formulae in children (185).  This inter-1775 
vention (polymeric vs elemental) is amenable to blinding, and indeed a recent blinded, ran-1776 
domised, controlled trial concluded that there was no difference in the rate of induction of 1777 
remission (93% with elemental and 79% with polymeric feeding) (93). We feel that the cor-1778 
rect conclusion here is that there is no major advantage in using a particular formula rather 1779 
than (as the meta-analysis would have it) that the treatment is ineffective because there was 1780 
no placebo arm. 1781 
It is acknowledged also that some of the recommendations are beyond the means of some 1782 
countries in Europe and of most of those in the developing world.  Average salaries below 1783 
250 euros per month do not permit what richer countries take for granted.  Hence the finan-1784 
cial aspects of applying artificial nutrition may become the sole responsibility of the patient 1785 
and family.  Furthermore it is common for there to be limited availability of nutritional products 1786 
(for example because only one of the supply companies is active in a given region, or be-1787 
cause a company chooses to restrict its offerings in a particular geographical zone).  Typical-1788 
ly the more patient-friendly preparations are most vulnerable to this sort of restrictive prac-1789 
tice.  1790 
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Even the most economical formulations of parenteral nutrition are still more than 40 euros 1791 
per bag. While it may be possible on life or death grounds to obtain this in hospital it is not 1792 
unusual for less-informed governmental bodies to obstruct this; it is common for home paren-1793 
teral nutrition to be unobtainable.   1794 
Creative adaptation of the advice given here will therefore sometimes be necessary. 1795 
We have tried to address each of these difficult areas and hope our Guideline indicates 1796 
clearly where the interpretations are ours and based on a less than secure evidence base. 1797 
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Appendix A 
PubMed search terms for the PICO questions (undertaken after the initial systematic review 
by the Cochrane Centre) 
PICO 1 
(Diet OR nutrition OR food) AND (Crohn OR colitis OR IBD) AND (Etiology OR incidence) 
PICO 2 
Breastfeeding AND (Crohn or colitis or IBD) 
PICO 3 
((((Crohn$) OR Ulcerative Colitis) OR Inflammatory Bowel Disease)) AND ((((nutritional con-
sequences[Title/Abstract]) OR nutritional status[Title/Abstract]) OR nutrition assess-
ment[Title/Abstract]) OR malnutrition[Title/Abstract])  - 680 hits 27 relevant 
PICO 4 
(energy expenditure[Title/Abstract]) AND (((Ulcerative Colitis) OR Crohn$) OR Inflammatory 
Bowel Disease)  - 68 results, 34 relevant 
PICO 5 
(((body protein[Title/Abstract]) OR protein turnover[Title/Abstract]) OR protein require-
ment[Title/Abstract]) OR protein metabolism[Title/Abstract]) AND (((Ulcerative Colitis) OR 
Crohn$) OR Inflammatory Bowel Disease) - 47 hits, 13 relevant 
PICO 6 
(((((((micronutrient[Title/Abstract]) OR trace element[Title/Abstract]) OR miner-
al[Title/Abstract]) OR vitamin[Title/Abstract]) AND (((Ulcerative Colitis) OR Crohn$) OR In-
flammatory Bowel Disease)) AND Humans[Mesh])) NOT review - 811 hits, 20 most relevant 
PICO 7 
(Iron OR ferrous OR anemia) and (Crohn OR colitis OR IBD) 
PICO 8 
((diet or exclusion diet or exclusive diet or restricted diet or experimental diet or nutrition sup-
port) and Active and (ibd or inflammatory bowel disease or Crohn or colitis) not review), 12 
references 
PICO 9 
(IBD or Crohn or colitis) and (diarrhea or diarrhoea or stoma) and (nutrition or fluid or diet) 34 
retrieved, 6 references pertinent 
PICO 10 
((diet or nutrition or enteral nutrition or fluid or total parenteral nutrition or TPN) and (stricture 
or stenos*) and (ibd or inflammatory bowel disease or Crohn) not review) 97 retrieved, 2 ref-
erences used 
PICO 11 
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((diet or nutrition or calcium or vitamin D) and (steroid or corticosteroid) and (IBD or inflam-
matory bowel disease or Crohn or colitis) not review) 942 retrieves, 12 references. 
PICO 12 
1)  Crohn, malabsorption and colestyramine yielded 14 items, one of which was relevant to 
the topic.  
2)  Crohn, fat malabsorption and bile yielded 12 items, two of which were relevant, and one 
was useful as a review.  
3)  IBD, malabsorption, steatorrhoea and hyperoxaluria yielded 31 items, 3 of them were 
relevant.  
PICO 13 
Crohn and exclusion diet yielded 32 items, 6 of these were relevant. 
PICO 14 
1) Crohn, probiotics and pediatric, using a filter for randomised controlled trials yielded 1 
result.   
2) ulcerative colitis, probiotics and pediatric, using a filter for randomised controlled trials 
yielded 2 results, both relevant.  
PICO 15 
 (Inflammatory bowel disease or Crohn Or ulcerative colitis) AND (Nutrition Supplements, OR 
enteral nutrition OR parenteral nutrition). This yielded 1752 papers. Papers retrieved by the 
previous systemic search done at the Tel-Aviv University were reviewed as well. 
PICO 16 
(enteral nutrition OR parenteral nutrition) and (inflammatory bowel disease or Crohn). This 
yielded 1634 papers. Papers retrieved by the previous search done at the Tel-Aviv University 
were reviewed as well. 
PICO 17 
(Crohn or colitis or IBD) AND (nutrition or enteral nutrition or TPN or nasogastric or gastros-
tomy) AND (therapy or treatment) 
PICO 18 
(Crohn or colitis or IBD) AND (nutrition or enteral nutrition or TPN or nasogastric or gastros-
tomy) AND (polymeric or oligomeric or peptide or elemental) 
PICO 19 
Crohn AND (Thrombosis or thrombotic or coagulation) 
PICO 20 
(Crohn or colitis or IBD) AND Fistula AND (Nutrition or malnutrition) 
PICO 21 
Crohn and refeeding syndrome 
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PICO 22 
(Colitis or ulcerative colitis) AND (Artificial nutrition or PEG or enteral feed or parenteral feed 
or TPN) 
PICO 23 to PICO 27 
Source material taken from the ESPEN Guidelines for Nutrition in Surgery 2016 
PICO 28 & 28a 
 (“Dietician” OR “Nutritionist”) AND (“Crohn” OR “Colitis” OR “IBD”) generates 11 papers, 
only two of which present original data (which from this point of view were irrelevant in one 
case).   
PICO 29 
restricted to human data - (“Diet” AND “Remission”) AND (“IBD” OR “Crohn” OR “colitis”) 
yielded 327 citations. Excluding case reports, reviews and opinion pieces and papers con-
cerned with treatment of active disease leaves 47 papers for consideration.   
PICO 30 
(Crohn OR colitis OR IBD) AND (fat OR lipid OR omega OR fish oil) AND (remission) AND 
(human) generated 286 citations.   
PICO 31 
(Crohn OR colitis OR IBD) AND (remission) AND (fiber) yielded 52 citations.   
PICO 32 and 33 
E.Coli Nissle 1917[Title] OR VSL#3[Title] OR probiotic[Title] AND (((Ulcerative Colitis) OR 
Crohn$) OR Inflammatory Bowel Disease).  265 results 30 relevant  
PICO 34 
(crohn OR ulcerative colitis OR ibd) AND (enteral nutrition or parenteral nutrition) AND 
(maintenance OR remission): 371 results retrieved, 20 relevant 
PICO 35 
(((("crohn") OR "ulcerative colitis") OR "ibd")) AND (((((((((("enteral nutrition formula" OR "en-
teral nutrition formulas" OR "enteral nutrition formulation" OR "enteral nutrition formulations" 
OR "enteral nutrition mixtures" OR "enteral nutrition products" OR "enteral nutrition regimen" 
OR "enteral nutrition regimens" OR "enteral nutrition supplement" OR "enteral nutrition sup-
plementation" OR "enteral nutritional formula" OR "enteral nutritional formulae" OR "enteral 
nutritional formulas" OR "enteral nutritional products" OR "enteral nutritional solutions" OR 
"enteral nutritional supplementation" OR "enteral nutritional supplements" OR "enteral omega 
3 fa" OR "enteral omega 3 fatty" OR "enteral omega 3 fatty acid" OR "enteral pharmaconutri-
tion" OR "enteral probiotic supplementation" OR "enteral probiotics" OR "enteral probiotics 
administration" OR "enteral probiotics supplementation" OR "enteral product" OR "enteral 
products"))) OR (("parenteral nutrition additives" OR "parenteral nutrition admixture" OR 
"parenteral nutrition admixtures" OR "parenteral nutrition emulsion" OR "parenteral nutrition 
emulsions" OR "parenteral nutrition formula" OR "parenteral nutrition formulae" OR "paren-
teral nutrition formulas" OR "parenteral nutrition formulation" OR "parenteral nutrition formu-
lations" OR "parenteral nutrition lipid emulsions" OR "parenteral nutrition mixture" OR "paren-
teral nutrition mixtures" OR "parenteral nutrition preparation" OR "parenteral nutrition prepa-
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rations" OR "parenteral nutrition product"))) OR "oral nutritional supplements") OR "gluta-
mine") OR fatty acids) OR "pharmaconutrition") OR (("immunonutrition" OR "immunonutrition 
formula"))) OR (("immune enhancing diet" OR "immune enhancing diets" OR "immune en-
hancing diets ieds" OR "immune enhancing effect" OR "immune enhancing effects" OR "im-
mune enhancing enteral diet" OR "immune enhancing enteral diets" OR "immune enhancing 
feeds" OR "immune enhancing formula" OR "immune enhancing formulae" OR "immune en-
hancing formulas" OR "immune enhancing function" OR "immune enhancing functions" OR 
"immune enhancing ingredients" OR "immune enhancing nutrients" OR "immune enhancing 
nutrition" OR "immune enhancing oral formula" OR "immune enhancing oral formulas" OR 
"immune enhancing substrates"))) AND (maintenance OR remission) AND Humans AND 
Clinical trials: 45 results retrieved, 8 relevant 
PICO 36 
cobalamin deficiency OR B12 AND crohn: 157 results retrieved, 10 relevant 
PICO 37 
folate deficiency OR B9 AND (crohn OR ulcerative colitis OR IBD): 141 results retrieved, 16 
relevant 
PICO 38 
pregnancy AND (crohn or IBD OR ulcerative colitis) AND nutrition): 60 results retrieved, 0 
relevant 
PICO 39 
(((("crohn") OR "ulcerative colitis") OR "ibd")) AND (((((((("sarcopenia") OR "myopenia") OR 
"dynapenia") OR "muscle mass") OR "muscle strength") OR "muscle function") OR "muscle 
performance") OR "exercise"): 191 results retrieved, 30 relevant 
PICO 40 
("obesity/therapy") AND ((("crohn") OR "ulcerative colitis") OR "ibd"): 11 results retrieved, 0 
relevant 
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Appendix B 
Evidence table 
Recommendation 1: 
A diet rich in fruit and vegetables, rich in n-3 fatty acids, and low in n-6 fatty acids is associated with a decreased risk of developing Crohn's dis-
ease or ulcerative colitis and is therefore recommended.  
Grade of recommendation C – strong consensus (90 % agreement) 
1. Hou JK, Abraham B, El-Serag H. Dietary Intake and Risk of Developing Inflammatory Bowel Disease: A Systematic Review of the Literature. Am J Gastroen-
terol 2011;106:563–73. [13] 
Study Type/ 
Evidence Level 
Study details/limitations Patient characteristics Interventions 
Systematic 
review 
2++ 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Houston Veterans 
Affairs Health Services Research and Devel-
opment Center of Excellence grant HFP90-
020 and National Institutes of Health/National 
Institute of Diabetes and Digestive and Kid-
ney Diseases 
Center Grant P30 DK56338 
Dropout rates: 
Study limitations: 
-Given the heterogeneity among study de-
sign, nutrient cutoffs and study populations 
pooling of  data from different studies was not 
possible  
-limitations of included studies , publications 
bias 
-no independent verifying of  IBD  diagnosis 
in the studies 
-possible occurrence of recall bias because 
of retrospective nature of the majority of stud-
Total no. patients: n = 2609 (18 case-control studies, 1 co-
hort-study) 
 Cases with Crohn's disease n=1,269  
 cases with ulcerative colitis n=1340 
 
Inclusion criteria: Fully published case-control and cohort 
studies of the association between pre-illness diet and IBD 
risk 
 
Exclusion criteria: studies investigating diet as therapy for 
IBD; ecological studies 
 
We performed a systematic 
review using guideline-
recommended methodology to 
evaluate the association be-
tween pre-illness intake of nutri-
ents (fats, carbohydrates, pro-
tein) and food groups (fruits, 
vegetables, meats) and the risk 
of subsequent IBD diagnosis. 
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ies 
- heterogeneity among studies in time from 
IBD diagnosis to diet-pattern ascertainment 
-different aged populations (may reflect dif-
ferent dietary patterns or subsets of IBD ) 
- no exploration on the influence of diet on 
current disease activity  
 
Notes Risk estimates were reported for highest level of intake, with daily-intake cutoffs included where data were available 
Author’s Conclusion: 
High dietary intakes of total fats, PUFAs, omega-6 fatty acids, and meat were associated with an increased risk of CD and UC. High fiber and 
fruit intakes were associated with decreased CD risk, and high vegetable intake was associated with decreased UC risk. 
Outcome 
measures/resu
lts 
dietary fats (total fat intake, saturated fat, 
monounsaturated fatty acids (MUFAs), total  
polyunsaturated fatty acids (PUFAs), omega-
3 fatty acids, long-chain omega-3 fatty acids, 
and omega-6 fatty acids);carbohydrates (total 
carbohydrates, mono- and disaccha-
rides,polysaccharides);proteins (total protein, 
animal protein, vegetable protein); food 
groups: fruits, vegetables, fiber, meat, fish, 
dairy, eggs 
Nineteen studies were included, encompassing 2,609 IBD patients (1,269 Crohn’s disease 
(CD) 
and 1,340 ulcerative colitis (UC) patients) and over 4,000 controls. Studies reported a positive 
association between high intake of saturated fats, monounsaturated fatty acids, total polyun-
saturated fatty acids (PUFAs), total omega-3 fatty acids, omega-6 fatty acids, mono- and di-
saccharides, and meat and increased subsequent CD risk. Studies reported a negative associ-
ation between dietary fiber and fruits and subsequent CD risk. High intakes of total fats, total 
PUFAs, omega-6 fatty acids, and meat were associated with an increased risk of UC. High 
vegetable intake was associated with a decreased risk of UC. 
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2. Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, et al. A prospective study of long-term intake of dietary fiber and risk of 
Crohn's disease and ulcerative colitis. Gastroenterology 2013;145(5):970-7. [14] 
Study Type/  
Evidence Level 
Study details/limitations Patient characteristics Interventions 
Prospective study 
2+ 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Research Scholars Award of the American Gastroenter-
ological Association (A.N.A), Crohn’s and Colitis Foun-
dation of America (H.K.), the Broad Medical Research 
Program of the Broad Foundation (A.T.C), and the Na-
tional Institutes of Health 
 
Dropout rates: 
 
Study limitations: 
- results are limited to IBD with onset at older ages 
- cohort consisted entirely of women, mostly of Cauca-
sian race, there are limited data to suggest a differential 
effect of environmental exposures on IBD risk based on 
race or sex 
- attenuation in the magnitude of association of total fiber 
with CD (lag of 4–8 years between the final time point of 
assessment of diet and the diagnosis of CD or UC) 
-limited number of cases across each quintile 
- observational study design ( no exclusion of possible 
confounders)  
Total no. patients: 
170.776 (76.738 NHS I 
und 94.038 NHS II) 
 269 cases of CD 
 338 cases of UC 
 
Inclusion criteria: woman, 
who completed a detailed 
FFQ in 1984 in NSH I and 
in 1991 in NHS II 
 
Exclusion criteria: Women 
who were deceased prior 
to the first dietary ques-
tionnaire, had a diagnosis 
of cancer (except non-
melanoma skin cancer) or 
were diagnosed with IBD 
prior to this baseline diet 
questionnaire 
 
We performed this prospective trial to examine the 
association between long-term intake of dietary 
fiber and risk of incident CD and UC. Furthermore, 
we examined the impact of fiber intake from differ-
ent sources to shed light on the specific mecha-
nisms through which dietary fiber intake may modu-
late risk of disease. Therefore we collected and 
analyzed data from 170,776 women, followed over 
26 y, who participated in the Nurses’ Health Study, 
followed for 3,317,425 person-y. Dietary information 
was prospectively ascertained via administration of 
a validated semi-quantitative food frequency ques-
tionnaire every 4 y. Self-reported CD and UC were 
confirmed through review of medical records.  
Notes Author’s Conclusion: 
In conclusion, we demonstrate that high long-term intake of dietary fiber was associated with a reduction in risk of CD, particularly for fiber 
intake from fruits and potentially from overall vegetables and cruciferous vegetables. This association supports experimental findings sug-
gesting the importance of dietary fiber in modulating the gut microbiome or as a source of aryl hydrocarbon receptor. Further studies explor-
ing these potential mechanisms as well a potential role for dietary fiber in the prevention or treatment of CD merits further study. 
Outcome 
measures/results Primary outcome measure: Intake of dietary fiber 
We confirmed 269 incident cases of CD (incidence 8/100,000 person-y) and 
338 cases of UC (incidence 10/100,000 person-y). Compared to the lowest 
quintile of energy-adjusted cumulative average intake of dietary fiber, intake of 
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Secondary outcome measures: total energy intake; fruit 
and vegetables consumption; Ascertainment/diagnosis 
date of CD and UC; cigarette smoking; menopausal 
status; use of oral contraceptives; post-menopausal 
hormone use; aspirin, non-steroidal anti-inflammatory 
drugs  (NSADs); weight 
 
the highest quintile (median of 24.3 g/day) was associated with a 40% reduc-
tion in risk of CD (multivariate HR for CD, 0.59; 95% confidence interval [CI], 
0.39–0.90). This apparent reduction appeared to be greatest for fiber derived 
from fruits; fiber from cereals, whole grains, or legumes did not modify risk. In 
contrast, neither total intake of dietary fiber (multivariate HR, 0.82; 95% CI 
0.58–1.17) nor intake of fiber from specific sources appeared to be significantly 
associated with risk of UC. 
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3. Li F, Liu X, Wang W, Zhang D. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: a meta-analysis. Eur J Gastroenterol Hepatol. 
2015;27:623-30. [15] 
Study Type/ 
Evidence Level 
Study details/limitations Patient characteristics Interventions 
Meta-analysis 
1- 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
-results based on case-control studies were were 
prone to recall bias and interviewer 
Bias 
-different adjustment of confounders in studies (may 
influence associations between intake of vegetables 
and fruit and the risk of IBD) 
-different diet assessment methods and the retro-
spective among studies led to  
incomparability in the results to some extent 
-limited number of studies in the subgroup 
analysis  
Total no. patients: n = 2762 (14 case-control 
studies) 
 Cases of UC n = 1419 
 Cases of CD n = 1343 
 
Inclusion criteria: observational studies pub-
lished originally; topic of interest was consump-
tion of vegetables and/or fruit; outcome was UC 
and/or CD; odds ratios (ORs) or relative risks 
with corresponding 95% confidence intervals 
(CIs) were reported or could be calculated from 
the data presented in articles; studies were re-
ported in English or Chinese 
 
Exclusion criteria: 
 
We carried out a comprehensive 
meta-analysis by combining the 
results from all available observa-
tional studies to assess the risk of 
UC and CD for highest versus low-
est consumption of vegetables and 
fruit separately and explore the 
potential between study heteroge-
neity and publication bias. 
Notes Subgroup analysis was carried out by the continent (Asia and Europe) and the status (yes or no) of adjusting for smoking. 
Author’s Conclusion: 
This meta-analysis indicates that consumption of vegetables and fruit might be associated inversely with the risk of UC and CD, and the results 
need to be further confirmed. 
Outcome 
measures/resu
lts 
consumption of 
vegetables 
and/or fruit; 
occurrence of 
UC and/or CD 
A total of 14 case–control studies were included in this meta-analysis. On the basis of the highest versus the lowest analy-
sis, consumption of vegetables was associated inversely with the risk of ulcerative colitis (UC) (OR =0.71, 95% CI 0.58–
0.88, n= 9 studies), but not with Crohn’s disease (CD) (OR =0.66, 95% CI 0.40–1.09, n =8 studies). Higher consumption of 
fruit was associated inversely with the risk of UC (OR =0.69, 95% CI 0.49–0.96, n =8 studies) and CD (OR =0.57, 95% CI 
0.44–0.74, n =10 studies). For intake of vegetables and the risk of CD, subgroup analysis showed a significant association 
for studies carried out in Europe (OR =0.36, 95% CI 0.23–0.57), but not in Asia (OR =1.00, 95% CI 0.50–2.03). No signifi-
cant publication bias was found for the analysis of intake of vegetables and the risk of UC, intake of fruit and the risk of UC, 
and intake of vegetables and the risk of CD. 
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4. Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Fuchs CS, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's 
disease. Gut 2014;63(5):776-84. [16] 
Study Type/ 
Evidence Level 
Study details/limitations Patient characteristics Interventions 
Prospective study 
and systematic 
review 
2+ 
Countries: 
Centres: 
Setting: 
 
Funding Sources: 
Research Scholars Award of the Amer-
ican Gastroenterological Association 
(A.N.A.), Crohn’s and Colitis Founda-
tion of America (H.K.), the Broad Med-
ical Research Program of the Broad 
Foundation (A.T.C), and the National 
Institutes of Health 
 
Dropout rates 
: 
Study limitations: 
-cohort consisted entirely of female 
health professionals, most of whom 
were Caucasian (limited data to sup-
port a differential effect of diet on risk 
of IBD according to gender, race, or 
profession) 
-observational study design and there-
fore unable to confirm causality  
 
Total no. patients: n= 238386 (121,700  Nurses 
Health Study I; 116,686 Nurses Health Study II) 
 Cases of CD n= 269 
 Cases of UC n= 338 
 
Inclusion criteria: women who first completed a 
detailed dietary assessment 
 
Exclusion criteria: Women who were deceased 
prior to the first dietary questionnaire, reported a 
diagnosis of IBD prior to the baseline dietary 
assessment, or had a history of cancer (exclud-
ing non-melanoma skin cancer) 
 
We conducted a prospective study of women 
enrolled in the Nurses’ Health Study cohorts. 
Diet was prospectively ascertained every four 
years using a validated semi-quantitative food 
frequency questionnaire. Self-reported CD and 
UC were confirmed through medical record re-
view. We examined the effect of energy-
adjusted cumulative average total fat intake as 
well as specific types of fat and fatty acids on 
the risk of CD and UC using Cox proportional 
hazards models adjusting for potential con-
founders. As well we performed a systematic 
review of the literature examining the associa-
tion between overall dietary fat intake or intake 
of specific fatty acids and risk of CD and UC. 
Notes The systematic review included 15 studies. 
Covariates/base line characteristics associated with IBD were selected for inclusion in the multivariate model : Body mass index (BMI); Ciga-
rette smoking (current, past, or never), oral contraceptive use (ever or never), post-menopausal hormone use (premenopausal, never, cur-
rent, or past use); use of aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) 
Author’s Conclusion: 
In conclusion, using two large prospective cohorts of women, we demonstrate that total fat, saturated or unsaturated fat, or individual PUFA 
did not influence risk of CD. However, our results suggest that women in the highest quintile of long-term dietary intake of long-chain n-3 
PUFA may have a significantly reduced risk while those with high trans-saturated fat intake may have an increased risk of UC. Our findings 
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support experimental data demonstrating the importance of n-3 PUFA in modulating the production of inflammatory mediators such as pros-
taglandins and leukotrienes, maintenance of the intestinal barrier, regulation of the adaptive immune response, and immune cell adhesion 
and trafficking. Further studies are needed to confirm our results and explore the potential of modifying fatty acid intake in the prevention or 
treatment of UC. 
Outcome 
measures/result
s 
total dietary fat; saturated fats 
(SFA), trans-unsaturated fat, 
poly-unsaturated fatty acids 
(PUFA), mono-unsaturated 
fats (MUFA), n-3 fatty acids; 
linoleic acid, eicosapentae-
noic acid (EPA); docosahex-
aenoic acid (DHA) 
Among 170,805 women, we confirmed 269 incident cases of CD (incidence 8/100,000 person-years) and 
338 incident cases of UC (incidence 10/100,000 person-years) over 26 years and 3,317,338 person-years of 
follow-up. Cumulative energy-adjusted intake of total fat, saturated fats, unsaturated fats, n-6 and n-3 poly-
unsaturated fatty acids (PUFA) were not associated with risk of CD or UC. However, greater intake of long-
chain n-3 PUFA was associated with a trend towards lower risk of UC (Hazard ratio (HR) 0.72, 95% CI 0.51 – 
1.01). In contrast, high long-term intake of trans-unsaturated fatty acids was associated with a trend towards 
an increased incidence of UC (HR 1.34, 95% CI 0.94 – 1.92). 
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5. Tjonneland A, Overvad K, Bergmann MM, Nagel G, Linseisen J, Hallmans G, et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of 
ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut 2009;58(12):1606-11. [17] 
Study Type/ 
Evidence Level 
Study details/limitations Patient characteristics Interventions 
a nested case–
control study 
2+/- 
Countries: 
Centres:  
Setting: 
 
Funding Sources: 
The Sir Halley Stewart Trust, The National Association for 
Colitis and Crohn’s Disease and The NHS Executive 
Eastern Region. EPIC-Norfolk is supported by Cancer 
Research UK and The Medical Research Council, UK. 
EPIC-Malmö is supported by The Swedish Cancer Socie-
ty, The Swedish Research Council and The Region of 
Skane. EPIC-Denmark is supported by The Danish Can-
cer Society. EPIC-Heidelberg is supported by “Stiftung 
Landesbank Baden-Württemberg”, the European Union 
and Deutsche Krebshilfe. EPIC-Potsdam is supported by 
the Federal Ministry of Research and Technology, the 
European Union and Deutsche Krebshilfe. EPIC-Florence 
is supported by the Associazione Italiana per la Ricerca 
contro il Cancro (AIRC-Milan) and Regione Toscana. 
 
Dropout rates: 
 
Study limitations: 
-data on smoking were only available at recruitment and 
not during subsequent follow-up 
-The generalisability of any cohort study, namely its exter-
nal validity, needs to be considered 
-under-representation of younger women with ulcerative 
colitis 
- no detection of a negative association with cigarette 
smoking at recruitment, this may be because healthier 
volunteers are more likely to participate in a cohort study  
 
Total no. patients: n = 203193 
 incident cases of ulcerative 
colitis 
 n= 126 
 
Inclusion criteria: 
 
Exclusion criteria: 
 
To investigate the effect of dietary linoleic 
acid intake and the risk of developing inci-
dent  ulcerative colitis dietary data from 
participates (resident in the UK, Sweden, 
Denmark, Germany or Italy) of a prospec-
tive cohort study, the European Prospective 
Investigation into Cancer and Nutrition (EP-
IC), were available and analyzed. These 
participants were followed up for the diag-
nosis of ulcerative colitis. Each case was 
matched with four controls and the risk of 
disease calculated by quartile of intake of 
linoleic acid adjusted for gender, age, 
smoking, total energy intake and centre. 
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Notes -Nutrient intake was calculated by multiplying the frequency of consumption of relevant foods by their fatty acid content as determined from 
national databases of food content. The dietary fatty acids which were calculated were: linoleic acid (n-6 PUFA), α-linolenic acid, eicosapen-
taenoic acid, docosahexaenoic acid (n-3 PUFAs) and oleic acid (an n-9 monounsaturated fatty acid).  
Author’s Conclusion: 
The data support a role for dietary linoleic acid in the aetiology of ulcerative colitis. An estimated 30% of cases could be attributed to having 
dietary intakes higher than the lowest quartile of linoleic acid intake. 
Outcome 
measures/resu
lts 
Intake of linoleic acid (n-6 PUFA), 
α-linolenic acid, eicosapentaenoic 
acid, docosahexaenoic acid (n-3 
PUFAs) and oleic acid (an n-9 
monounsaturated fatty acid); oc-
currence of ulcerative colitis 
A total of 126 participants developed ulcerative colitis (47% women) after a median follow-up of 4.0 years 
(range, 1.7–11.3 years). The highest quartile of intake of linoleic acid was associated with an increased 
risk of ulcerative colitis (odds ratio (OR) = 2.49, 95% confidence interval (CI) = 1.23 to 5.07, p = 0.01) with a 
significant trend across quartiles (OR = 1.32 per quartile increase, 95% CI = 1.04 to 1.66, p = 0.02 for trend). 
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Recommendation 2: 
Breastfeeding can be recommended, because it is the optimal food for infants and it reduces the risk of IBD.  
Grade of recommendation B – strong consensus (93 % agreement) 
6. Corrao G, Tragnone A, Caprilli R, Trallori G, Papi C, Andreoli A, Di Paolo M, Riegler G, Rigo GP, Ferraù O, Mansi C, Ingrosso M, Valpiani D. Risk of inflam-
matory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the 
Italian Group for the Study of the Colon and the Rectum (GISC). Int J Epidemiol. 1998 Jun;27(3):397-404. [29] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
Case-control study 
2- 
Countries: Italy 
Centres: 
Setting: 
Funding Sources: 
 
Dropout rates: n= 39 (4,5%) 
 
Study limitations: 
- sources of bias (selection of 
the samples and confounding 
effects)  might affect the va-
lidity of results 
Total no. patients: n= 858 
 cases of UC n= 594 
 cases of CD n= 225 
 cases of controls n= 819 
 
Inclusion criteria:patients aged 18-65 years; patients in 
whom the first diagnosis of IBD had been made between 
I January 1989 and 31 December 1992 
 
Exclusion criteria: cases diagnosed within the study 
areas but resident elsewhere; Patients with a diagnosis 
of IBD made prior to 1989;patients with  infectious dis-
ease, from pneumology, gynaecology and obstetric de-
partments and patients with gastrointestinal, metabolic, 
neoplastic and cardiovascular diseases 
 
We carried out a matched case-control study by 
using data from a case-control study carried out 
in Italy 1989-1992. We estimated the odds ratios 
(OR) and the population attributable risks (AR) 
for inflammatory bowel diseases in relation to 
smoking, oral contraception and breastfeeding in 
infancy. 
Notes Controls were randomly selected from the patients resident in the areas considered, who were either examined by or admitted to the same 
hospital as the cases and 1:1 matched to each case by gender and age at diagnosis (±3 years). Controls had acute diseases not related to 
smoking, oral contraceptive use or immunological disorders. 
Author’s Conclusion: 
Taken together, the considered factors were responsible for a proportion of IBD ranging from 26% (CD females) to 36% (CD males). It is 
concluded that other environmental and genetic factors may be involved in the aetiology of IBD. 
Outcome 
measures/results 
anamnestic and lifestyle 
information, breastfeeding 
in infancy, smoking habits 
and use of oral contracep-
tives (OC) 
Compared with non-smokers, former smokers were at increased risk of UC (OR= 3.0; 95% confidence inter-
val [CI] : 2.1^.3), whereas current smokers were at increased risk of CD (OR = 1.7; 95% CI: 1.1-2.6). Fe-
males who reported use of oral contraceptives for at least one month before onset of symptoms had a higher 
risk of CD (OR = 3.4; 95% CI : 1.0-11.9), whereas no significant risk was observed for UC. Lack of breast-
feeding was associated with an increased risk of UC (OR = 1.5; 95% CI : 1.1-2.1) and CD (OR = 1.9; 95% CI 
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: 1.1-3.3). Being a 'former smoker' was the factor with the highest attributable risk of UC both 
in males (AR '= 28%; 95% CI : 20-35 %) and in females (AR = 12%; 95% CI : 5-18%). Smoking was the fac-
tor with the highest attributable risk for CD in males (AR = 31%; 95% CI : 11-50%). Lack of breastfeeding 
accounted for the highest proportion of CD in females (AR = 11%; 95% CI : 1-22%). Oral contraceptive 
use accounted for 7% of cases of UC and for 11% of cases of CD. 
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7. Hansen TS, Jess T, Vind I, Elkjaer M, Nielsen MF, Gamborg M, Munkholm P. Environmental factors in inflammatory bowel disease: a case-control study 
based on a Danish inception cohort. J Crohns Colitis. 2011 Dec;5(6):577-84. [31] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
Case-control study 
2- 
Countries: Denmark  
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
 
Study limitations: 
-limited power to detect associations because of one-to-one 
match of cases and controls 
- orthopaedic controls may not be entirely comparable to 
the general population 
- combined results for IBD may not be appropriate, recog-
nizing that CD and UC are different disease entities with 
suggested differences in aetiology  
- testing of a relatively large number of environmental fac-
tors may in some cases have resulted in falsely rejection of 
the null hypothesis  
-some questions regarding early lifetime  factors may have 
been affected byrecall bias 
-no  formal validation or forward/backward translation of the 
Adapted questionnaire 
Total no. patients: n= 267  
 cases with CD n= 123 
 cases with UC n=144 
 
Inclusion criteria: patients were 
diagnosed with IBD (CD, UC 
or indeterminate colitis) 
 
Exclusion criteria: 
 
We performed a case-control trial to asses 
the influence of exposure to specific envi-
ronmental factors on development of CD 
and UC. Patients diagnosed with Crohn's 
disease (CD) and with ulcerative colitis 
(UC) in Copenhagen (2003–2004) were 
matched 1:1 on age and gender to ortho-
paedic controls. Participants received a 
questionnaire with 87 questions concerning 
environmental factors prior to 
IBD/orthopaedic admission.  
Notes Author’s Conclusion: 
Among Danish patients with CD and UC belonging to an unselected cohort, disease occurrence was found to be associated both with well-
known factors such as smoking and appendectomy, and with more debated factors including breastfeeding, tonsillectomy, childhood vac-
cinations, childhood infections, and dietary intake of fibres and sugar. 
Highlights: ► The aetiology of inflammatory bowel diseases remains uncertain. ► Smoking was positively associated with CD and nega-
tively associated with UC. ► Low consumption of dietary fibres and high consumption of sugar increased the risk for IBD. ► Appendectomy 
decreased the risk for UC. Tonsillectomy decreased the risk for both UC and CD. ► Childhood infections and vaccinations may also play an 
aetiological role in IBD. 
Outcome 
measures/results 
questionnaire with 87 questions concerning environmental fac-
tors: 
1) markers of immunity and infections (breast feeding; appen-
dectomy before age 20 and > 1 year prior to diagnosis; tonsillec-
Being breastfed > 6 months (OR, 0.50; 95% CI, 0.23–1.11) and under-
going tonsillectomy (OR, 0.49; 95% CI, 0.31–0.78) decreased the odds 
for IBD, whereas appendectomy decreased the odds for UC only (OR, 
0.29; 95% CI, 0.12–0.71). Vaccination against pertussis (OR, 2.08; 95% 
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tomy before age 20 and > 1 year prior to diagnosis; childhood 
vaccinations against tuberculosis, pertussis, measles, rubella, 
diphtheria, tetanus, or polio; childhood infections including mea-
sles, pertussis, rubella, chickenpox, mumps, and scarlet fever; 
sanitary conditions before age 20 [access to running water at 
home]) 
2) diet (daily, weekly or rarer consumption of fruit, vegetables, 
egg, bread, cereal, sugar, and coffee) 
3) use of oral contraceptives 
4) Smoking habits at diagnosis (classified as non-smoker, ex-
smoker, or active smoker [defined as a daily consumption of 
tobacco for at least 6 months]). 
CI, 1.07–4.03) and polio (OR, 2.38; 95% CI, 1.04–5.43) increased the 
odds for IBD, whereas measles infection increased the odds for UC (OR, 
3.50; 95% CI, 1.15–10.6). Low consumption of fibres and high consump-
tion of sugar were significantly associated with development of CD and 
UC. Smoking increased the risk for CD and protected against UC. 
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8. Ng SC, Tang W, Leong RW, Chen M, Ko Y, Studd C, Niewiadomski O, Bell S, Kamm MA, de Silva HJ, Kasturiratne A, Senanayake YU, Ooi CJ, Ling KL, Ong 
D, Goh KL, Hilmi I, Ouyang Q, Wang YF, Hu P, Zhu Z, Zeng Z, Wu K, Wang X, Xia B, Li J, Pisespongsa P, Manatsathit S, Aniwan S, Simadibrata M, Abdullah 
M, Tsang SW, Wong TC, Hui AJ, Chow CM, Yu HH, Li MF, Ng KK, Ching J, Wu JC, Chan FK, Sung JJ; Asia-Pacific Crohn's and Colitis Epidemiology Study 
ACCESS Group. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut. 2015 Jul;64(7):1063-
71. [33] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
Case-control study 
2- 
Countries: China, Hong Kong, Indonesia, Sri Lanka, Macau, 
Malaysia, Singapore, Thailand, Australia 
 
Centres: 
Setting: 
 
Funding Sources: 
Ferring Pharmaceuticals, Hong Kong, and Direct Grant Fac-
ulty of Medicine Chinese University of Hong Kong 
 
Dropout rates: 
 
Study limitations: 
-no randomly recruitment of controls 
- missing data  
- some questions 
(early lifetime factors) are likely to be subjected to recall bias 
-possible occurrence of false positive results due to chance 
arising from the evaluation of 87 questions 
-no conduction of the formal validation of the IOIBD ques-
tionnaire  
Total no. patients: n= 
442 
 cases of CD n= 
186 
 cases of UC n= 
256 
 cases of con-
trols n= 940 
 
Inclusion criteria: diag-
nosis remained con-
firmed at 6-month fol-
low-up 
 
Exclusion criteria: 
 
This prospective population-based case-control 
study in Asia-Pacific examined risk factors prior 
to patients developing IBD. Therefore IBD cases 
diagnosed between 2011 and 2013 from eight 
countries in Asia and Australia and  controls 
(frequency-matched by sex, age and geograph-
ical location) completed an environmental factor 
questionnaire at diagnosis. Unconditional logistic 
regression models were used to estimate ad-
justed ORs (aOR) and 95% CIs. 
Notes Author’s Conclusion: 
This first population-based study of IBD risk factors in Asia-Pacific supports the importance of childhood immunological, hygiene and dietary 
factors in the development of IBD, suggesting that markers of altered intestinal microbiota may modulate risk of IBD later in life. 
Outcome 
measures/results 
questionnaire of 87 questions proposed to be environmental 
risk factors for CD and/or UC: 
 (i) Childhood factors up to 20 years including breast feeding, 
appendectomy, tonsillectomy, eczema, vaccinations (tubercu-
losis, pertussis, measles, rubella, diphtheria, tetanus, polio), 
childhood infections (measles, pertussis, rubella, chickenpox, 
In multivariate model, being breast fed >12 months (aOR 0.10; 95% CI 
0.04 to 0.30), antibiotic use (aOR 0.19; 0.07 to 0.52), having dogs (aOR 
0.54; 0.35 to 0.83), daily tea consumption (aOR 0.62; 0.43 to 0.91) and 
daily physical activity (aOR 0.58; 0.35 to 0.96) decreased the odds for CD 
in Asians. In UC, being breast fed >12 months (aOR 0.16; 0.08 to 0.31), 
antibiotic use (aOR 0.48; 0.27 to 0.87), daily tea (aOR 0.63; 0.46 to 0.86) 
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mumps, scarlet fever) and pet ownership 
(ii) food habits before diagnosis including daily, weekly or less 
frequent consumption of fruit, vegetables, egg, cereal, bread, 
cereal, coffee, tea, juice, sugar and fast food 
(iii) smoking habits (current smoker, non-smoker, ex-smoker); 
(iv) sanitary conditions such as the availability of inhouse water 
tap, hot water tap or flush toilet 
(v) others factors including daily physical activity, oral contra-
ceptive pill and stressful events before diagnosis 
or coffee consumption (aOR 0.51; 0.36 to 0.72), presence of hot water tap 
(aOR 0.65; 0.46 to 0.91) and flush toilet in childhood (aOR 0.71; 0.51 to 
0.98) were protective for UC development whereas ex-smoking (aOR 
2.02; 1.22 to 3.35) increased the risk of UC. 
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Recommendation 7 A: 
Iron supplementation is recommended in all IBD patients when iron deficiency anaemia is present. The goal of iron supplementation is to normal-
ize haemoglobin levels and iron stores. 
Grade of recommendation A – strong consensus (100 % agreement) 
Recommendation 7 B: 
Oral iron should be considered as first-line treatment in patients with mild anaemia, whose disease is clinically inactive, and who have not been 
previously intolerant to oral iron: 
Grade of recommendation A – strong consensus (100 % agreement) 
Recommendation 7 C: 
Intravenous iron should be considered as first-line treatment in patients with clinically active IBD, those with previous intolerance to oral iron, 
those with haemoglobin below 100 g/L, and in patients who need erythropoiesis-stimulating agents: 
Grade of recommendation A – strong consensus (93 % agreement) 
9. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in haemoglobin level on quality of life and cognitive function in inflammatory bowel disease pa-
tients. Inflamm Bowel Dis 2006;12:123–30. [86] 
Study 
Type/ Evi-
dence 
Level 
Study details/limitations Patient characteristics Interventions 
RCT 
1- 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: n=30 (37,5%) 
Study limitations: 
Total no. patients: n=80 
 Intervention group n=21 
 controls n=29 
 
Inclusion criteria: Patients with IBD who had been 
anemic (Hb ≤ 11.5 g/dL in females and ≤13.0 g/dL in 
males) in the preceding 12 months; nonanemic pa-
tients with active IBD, who were deemed to be at 
risk for becoming anemic 
 
Exclusion criteria: 
The present study examined the association between 
changes in hemoglobin (Hb) in a population of IBD patients 
and changes in quality of life (QOL) and cognitive function 
(CF) independent of change in disease activity (DA). Sub-
sidiary aims were to assess whether the use of iron was 
associated with worsening DA. Iron replacement was given 
to 21 patients with low Hb. 
 
Intervention group (patients with anemia, iron-treated group) 
-Oral ferrous sulfate (200 mg t.d.s.)or intravenous iron su-
crose (200-mg intravenous aliquots twice per week) 
  105 
  
Control group (patients without anemia) 
-no treatment 
Notes 3-month review: All patients treated with iron were reviewed at 3 months with measurement of Iron ferritin level. Response to iron was defined as full 
(Hb rise of ≥2 g/dL), partial (Hb riseof 1–1.9 g/dL), or no response (Hb change of <1 g/dL). Patients with a full or partial response to oral iron were 
continued on this treatment. Patients with no response to oral iron were offered treatment with intravenous iron sucrose. Patients given intravenous 
iron sucrose with a <2 g/dL rise in Hb were offered further treatment with this medication. 
6-month review: all enrolled patients were reviewed at 6 months  with following measurements: blood count and ferritin, QOL and CF assessments.  
definitions to grade the Hb response to treatment: ≥2 g/dL was a significant response, 1 to 2 g/dL was a moderate response, 0.5 to 1.0 g/dL was a 
slight 
response, 20.5 to 0.5 g/dL was defined as no change, and a fall of >0.5 g/dL was defined as a decrease. 
Author’s Conclusion: 
Treatment of IBD-associated anemia with iron may lead to improvement in patients' QOL. 
Outcome 
measures/
results 
Quality of life (QOL), cognitive func-
tion (CF), disease activity (DA), Hb 
were recorded at baseline and at 6 
months 
The iron-treated group had lower Hb and higher DA scores compared with the non-iron-treated group at 
baseline. In a hierarchical regression model, changes in DA accounted for 13% (P=0.17) and changes in Hb 
accounted for 18% (P=0.005) of the variance in change in SF-36 and 12% (P=0.23) and 17% (P=0.009) in 
the Inflammatory Bowel Disease Questionnaire. In this pilot study, although no associations were identified 
between changes in Hb or DA and CF, increases in Hb improved QOL scores in IBD patients independent of 
changes in DA. We found no similar effect with CF, but again, the sample size was small. We found no evi-
dence that iron therapy causes worsening of DA. 
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10. Bonovas S, Fiorino G, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L, Danese S. Intravenous Versus Oral Iron for the Treatment of Anaemia in Inflammato-
ry Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2016;95:e2308. [87] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
Meta-anaylsis 
1- 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
-occurrence of risk of bias in 
all included trials(treatments 
were not evaluated in terms 
of cost;no distinction was 
made between different 
preparations of IV or oral 
iron) 
- quality of evidence in the 
performed review is moder-
ate 
Total no. patients: n=694 (within 5 RCTs) 
 
Inclusion criteria: randomized controlled trials (RCTs) with 
either a parallel or crossover design; adult patients with IBD; 
trials comparing IV versus oral iron supplementation against 
each other (ie, head-to-head trials) for correcting anemia (We 
accepted any definition of anemia used by study authors, 
provided that all male participants had <13.0 g/dL and all the 
female participants had <12.0 g/dL of hemoglobin (ie, all par-
ticipants met the WHO criteria for anemia for adult males and 
nonpregnant females)) 
 
Exclusion criteria: observational studies; no investigation of 
patients with IBD; no reported (or provided insufficient data 
for) outcomes of interest; studies conducted in pediatric 
populations 
We conducted a systematic review and 
meta-analysis to integrate evidence from 
randomized controlled trials having enrolled 
adults with IBD, and comparing IV versus 
oral iron (head-to-head) for correcting iron-
deficiency anemia 
Notes Author’s Conclusion: 
In conclusion, synthesis of the existing randomized evidence supports that IV iron is more effective and better tolerated than oral iron sup-
plementation for correcting anemia in adult patients with IBD. 
Outcome 
measures/results 
Primary outcome measure: 
effect of treatments on the hemoglobin response (defined as 
the rate of patients who achieved an increase of at least 
2.0 g/dL in hemoglobin concentration at the end of the follow-
up) 
 
Secondary outcome measures: 
rates of discontinuation of the intervention due to adverse 
events or intolerance; occurrence of serious adverse events 
(SAEs) (defined as any untoward medical occurrence that 
results in death, requires hospital admission or prolongation 
of existing hospital stay, causes persistent or significant disa-
bility/ incapacity, or is life threatening);rates of gastrointestinal 
adverse events (nausea, vomiting, abdominal pain, diarrhea) 
Five eligible studies, including 694 IBD patients, were identified. In meta-
analysis, IV iron demonstrated a higher efficacy in achieving a hemoglobin 
rise of ≥2.0 g/dL as compared to oral iron (OR: 1.57, 95% CI: 1.13, 2.18). 
Treatment discontinuation rates, due to adverse events or intolerance, were 
lower in the IV iron groups (OR: 0.27, 95% CI: 0.13, 0.59). Similarly, the 
occurrence of gastrointestinal adverse events was consistently lower in the 
IV iron groups. On the contrary, serious adverse events (SAEs) were more 
frequently reported among patients receiving IV iron preparations (OR: 
4.57, 95% CI: 1.11, 18.8); however, the majority of the reported SAEs were 
judged as unrelated or unlikely to be related to the study medication. We 
found no evidence of publication bias, or between-study heterogeneity, 
across all analyses. Risk of bias was high across primary studies, because 
patients and personnel were not blinded to the intervention. 
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Recommendation 11: 
In IBD patients (adults and children) with active disease and those who are steroid-treated, serum calcium and 25(OH) vitamin D should be moni-
tored and supplemented if required to help prevent low bone mineral density.  Osteopenia and osteoporosis should be managed according to cur-
rent osteoporosis guidelines.   
Grade of recommendation B – strong consensus (96 % agreement) 
11. Abraham BP, Prasad P, Malaty HM Vitamin D deficiency and corticosteroid use are risk factors for low bone mineral density in inflammatory bowel disease 
patients. Dig Dis Sci 2014 Aug;59(8):1878-84. [110]  
Study Type/ 
Evidence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
Prospective 
Study 
2+ 
Countries: 
Centres: Baylor Clinic 
IBD Center 
Setting: 
Funding Sources: 
 
Dropout rates: n= 2 
(1,2%) 
 
Study limitations: 
Total no. patients: n= 168 (cases with CD n= 105; 
cases with UC n= 61 ) 
 patients with abnormal BMD n= 66 
 patients with osteopenia n= 54 
 patients with osteoporosis n= 14 
  
Inclusion criteria: 
Exclusion criteria: 
 
We conducted a prospective cross-sectional study in adult 
IBD patients to investigate the role of vitamin D in low BMD 
while controlling for other risk factors in inflammatory bowel 
diseases (IBD) patients. Demographic data including age, 
gender, ethnicity, BMI, along with disease type and location, 
vitamin D levels, prior corticosteroid use, and anti-TNF use 
were recorded and evaluated with DEXA results. 
Notes BMD: WHO classification of lumbar spine and hip T scores as osteopenia defined as <−1.0 or osteoporosis defined as <−2.5. Low BMD was 
defined by the presence of either osteopenia or osteoporosis 
Vitamin D: vitamin D insufficiency defined as serum vitamin D 25-hydroxy levels between 20 and <30 ng/mL; vitamin D deficiency defined as 
serum vitamin D 25-hydroxy levels <20 ng/mL 
Author’s Conclusion: 
Low vitamin D, male gender, Asian ethnicity, CD, and corticosteroid use significantly increased the risk of having low BMD, while age and 
disease location did not affect BMD in our IBD population. It remains important to evaluate for vitamin D nutritional deficiency and limit corti-
costeroid use to help prevent low BMD in IBD patients. 
Outcome 
measures/results 
bone mineral density 
(BMD); vitamin D level; 
demographic data (age, 
gender, ethnicity), BMI, IBD 
type (CD, UC), disease 
location, medication use 
A total of 166 patients [105 Crohn’s disease (CD), 61 ulcerative colitis (UC)] qualified for the study. Low BMD 
was found in 40 %, twice as frequently in CD than in UC (p = 0.048). Higher prevalence of low BMD was 
associated with those of male gender (p = 0.05), Asian ethnicity (p = 0.02), and history of corticosteroid use 
(p = 0.001). Age, body mass index, or disease location did not increase the risk of low BMD. The overall 
prevalence of low vitamin D was 60 %, with insufficiency (25-hydroxy levels between 20 and 30 ng/mL) found 
in 37 % and deficiency (levels <20 ng/mL) found in 23 % of the patients. Vitamin D insufficient and deficient 
patients were two times (p = 0.049) and almost 3 times (p = 0.02) as likely to have low BMD, respectively. 
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12. Bakker SF, Dik VK, Witte BI, Lips P, Roos JC, Van Bodegraven AA. Increase in bone mineral density in strictly treated Crohn's disease patients with concomi-
tant calcium and vitamin D supplementation. J Crohns Colitis. 2013 Jun;7(5):377-84. [111] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
cohort study 
2 - 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
-retrospective, observational 
study and therefore associa-
tions may not reflect causality 
- Sizeable bias in patient se-
lection exists regarding BMD 
assessment at baseline and 
during follow-up 
- Potentially, this was a popu-
lation with a more complicated 
disease course (more prone to 
have detrimental metabolic 
bone disease so, treated by a 
stricter approach) 
Total no. patients: n= 567 
 CD patients with DXA scan n = 205 
 CD patients without DXA n = 367 
 
 
Inclusion criteria: documented Crohn’s disease (at 
least 5 years) by means of standard clinical, labora-
tory, endoscopic and histological features, age old-
er than 18 years at first DXA, BMD measurement 
had to be performed in the period between January 
1998 and January 2010 with a Hologic Delphi in our 
institute 
 
Exclusion criteria: use of any bisphosphonate de-
rivative at the moment of the first scan and/or dur-
ing follow-up, documented osteomalacia due to 
vitamin D deficiency 
 
We performed a cohort study to evaluate the 
natural course of bone density change in BMD 
over time when CD is actively and strictly treated 
whilst vitamin D and calcium were supplement-
ed, and  to investigate the influence of several 
clinical and medical factors on BMD in CD pa-
tients. 
Therefore CD patients were enrolled when 
measurement of BMD by dual X-ray absorp-
tiometry (DXA) was available. Follow-up DXA 
scan was performed in subjects with known risk 
factors besides Crohn indicative for low BMD. 
Treatment of CD patients was according to a 
protocol which is comparable to the current (in-
ter)national guidelines. In osteopenic patients, 
supplemental vitamin D (800 IU) and Calcium 
(500–1000 mg) were prescribed. 
Notes BMD assessments were indicated and performed when CD patients had known risk factors for decreased BMD, such as previous gluco-
corticosteroid use, low body mass index (BMI), postmenopausal status, short bowel syndrome, or clinically suspected insufficient dietary 
intake of calcium. 
Author’s Conclusion: 
Higher age, male sex, low BMI, and a higher age at diagnosis of CD were associated with low BMD. Follow-up of BMD in CD patients 
showed a contraintuitive small increase of BMD at lumbar spine and total hip in CD patients only using supplemental vitamin D and cal-
cium next to strict treatment of CD. 
Outcome 
measures/results 
age, sex, date of diagnosis of CD, dura-
tion of CD, age at first dual-energy X-ray 
absorptiometry (DXA), BMI (kg/m2) dur-
ing DXA measurement, cumulative glu-
cocorticosteroid use, smoking history, 
surgical history 
Mean BMD at baseline was 0.97 ± 0.16 gram/cm2 in lumbar spine and 0.87 ± 0.12 gram/cm2 
in the total hip. At baseline, higher age and low Body Mass Index (BMI), were negatively cor-
related with BMD. Eighty-four patients underwent a second BMD assessment with a median 
interval period of 4 years (IQR 3–6). A mean annual increase of + 0.76% (95%CI: − 2.63%; + 
3.87%) in lumbar spine and + 0.43% (95%CI: − 2.65% ; + 1.11%) in total hip was observed. 
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13. Lopes LH, Sdepanian VL, Szejnfeld VL, de Morais MB, Fagundes-Neto U. Risk factors for low bone mineral density in children and adolescents with inflam-
matory bowel disease.Dig Dis Sci. 2008 Oct;53(10):2746-53. [112] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
transversal study 
2- 
Countries: 
Centres: 
Setting: 
Funding Sources:  
Dropout rates: 
Study limitations: 
Total no. patients: n = 40 
 Patients with ulcerative colitis n = 26 
 Patients with Crohn’s disease n = 14 
 
Inclusion criteria: diagnosis of ulcerative colitis or 
Crohn’s disease (diagnosis being based on clinical, 
endoscopic, and histological criteria); minimum age 
of 5 years, and maximum of 20 years old; informed 
consent by the patients and parents to participate in 
the study 
 
Exclusion criteria: patients with the following associ-
ated diseases: chronic rheumatism, nephropathy, 
endocrinopathy, primary or secondary immunodefi-
ciency, malabsorption syndrome (except when relat-
ed to the IBD); patients with other associated dis-
eases whose treatment involved chronic use of corti-
costeroids 
We performed this trial to evaluate bone mineral density of 
the lumbar spine in children and adolescents with inflamma-
tory bowel disease, and to identify the clinical risk factors 
associated with low bone mineral density. 
Notes -Anthropometric indicators were expressed in terms of Z score, recommended by the World Health Organization. 
- Three-day food records using a self-completed questionnaire of total food and beverage intake at the time of bone densitometry measure-
ments were used to measure calcium intake 
-calcium Intake was analyzed by the information of 25 patients (15 patients did not hand in the requested nutritional questionnaire) 
Author’s Conclusion: 
The prevalence of low bone mineral density in children and adolescents with inflammatory bowel disease is considerably high and inde-
pendent risk factors associated with bone mineral density are corticosteroid cumulative dose in milligrams, height-for-age Z-score, and BMI 
Z-score. 
Outcome 
measures/results 
bone mineral density Z-score 
and age, height-for-age Z-
score, BMI Z-score, cumula-
tive corticosteroid dose in 
milligrams and in milligrams 
per kilogram, disease dura-
tion, number of disease re-
lapses, calcium intake 
Low bone mineral density (Z-score bellow −2) was observed in 25% of patients. Patients with Crohn’s dis-
ease and ulcerative colitis had equivalent prevalence of low bone mineral density. Multiple linear regression 
models demonstrated that height-for-age Z-score, BMI Z-score, and cumulative corticosteroid dose in mg 
had independent effects on BMD, respectively, β = 0.492 (P = 0.000), β = 0.460 (P = 0.001), β = –0.014 
(P = 0.000), and these effects remained significant after adjustments for disease duration, respectively, 
β = 0.489 (P = 0.013), β = 0.467 (P = 0.001), and β = −0.005 (P = 0.015). The model accounted for 54.6% 
of the variability of the BMD Z-score (adjusted R2 = 0.546). 
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14. van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, 
Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P; Dutch Initiative on Crohn and Colitis (ICC). Treatment of bone loss in osteo-
penic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin 
D supplementation. Gut. 2014 Sep;63(9):1424-30. [117] 
Study Type/ 
Evidence Level 
Study details/limitations Patient characteristics Interventions 
RCT  
1+ 
Countries: 
Centres: 
Setting: 
 
Funding Sources: 
Alliance for Better Bone 
Health (Warner Chilcott, 
Rockaway, New Jersey, 
USA, formerly Procter & 
Gamble Pharmaceuticals, 
Cincinnati, Ohio, USA, and 
Sanofi-Aventis, Bridgewater, 
New Jersey, USA). 
 
Dropout rates: n = 14 
(10,6%) 
 
Study limitations: 
Total no. patients: n = 132 
 Risedronate group n = 56 
 Placebo group n = 62 
 
Inclusion criteria: established quiescent CD by standard 
clinical, histological, endoscopic criteria and osteopenia; 
patients between 18 and 70 years; No glucocorticoid ther-
apy (more than 7.5 mg prednisolone-equivalent daily) 3 
months prior to screening or during the screening phase; 
No use of bisphosphonates for 12 months prior to study 
 
Exclusion criteria: patients with malabsorptive syndromes; 
patients with documented diseases with an impact on 
bone metabolism; medication specifically aimed to im-
prove bone metabolism; Vitamin D deficiency ( < serum 
25-hydroxyvitamin D concentration 25 nmol/L); Pregnancy 
or wish to become pregnant  
 
This double-blind, placebo-controlled randomised 
trial of risedronate with calcium and vitamin D 
supplementation was performed in osteopenic 
Crohn's disease patients. Patients were treated 
for 2 years with follow-up after 3 and after every 6 
months. Disease characteristics and activity and 
bone turnover markers were assessed at all visits; 
dual x-ray absorptiometry was performed at base-
line, 12 and 24 months; radiographs of the spine 
at baseline and 24 month. 
 
Intervention group 
- 35 mg risedronate (Actonel) once per; calcium 
and vitamin D (1000 mg and 800 IU, respectively, 
Calci-Chew D3) daily at night-time; Treatment was 
continued for 24 months. 
 
Placeo group 
-placebo; calcium and vitamin D (1000 mg and 
800 IU, respectively, Calci-Chew D3) daily at 
night-time; Treatment was continued for 24 
months. 
Notes Author’s Conclusion: 
A 24-month treatment course with risedronate 35 mg once weekly, concomitant with calcium and vitamin D supplementation, in osteopenic 
Crohn's disease patients improved bone density at lumbar spine. 
Outcome 
measures/resu
lts 
Primary outcome measure: 
change in BMD and T-score at 
lumbar spine and/or total hip 
derived from DXA after 24 
Of 132 consenting patients, 131 were randomised (67 placebo and 64 risedronate). Patient characteristics 
were similar in both groups, although the risedronate group was slightly heavier (body mass index 24.3 vs 
23.0 kg/m2). Bone mineral density at lumbar spine increased 0.04 g/cm2 on average in the risedronate group 
versus 0.01 g/cm2 in the placebo group (p=0.007). The mean increase in total hip bone mineral density was 
0.03 versus 0.01 g/cm2, respectively (p=0.071). Fracture prevalence and incidence were similar. Change of 
T-scores and concentrations of bone turnover markers were consistent with a beneficial effect of risedronate 
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months treatment with 
risedronate  
Secondary outcome measures: 
changes in markers of bone 
metabolism; number of verte-
bral fractures; CD activity and 
safety of drug administration 
were monitored by clinical 
scores (CDAI, CRP); routine 
clinical, haematological and 
biochemical parameters 
when compared with placebo. The effect of risedronate was primarily demonstrated in the first 12 months of 
treatment. No serious unexpected suspected adverse events were observed. 
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Recommendation 14 A: 
Probiotic therapy using E. coli Nissle 1917 or VSL#3, but not necessarily other probiotics, can be considered for use in patients with mild to mod-
erate UC for the induction of remission. 
Grade of recommendation 0 – strong consensus (92 % agreement) 
 
15. Oliva S, Di Nardo G, Ferrari F, Mallardo S, Rossi P, Patrizi G, Cucchiara S, Stronati L. Randomised clinical trial: the effectiveness of Lactobacillus reuteri 
ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012 Feb;35(3):327-34. [130] 
Study Type/ 
Evidence Level 
Study details/limitations Patient characteristics Interventions 
RCT  
1- 
Countries: 
Centres: Pediatric Gastro-
enterology and Liver Unit of 
the Sapienza University of 
Rome 
Setting: 
Funding Sources: 
Dropout rates: n = 9 
(22,5%) 
Study limitations: 
Total no. patients: n = 40 
 Intervention group n = 16 
 Placebo group n = 15 
 
Inclusion criteria: patients with confirmed endoscopic and 
histological diagnosis of ulcerative procti-
tis/proctosigmoiditis with mild to moderate disease activity 
 
Exclusion criteria: other causes of active proctitis or proc-
tosigmoiditis such as infections, medical drugs and CD; 
patients who had received either oral or topical cortico-
steroids, topical aminosalicylates, antibiotics during the 
previous 12 weeks; immunomodulators during the previ-
ous 20 weeks  
 
We performed this prospective randomised, place-
bo-controlled study to assess in children with active 
distal UC the effectiveness of Lactobacillus (L) reu-
teri ATCC 55730 enema on inflammation and cyto-
kine expression of rectal mucosa. 
 
Intervention group 
-administration of an enema solution containing 
1010 CFU of L. reuteri ATCC 55730 for 8 weeks in 
addition to chronic oral mesalazine at a dose rang-
ing from 50 to 75 mg/kg/day during the last 
12 weeks 
 
Placebo group 
- enema solution with placebo for 8 weeks in addi-
tion to oral mesalazine at a dose ranging from 50 to 
75 mg/kg/day during the last 12 weeks 
Notes Disease activity: Remission was defined as a final DAI score of <2.0 points; clinical response was defined as a reduction in the DAI of ≥2 
points. Clinical relapse was defined as the occurrence or worsening of symptoms, accompanied by an increase in the DAI score to 4 and ne-
cessitating a change in therapy. 
Author’s Conclusion: 
In children with active distal ulcerative colitis, rectal infusion of L. reuteri is effective in improving mucosal inflammation and changing mucosal 
expression levels of some cytokines involved in the mechanisms of inflammatory bowel disease.  
Outcome 
measures/resu
lts 
Primary outcome measure: 
variation in the disease activity 
as defined by Mayo DAI 
Thirty-one patients accomplished the trial (17 males, median age 13 year, range 7–18). Mayo score (includ-
ing clinical and endoscopic features) decreased significantly in the L. reuteri group (3.2 ± 1.3 vs. 8.6 ± 0.8, 
P < 0.01) compared with placebo (7.1 ± 1.1 vs. 8.7 ± 0.7, NS); furthermore, histological score significantly 
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secondary outcome measure: 
changes in the rectal histology; 
changes in the inflammatory 
cytokine mucosal expression 
decrease only in the L. reuteri group (0.6 ± 0.5 vs. 4.5 ± 0.6, P < 0.01) (placebo: 2.9 ± 0.8 vs. 4.6 ± 0.6, NS). 
At the post-trial evaluation of cytokine mucosal expression levels, IL-10 significantly increased (P < 0.01) 
whereas IL-1β, TNFα and IL-8 significantly decreased (P < 0.01) only in the L. reuteri group. 
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16. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remis-
sion in children with ulcerative colitis. Am J Gastroenterol 2009;104(2):437-43. [131] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
RCT 
1+ 
Countries: Italy 
Centres: Department of 
Pediatrics of the Univer-
sity of Naples "Federico 
II" 
Setting: 
Funding Sources: 
Dropout rates:n= 4 
(12,1%) 
Study limitations: 
Total no. patients: n= 33 
 Intervention group n= 14 
 Placebo group n= 15 
 
Inclusion criteria: patients with new diagnosis 
of UC, established on accepted historical, 
endoscopic, histologic, and/or radiologic cri-
teria, which needed a steroid therapy to in-
duce the remission of the disease 
 
Exclusion criteria: children who had received 
therapy inducing remission of UC; children 
who required outpatient antibiotic therapy 
and/or required surgery for complications 
related to UC; children with documented 
history of allergic reaction to Lactobacillus or 
other probiotic compound or with history of 
endocarditis, rheumatic valvular disease, 
congenital cardiac malformations, or cardiac 
surgery; and children who had received Lac-
tobacillus, Bifidobacterium, Enterococcus, 
Saccharomyces, or any other probiotic bacte-
rial supplement within the past 10 days 
 
to assess the efficacy of VSL#3 on induction and maintenance of 
remission and to evaluate the safety and tolerability of the probi-
otic preparation therapy in children with active UC patients with 
newly diagnosed UC were randomized to receive either VSL#3  
or an identical placebo  in conjunction with concomitant steroid 
induction and mesalamine maintenance treatment. Children 
were prospectively evaluated at four time points: within 1 month, 
2 months, 6 months, and 1 year after diagnosis or at the time of 
relapse 
 
Intervention group 
- Intake of VSL#3 (weight-based dose, range: 450–1,800 billion 
bacteria/day) containing viable lyophilized bacteria of four strains 
of Lactobacillus (L. paracasei, L. plantarum, L. acidophilus, and 
L. delbrueckii subsp. bulgaricus), three strains of Bifidobacterium 
(B. longum, B. breve, and B. infantis one strain of Streptococcus 
salivarius subsp. thermophilus (designated hereafter as S. ther-
mophilus) associated to concomitant steroid induction treatment 
(oral methylprednisolon: 1 mg/kg/day, maximum 40 mg/day per 
4 weeks) and oral mesalamine maintenance treatment 
(50 mg/kg/day) for 1 year or until relapse 
 
Placebo group 
- identical placebo associated to concomitant steroid induction 
treatment (oral methylprednisolon: 1 mg/kg/day, maximum 
40 mg/day per 4 weeks) and oral mesalamine maintenance 
treatment (50 mg/kg/day) for 1 year or until relapse 
 
 Children were prospectively evaluated at four time points: within 
1 month, 2 months, 6 months, and 1 year after diagnosis or at 
the time of relapse. Lichtiger colitis activity index and a physi-
cian's global assessment were used to measure disease activity. 
At baseline, within 6 months and 12 months or at the time of 
  115 
relapse, all patients were assessed endoscopically and histolog-
ically. 
Notes Lichtiger colitis activity index (LCAI): Individual scores for each section of the test including symptoms, characteristics of stool, and physical 
examination were computed. A sustained drop in LCAI to 2 after steroid therapy was considered remission. Response was defined by a 
decrease in LCAI 3 points, but final score 3. Clinical relapse was defined as the occurrence or worsening of symptoms, accompanied by 
an increase in LCAI>3 points, sufficient to require treatment with corticosteroids, azathioprine/immunosuppressive agents, or surger 
Author’s Conclusion: 
This is the first pediatric, randomized, placebo-controlled trial that suggests the efficacy and safety of a highly concentrated mixture of probi-
otic bacterial strains (VSL#3) in active UC and demonstrates its role in maintenance of remission. 
Outcome 
measures/results 
questionnaires regarding disease activity 
(stool frequency, stool consistency, hema-
tochezia, abdominal pain, extraintestinal 
manifestations of disease, and overall 
patient functioning); Lichtiger colitis activi-
ty index (LCAI), physician's global as-
sessment; Laboratory data (blood count, 
albumin, erythrocyte sedimentation rate, 
and C-reactive protein); colonoscopy with 
mucosal biopsy and histological scores (at 
time of relapse) 
All 29 patients responded to the inflammatory bowel disease (IBD) induction therapy. Remis-
sion was achieved in 13 patients (92.8%) treated with VSL#3 and IBD therapy and in 4 patients 
(36.4%) treated with placebo and IBD therapy (P<0.001). Overall, 3 of 14 (21.4%) patients 
treated with VSL#3 and IBD therapy and 11 of 15 (73.3%) patients treated with placebo and 
IBD therapy relapsed within 1 year of follow-up (P=0.014; RR=0.32; CI=0.025–0.773; NNT=2). 
All 3 patients treated with VSL#3 and 6 of 11 (54.5%) patients treated with placebo relapsed 
within 6 months of diagnosis. At 6 months, 12 months, or at time of relapse, endoscopic and 
histological scores were significantly lower in the VSL#3 group than in the placebo group 
(P<0.05). There were no biochemical or clinical adverse events related to VSL#3. 
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Recommendation 15 A: 
Oral Nutrition Supplements (ONS) are the first step when artificial nutrition is indicated in IBD, but generally are a minor supportive therapy used 
in addition to normal food.   
Grade of recommendation 0 - strong consensus (92 % agreement) 
Recommendation 15 B: 
If oral feeding is not sufficient then tube feeding should be considered as supportive therapy. Enteral feeding using formulas or liquids should 
always take preference over parenteral feeding, unless it is completely contraindicated.  
Grade of recommendation A – strong consensus (100 % agreement) 
Recommendation 15 C: 
PN is indicated in IBD (i) when oral or tube feeding is not sufficiently possible, (e.g. when the GI tract is dysfunctional or in CD patients with short 
bowel), (ii) when there is an obstructed bowel where there is no possibility of placement of a feeding tube beyond the obstruction or where this 
has failed, or (iii) when other complications occur such as an anastomotic leak or a high output intestinal fistula. 
Grade of recommendation B – strong consensus  (96 % agreement) 
17. Valentini L, Schaper L, Buning C, Hengstermann S, Koernicke T, Tillinger W, et al. Malnutrition and impaired muscle strength in patients with Crohn's disease 
and ulcerative colitis in remission. Nutrition 2008;24(7-8):694-702. [135] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
Prospective con-
trolled  
(Case-Cohort) 
Study 
2+ 
 
Countries: Germany, Austria, 
Italy 
Centres: 
Setting: 
Funding Sources: 
Charité-Universitätsmedizin 
Berlin; Austrian Society of 
Clinical Nutrition (AKE) 
Dropout rates: 
Study limitations: 
- no information was availa-
Total no. patients: n= 144 
 Patients with Crohn’s disease n= 94 
 Patients with ulcerative colitis n= 50 
 Controls n= 61 
 
Inclusion criteria: patients with IBD in clinical remis-
sion 
 
Exclusion criteria: evere concomitant diseases, preg-
nancy, ostomy, deliberate adherence to an extreme 
diet (e.g., macrobiotics, vegan), celiac disease, 
We performed this prospective, controlled, and 
multicentric study to evaluate nutritional status, 
body composition, muscle strength, and quality of 
life in patients with inflammatory bowel disease in 
clinical remission. In addition, possible effects of 
gender, malnutrition, inflammation, and previous 
prednisolone therapy were investigated. Therefore 
we compared patients with IBD with quiescent dis-
ease with healthy controls and a pair-matched sub-
group of well-nourished patients with no actual 
prednisolone intake by body mass index (BMI), sex, 
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ble on physical activity  proctitis, or proctosigmoiditis in UC and extensive 
small bowel resections in CD. Actual maintenance 
medication was recorded in all patients 
 
and age to healthy controls. 
Notes -Remission was defined as a Crohn's Disease Activity Index (CDAI) <150 or an Ulcerative Colitis Activity Index (CAI) <5 
-IBD patients: Pair-matched analysis involved a subgroup of 47 well-nourished patients with IBD being in remission for at least 3 mo (41 
female and 6 male, 30 with CD, 17 with UC). Well nourished was defined as an SGA grade A, a BMI within the normal range, and a serum 
albumin level >40 mg/L 
-Twenty-six patients took multivitamins and 15 patients were supplemented with intramuscular vitamin B12 
Author’s Conclusion: 
In CD and UC, selected micronutrient deficits and loss of BCM and muscle strength are frequent in remission and cannot be detected by 
standard malnutrition screening. 
Outcome 
measures/results 
Nutritional status (subjective global assessment 
[SGA], body mass index, albumin, trace ele-
ments), body composition (bioelectrical imped-
ance analysis, anthropometry); biochemical 
parameters (C-reactive protein (CRP), blood 
count, albumin, total protein, cholesterol, eryth-
rocytes, ferritin, hemoglobin, magnesium, sele-
nium, zinc, vitamin B12, and folate levels, (IL-6); 
food intake (food-frequency questionnaire); 
Handgrip strength; quality of life; fecal calprotec-
tin 
Most patients with inflammatory bowel disease (74%) were well nourished according to 
the SGA, body mass index, and serum albumin. However, body composition analysis 
demonstrated a decrease in body cell mass (BCM) in patients with CD (23.1 kg, 20.8–
28.7, P = 0.021) and UC (22.6 kg, 21.0–28.0, P = 0.041) compared with controls (25.0 
kg, 22.0–32.5). Handgrip strength correlated with BCM (r = 0.703, P = 0.001) and was 
decreased in patients with CD (32.8 kg, 26.0–41.1, P = 0.005) and UC (31.0 kg, 27.3–
37.8, P = 0.001) compared with controls (36.0 kg, 31.0–52.0). The alterations were seen 
even in patients classified as well nourished. BCM was lower in patients with moderately 
increased serum C-reactive protein levels compared with patients with normal levels. 
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18. Van Limbergen J, Haskett J, Griffiths AM, Critch J, Huynh H, Ahmed N, et al. Toward enteral nutrition for the treatment of pediatric Crohn disease in Canada: 
A workshop to identify barriers and enablers. Can J Gastroenterol Hepatol 2015;;29(7):351-6. [137] 
Study Type/ 
Evidence 
Level 
Study details/limitations Patient characteristics Interventions 
workshop 
report/ com-
mentary 
Countries: 
Centres: 
Setting: 
Funding Sources: Nestlé 
Health Science 
Dropout rates: 
Study limitations: 
Total no. patients: n=20 
Inclusion criteria: 
Exclusion criteria: 
 
In the present report, we discuss the findings of this work-
shop dedicated to enhancing the use of EEN as a treatment 
option in the treatment of pediatric CD in Canada. 
Twenty pediatric stakeholders attended the one-day work-
shop, including three nurses, two dietitians and 15 pediatric 
gastroenterologists. Participants completed a premeeting 
assignment identifying experience in their pediatric practice 
with barriers and enablers to using EEN related to the fol-
lowing influencers: health system (internal and external), 
patient/family, EN, physician/care team-related or other. 
These results were further ranked according to priority, 
highlighting similar barriers and enablers to the use of EEN 
as described in the literature. 
Notes Author’s Conclusion: 
EEN is an extremely safe but underused treatment for induction of remission in pediatric CD in North America. Guidelines from both the 
NASPGHAN IBD Committee as well as the recent ECCO/ESPGHAN guidelines recommend use of EEN as first-line induction therapy in pediat-
ric CD. During this thematic workshop focused on improving the framework for successful implementation of EEN therapy in pediatric CD in 
Canada, the panel ranked the need for EEN, the health care resources needed for a home EN program and cost implications as the top three 
barriers to its use. Identifying and understanding the barriers enables us to work on targeted strategies to overcome them, and help clinics im-
plement and improve their success using EEN. Overcoming the barriers is the next step in the process. 
Until we improve our understanding of the environmental and dietary triggers of CD, the effectiveness of EN will continue to rely on exclusion of 
the ‘prediagnosis’ diet. A standardized yet individualized approach (ie, by considering the caloric and other nutrient requirements of each patient) 
will optimize the use of limited dietetic resources, ideally with additional support for home nutrition programs. Polymeric formulas (which tend to 
be less expensive and more palatable) may be better suited if the oral route is chosen, with the option of dietetic guidance to flavour the formula 
used to avoid taste fatigue. Reducing the cost of EEN to the family will require ongoing advocacy for reimbursement by provincial ministries of 
health and private insurance companies. Further research to enhance our understanding of the mechanisms of action and the optimal application 
of EEN (or partial EN with additional dietary modifications) is necessary. Until such time, EEN should be recommended and supported as a high-
ly effective and safe treatment modality in CD. 
Outcome 
measures/res
ults 
 Factor Barriers Enablers 
Health System internal (hospital 
health authority) 
 Insufficient clinic re-
sources; allied health 
 Adequate numbers of 
trained team members 
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staff, knowledge, space* (nurses, dietitians, social 
work/psychology/child 
health) and dedicated 
space for teaching * 
Health system external (provin-
cial/regional) 
 Funding for supplies, 
formula 
 Coverage for EEN sup-
plies and formula* 
 Supportive home service 
Patient/ family  Fear of NG tube and/or 
loss of food 
 Difficulty sustaining diet 
 Limited support to fami-
ly/socialization 
 Involving parents/family in 
feeding choice 
 Support of diet, acknowl-
edging it may be difficult 
 Supportive dietitian 
throughout pocess 
Enteral nutrition  Exclusivity of enteral nu-
trition with no/limited oral 
intake* 
 Cost of enteral nutrition* 
 Taste 
 NG Tube 
 Evidence-based/reduced 
need for steroids 
 Few side effects 
 Oral option possible; reci-
pes 
Physician/care team-related  Lack of institutional expe-
rience or critical mass to 
“keep it going” * 
 Lack of standardization of 
enteral nutrition ap-
proach* 
 Consistent and systematic 
approach to EEN (proto-
cols, tools, talking points, 
defined roles for team 
members)* 
 Conviction of physician 
and team to support EEN 
 Quality review process 
 Resource sharing 
* Barriers and enablers identified as highest priority. 
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Recommendation 16: 
Exclusive EN is effective and is recommended as the first line of treatment to induce remission in children and adolescents with acute active CD.  
Grade of recommendation B – strong consensus  (92 % agreement) 
 
19. Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. Aliment Pharmacol Ther 
2007;26(6):795-806. [141] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
Meta-analysis 
1- 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
-no attempt to identify un-
published studies 
-low methodological quality and 
small sample sizes of included 
trials 
-lack of standardization of out-
come measures and marked 
clinical heterogeneity, variation 
in the length of the trials (follow-
up) and in the duration of the 
intervention 
-use of concomitant  treatment 
was allowed in some trials (in-
creasing risk of bias) 
Total no. patients: n= 394 (11 trials) 
 
Inclusion criteria: randomized and quasi-randomized 
(i.e., allocating participants according to date of birth, 
the number of hospital records, etc.) controlled trials ; 
children up to 18 years of age, both with newly diag-
nosed CD and with relapsed disease; Patients in the 
experimental groups received enteral formula, includ-
ing elemental (i.e., formulations of amino acids), 
semielemental (i.e., formulations of amino acids plus 
oligopeptides), or polymeric (whole protein) formula; 
Patients in the control group received corticosteroids 
or other types of enteral nutrition 
 
Exclusion criteria:  
 
We performed this meta-analysis to compare the 
effectiveness of enteral nutrition and corticoster-
oids in the treatment of acute CD in children, to 
investigate which type of enteral formula is most 
effective, including elemental formula, semiele-
mental formula and polymeric formula and to 
determine short-term and long-term advantages 
of enteral feeding, if any. 
Notes Author’s Conclusion: 
Limited data suggest similar efficacy for EN and corticosteroids. As the number of patients needed to provide a definite answer is too large, 
future studies should focus on detailed outcome measurements including growth and quality of life. 
Outcome 
measures/results 
Primary outcome measures: 
remission (percentage of subjects 
achieving remission); time until remis-
sion; duration of remission or time until 
the first relapse; relapse (number of 
We included 11 RCTs (n = 394). Seven RCTs (n = 204) compared EN with corticosteroid therapy. 
On the basis of pooled results of four RCTs (n = 144), we found no significant difference in the 
remission rates between groups (relative risk, RR 0.97, 95% CI 0.7–1.4, random effect model). 
Four RCTs (n = 190) compared two EN regimens. One of the four RCTs (n = 50) revealed a signif-
icant increase in the percentage of patients achieving remission in the total EN group compared 
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relapses per patient year during follow-
up) 
 
secondary outcome measures: 
growth parameters (weight gain, 
length/height gain); compliance (ac-
ceptance of treatment); quality of life; 
adverse effects 
with the partial EN group (RR 2.7, 95% CI 1–7.4). Because of lack of data, formal pooling of re-
sults was not possible for many outcomes (e.g., time until remission, duration of remission, growth 
data). 
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20. Grover Z, Lewindon P. Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn's Disease Treated 
Early with Thiopurines. Dig Dis Sci 2015;60(10):3069-74. [142] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
Cohort study 
2- 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates:94 (51,4%) 
Study limitations: 
-retrospective study design 
-bias of changing treatment 
paradigms with time 
-lack of propensity score 
matching 
-more accurate measure of 
intervention 
Total no. patients: n= 183 
 EEN group n=43 
 Steroid group n=46 
 
Inclusion criteria: 
 
Exclusion criteria: given EEN and CS concurrently; 
failure to commence early TP; inadequate follow-
up/data; primary anti-TNF induction for fistulising peri-
anal disease; failure to continue TP or ceased due to 
intolerance 
 
We performed this cohort study to evaluate the 
Impact of first-line induction therapy on medium-
term outcomes in the setting of early thiopurine (TP) 
use in children with Crohn’s disease, in particular 
whether choice of exclusive enteral nutrition (EEN) 
over corticosteroids (CS) for induction impacts clini-
cal outcomes at 12 and 24 months. 
 
-EEN:  a sole therapy using polymeric feeds either 
oral or NG tube to induce remission for a minimum 
period of 6 weeks (Nutrison (1 kcal/ml, Nutricia, UK, 
4 g protein, 3.9 g fat/100 ml) through nasogastric 
tube (NGT) or resource protein (1.25 kcal/ml, Nes-
tle, 9.4 g protein, 3.5 g fat/100 ml) orally based on 
their preference and dietetic consultation) 
-Early TP: defined as introduction within 6 months 
of diagnosis (Therapeutic TP levels were defined as 
6TG levels >250 pmol/8 × 108 red blood cells) 
-Steroid dependency: defined as 10 mg/day predni-
solone or clinical relapse within 3 months of taper-
ing steroids 
Notes -Height Z scores −1.64 corresponding to <5th percentile was denoted as the presence of growth failure  
- BMI Z scores were calculated using Centre for Disease Control (CDC) growth charts and BMI Z scores <−1, <−2, and <−3 defined grade 
1, grade 2, and grade 3 thinness, respectively, based on international expert guidelines  
- Clinical remission was defined as PCDAI ≤ 10 and biochemical remission CRP < 5 mg/l with PCDAI ≤ 10 
- Relapse was defined as PCDA > 15 on more than one occasion 1 week apart and/or CRP > 5 mg/l with clinically active disease. A 
PCDAI > 30 was considered moderate to severe pediatric CD  
-Endoscopic scores were determined retrospectively by authors separately based on electronically stored endoscopic images and reports 
description using the validated Simple Endoscopic Scoring system for Crohn’s disease (SES-CD). Mild, moderate, and severe endoscopic 
disease activity was defined as SES-CD 4–10 mildly active, 11–19 moderate active, and 19 severe active CD  
Author’s Conclusion: 
In the setting of early TP commencement, EEN induction is superior to CS induction for reducing growth failure, CS dependency, and loss of 
response to IFX over the first 2 years. 
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Outcome 
measures/results 
steroid dependency (relapse <3 months 
of tapering first course CS or inability to 
wean <10 mg prednisolone);  need for 
IFX (Infliximab use); linear growth; sur-
gical resections in those first treated with 
CS versus EEN over the first 2 years 
 
Choice of EEN over CS induction was associated with reduced linear growth failure (7 vs. 26 %, 
p = 0.02), CS dependency (7 vs. 43 %, p = 0.002), and improved primary sustained response to 
IFX (86 vs. 68 %, p = 0.02). Combined CS/IFX-free remission and surgical resection rates were 
similar. 
 
 
21. Li G, Ren J, Wang G, Hu D, Gu G, Liu S, Ren H, Wu X, Li J. Preoperative exclusive enteral nutrition reduces the postoperative septic complications of 
fistulizing Crohn's disease. Eur J Clin Nutr. 2014 Apr;68(4):441-6. [144] 
Study Type/ 
Evidence 
Level 
Study details/limitations Patient characteristics Interventions 
Retrospective 
trial 
2- 
Countries: 
 
Centres: Jinling Hospital 
Setting: 
 
Funding Sources: Research Talents of 
Jiangsu Province, China; National Science 
Foundation of China 
 
Dropout rates: n=61 (33,2%) 
 
Study limitations: 
- influence of EEN use on the inflammation of 
the diseased intestine and the output of 
ECFs  could not be assessed (retrospective 
design) 
-sump drain may influence differently in elder 
and younger patients   
-missing data (operation time, length of re-
sected bowel) 
 
Total no. patients: n=184 
 EEN group n=55 
 Controls n=68 
 
Inclusion criteria: 
 
Exclusion criteria: patients who underwent 
temporal enterostomy rather than defini-
tive operation for resection of fistulas; 
patients who underwent emergency sur-
geries and operations for perianal disease 
 
Our aim was to investigate the influence of pre-
operative 3-month Exclusive enteral nutrition (EEN) 
on the incidence of intra-abdominal septic complica-
tions (IASCs) and to clarify the risk factors of IASCs 
in fistulizing CD. 
 
EEN group 
-preopeative 3-months EEN with exclusion of a 
normal diet 
 
Controls 
-no preoperative 3-month EEN 
Notes Author’s Conclusion: 
Preoperative EEN reduced the risk of postoperative IASCs after operation for ECFs in CD. In addition, age at operation may be another factor of 
influence. 
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Outcome 
measures/res
ults 
Changes in serum albumin and C-
reactive protein CRP (at the time of 
operation and preoperative ); pre-
operative data to identify independ-
ent risk factors affecting the inci-
dence of postoperative IASCs; post-
operative data about options of med-
ication treatments and the incidence 
of IASCs 
Patients were similar in gender, age, fistula conditions and perioperative medications in the EEN and 
non-EEN groups. The EEN group had a significantly higher serum albumin level and lower CRP at oper-
ation, and suffered a lower risk of IASCs (3.6% vs 17.6%, P<0.05). Two years after operation when fol-
low-up ended, the two groups had comparable cumulative risk of IASCs (P=0.109). A logistic regression 
analysis identified age at operation and preoperative EEN as independent risk factors of postoperative 
IASCs. 
22. Grogan JL, Casson DH, Terry A, Burdge GC, El-Matary W, Dalzell AM. Enteral feeding therapy for newly diagnosed pediatric Crohn’s disease: a double-blind 
randomized controlled trial with two years follow-up. Inflamm Bowel Dis. 2012;18(2):246-253. [93] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
RCT 
1+ 
Countries:UK 
Centres:  
Alder Hey Children's NHS 
Foundation Trust 
Setting: 
Funding Sources: 
Dropout rates:n= 7 (17,1%) 
Study limitations: 
-The assumptions used for the 
power analysis were too optimis-
tic 
-lack of fecal calprotectin data 
from all patients  
Total no. patients: n= 41 
 Elemental formula group n= 15 
 Polymeric formula group n=19 
 
Inclusion criteria: Children who were newly 
diagnosed with active CD (clinical, radiological 
and endoscopic); Pediatric Crohn’s Disease 
Activity Index (PCDAI) >11 
 
Exclusion criteria: Children with only large 
bowel disease 
 
elemental formula (EF) group 
-6 weeks of an enteral Amino-acid based feed*: 
130kcal, 4.0g protein, 16.5g carbohydrate, 5.1g fat, 
ratio of n3:n6 fatty acids 13:1, 17% LCT, 83% MCT, 
5.4% energy from linoleic acid, 0.45% energy from α-
linolenic acid, 71mg Calcium, 0.72µg Vitamin D, 8.2mg 
Vitamin C, 1.8mg Vitamin E α-TE 
 
polymeric formula (PF) group 
-6 weeks of an enteral polymeric formula: 130kcal, 
4.3g protein, 16.8g carbohydrates, 5.1g fat, ratio of 
n3:n6 fatty acids 2:1, 50% LCT, 50% MCT, 3% energy 
from linoleic acid, 1.5% energy from α-Linolenic acid, 
124mg Calcium, 1.01µg Vitamin D, 20.8mg Vitamin 
C,3.5mg Vitamin E α-TE 
 
*Composition per 100mL 
Notes Author’s Conclusion: 
There was no significant difference between EF and PF in inducing remission. One-third of children maintained remission. Changes in 
plasma polyunsaturated fatty acid status were subtle and may be relevant; however, further evaluation is recommended. 
Outcome 
measures/results 
Primary outcome measure: 
clinical remission (PCDAI 
<11) at the end of week 6 
 
Secondary outcome 
Thirty-four children completed the study; EF: 15 (7 M, 8 F), PF: 19 (13 M, 6 F). The mean age was (years) 
EF: 12.6, PF: 11.7. Ninety-three percent of children (14/15) achieved remission in the EF group and 79% 
(15/19) in the PF group. One-third of patients maintained remission for 2 years. Mean time to relapse (days); 
EF: 183 (63–286), PF: 162 (53–301). Most children who relapsed used feed as a treatment for that relapse 
(EF: 9/10 and PF: 8/13). With PF, an increase of eicosapentanoic acid (EPA) and alpha linolenic acid was 
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measures:  
fecal calprotectin and plas-
ma fatty acid status at 0 and 
6 weeks of treatment; re-
lapse rate at 24 months 
following induction of remis-
sion; patients' choice of 
treatment for the first re-
lapse   
found with a reciprocal decrease in arachidonic acid (AA). With EF, AA and EPA levels were reduced with a 
significant decrease in docosahexaenoic acid. Fecal calprotectin measurements decreased significantly but 
did not normalize at the end of week 6. 
 
  126 
Recommendation 18 A: 
Standard EN (polymeric, moderate fat content, no particular supplements) can be employed for primary and supportive nutritional therapy in ac-
tive IBD. 
Grade of recommendation 0 – strong  consensus (96 % agreement) 
 
Recommendation 18 B: 
Specific formulations or substrates (e.g. glutamine, omega-3-fatty acids) are not recommended in use of EN or PN in IBD patients  
Grade of recommendation B – strong consensus (96 % agreement) 
23.  Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2007(3):CD005984. [150] 
Study Type/ 
Evidence Level 
Study details/limitations Patient characteristics Interventions 
Systematic re-
view 
1- 
Countries: 
Centres: 
Setting: 
Funding Sources:Canadian 
Institutes of Health Reseach 
(CIHR) Knowledge Translation 
Branch; the Canadian Agency fo 
Drugs and Technologies in 
Health (CADTH); the CIH Insti-
tutes of Health Services and 
Policy Research; Musculoskele-
tal Health and Arrthritis, Gender 
and Health, Human Develop-
ment, Child and Youth Health; 
Nutrition, Metabolism and Dia-
betes; and Infection and Im-
munity; Olive Stewart Fund 
Dropout rates: 
Study limitations: 
Total no. patients: n=84 (2RCTs) 
 
Inclusion criteria: Randomised controlled trials which compared 
enteral nutrition with no intervention, placebo or with any other 
intervention; patients of any age with Crohn’s disease whose 
disease was in remission at the time of entry into the study, Re-
mission should have been defined with a recognized Crohn’s 
disease activity index; types of interventions: Enteral nutrition 
supplements (polymeric, elemental or semi-elemental) adminis-
tered by any route (e.g. oral, nasogastric o gastrostomy); Con-
trols: no intervention, placebo or other interventions; report of 
occurrence of clinical of endoscopic relapse (expressed as a 
percentage of the number of patients randomized); report on 
secondary endpoints: improvements in anthropometric meas-
urements (including weight and height), improvements in quality 
of life, occurrence of adverse events 
 
Exclusion criteria: 
 
The aim of this systematic review was 
to summarise the available evidence 
concerning the use of enteral nutrition 
for the maintance of remission in 
Crohn’s disease. 
Notes Author’s Conclusion: 
The available evidence suggests that supplementary enteral nutritional may be effective for maintenance of remission in Crohn's disease. 
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Whilst larger studies are needed to confirm these findings, enteral nutritional supplementation could be considered as an alternative or as an 
adjunct to maintenance drug therapy in Crohn's disease. 
Outcome 
measures/result
s 
Primary outcome measure: 
occurrence of clinical of en-
doscopic relapse (expressed 
as a percentage of the num-
ber of patients randomized) 
 
secondary outcome 
measures: 
improvements in anthropo-
metric measurements (includ-
ing weight and height), im-
provements in quality of life, 
occurrence of adverse events 
 
Two studies were identified that met the inclusion criteria and were included in the review. Statistical pooling 
of the results of these studies was not possible because the control interventions, and the way outcomes 
were assessed differed greatly between the two studies. In one study (Takagi 2006), patients who received 
half of their total daily calorie requirements as elemental diet and the remaining half by normal diet had a 
significantly lower relapse rate compared to patients who received unrestricted normal diet (9 of 26 versus 16 
of 25; OR 0.3, 95% CI 0.09 to 0.94). In the other study (Verma 2001), elemental and polymeric feeds (provid-
ing between 35 and 50% of patients' pretrial calorie intake in addition to unrestricted normal food) were 
equally effective for maintenance of remission and allowing withdrawal of steroid therapy (8 of 19 versus 6 of 
14; OR 0.97, 95% CI 0.24 to 3.92). 
 
24. Yamamoto T, Shiraki M, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition to suppress postoperative Crohn's disease recurrence: a five-year pro-
spective cohort study. Int J Colorectal Dis. 2013 Mar;28(3):335-40. [157] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
cohort study 
2- 
Countries: 
Centres: Yok-
kaichi Social In-
surance Hospital 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
Total no. patients: n= 40 
 EN group n= 20 
 Control group n= 20 
 
Inclusion criteria: age between 15 and 75 years; endo-
scopic and histological diagnosis of CD;  patient required 
resection for ileal or ileocolic (including ileocecal) 
CD;patient had experienced EN therapy including ele-
mental diet infusion at least one time before operation; 
patient agreed to continue with the assigned treatment 
(with or without EN) for 5 years after operation; patient 
agreed to have ileocolonoscopy when clinical symptoms 
occur 
 
Exclusion criteria: patients with colonic CD alone; patients 
with diffuse small bowel CD; patient received corticoster-
oids, immunosuppressive drugs, or infliximab following 
Before surgery, all patients had experienced elemental 
diet infusion. Patients with a good EN-theraopy compli-
ance were assigned to EN group, patients with a poor 
compliance were assigned to the control group 
 
 
Intervention group (EN group) 
- continuous enteral elemental diet infusion starting 1 or 2 
weeks postoperatively, administration during the nighttime 
(1 kcal/mL with an osmolarity of 760 mosm/L; amino ac-
ids, very little fat, vitamins, trace elements, major energy 
source was dextrin); a low-fat diet (20–30 g/day) during 
the daytime, Patients were advised to take 35–40 kcal/kg 
body weight/day, approximately half of the total calories to 
come from elemental diet 
 
Control group 
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operation 
 
- no dietary restriction during entire study period 
Notes -All patients received mesalamine (Pentasa 3,000 mg/day) as a prophylactic medication during the study (no patient received corticosteroid, 
immunosuppressive drugs, or infliximab except patients who developed recurrence) 
- The clinical disease activity was assessed as CD activity index (CDAI); recurrence was defined as CDAI ≥200 
-When a patient developed clinical symptoms, ileocolonoscopy was conducted to investigate endoscopic inflammation 
- recurrence will be initially treated with corticosteroids (prednisolone 20–60 mg/day) and if recurrence could not be managed with predniso-
lone, infliximab (Remicade 5 mg/kg/day) at weeks 0, 2, and 6 as induction therapy, and then at 8-week intervals as maintenance therapy 
was to be given. During infliximab therapy, concomitant azathioprine (Imuran 25–50 mg/day) was to be added if patients agreed to receive 
immunosuppressants 
Author’s Conclusion: 
The outcomes of this study suggest that EN therapy reduces the incidence of postoperative CD recurrence. 
Outcome 
measures/results 
recurrence requiring 
biologic therapy or re-
operation 
In the EN group, four patients could not continue tube intubation for elemental diet intake. Two patients (10 %) in 
the EN group and nine patients (45 %) in the control group developed recurrence requiring infliximab therapy 
(P = 0.03). The cumulative recurrence incidence rate requiring infliximab was significantly lower in the EN group 
vs the control group (P = 0.02). One patient (5 %) in the EN group and five patients (25 %) in the control group 
required reoperation for recurrence (P = 0.18). The cumulative incidence of reoperation was lower in the EN 
group vs the control group, the difference not being significant (P = 0.08). 
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Recommendation 20 A: 
CD patients with a distal (low ileal or colonic) fistula and low output can usually receive all nutritional support via the enteral route (generally as 
food).   
Grade of recommendation C – strong consensus (100 % agreement) 
Recommendation 20 B: 
CD patients with a proximal fistula and/or a very high output should receive nutritional support by partial of exclusive PN. 
Grade of recommendation B – strong consensus (96 % agreement) 
 
25. Yan D, Ren J, Wang G, Liu S, Li J. Predictors of response to enteral nutrition in abdominal enterocutaneous fistula patients with Crohn's disease. Eur J Clin 
Nutr. 2014 Aug;68(8):959-63. [167] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
cohort study 
2++ 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
Total no. patients: n= 48 
 
Inclusion criteria: patients with Enterocutaneous 
fistula (ECF) treated with short-peptide-based EN for 
3 months 
Exclusion criteria: 
 
This study was performed to identify predictors of response 
to EN in CD, which may lead to a better selection of fistula 
patients for this therapy. Therefore patients with ECF were 
treated with short-peptide-based EN for 3 months and were 
followed up for at least 6 months. 
Notes Author’s Conclusion: 
In CD patients with ECF, lower CRP and higher BMI are associated with higher possibility of closure after EN treatment. EN therapy can 
lead to a closure of ECF in a certain proportion of patients. EN therapy could also ameliorate inflammatory condition and improve nutrition 
status. 
Outcome 
measures/results 
Inflammatory parameters 
(erythrocyte sedimentation 
rate, C-reactive protein 
(CRP) and platelet count); 
Nutrition status (body 
weight, body mass index 
(BMI), hemoglobin, serum 
albumin (ALB), serum 
prealbumin and total protein 
In total, 30 out of 48 patients were confirmed with a successful closure of fistula after 3 months' EN therapy. 
The average closure time was 32.4±8.85 days. Inflammatory parameters (erythrocyte sedimentation rate, C-
reactive protein (CRP) and platelet count) improved significantly after EN therapy in all enrolled patients. 
Specifically, the improvement of CRP after therapy in closed group was more important compared with that in 
unclosed group (P=0.035). Nutrition status (body weight, body mass index (BMI), hemoglobin, serum albumin 
(ALB), serum prealbumin and total protein (TP)) improved as well (P<0.05). Similarly, after treatment, the 
improvement of serum albumin (P=0.046) and prealbumin (P=0.006) in closed group was much more im-
portant than those in unclosed group. Logistic regression analysis discovered that a decreased CRP level 
and an elevated BMI level would be beneficial to the response to EN in CD patients with ECF. 
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(TP)) 
 
26. Visschers RG, Olde Damink SW, Winkens B, Soeters P, van Gemert WG. Treatment strategies in 135 consecutive patients with enterocutaneous fistulas. 
World J Surg. 2008;32:445-453. [168] 
Study Type/ 
Evidence Level 
Study details/limitations Patient characteristics Interventions 
Retrospective 
Study 
2+/- 
Countries: 
Centres: 
Setting: 
 
Funding Sources: Netherlands 
Organisation for Health Re-
search and Development to 
Steven W. M. Olde Damink 
 
Dropout rates: 
Study limitations: 
Total no. patients: n= 135 
 
Inclusion criteria: patients with Enterocutane-
ous fistulas (ECF) treated according to the 
SOWATS guideline  
 
Exclusion criteria: Patients with gastroduode-
nal, pancreatic, biliary, and perianal fistulas 
 
We performed this study to assess the SOWATS guideline 
and determine prognostic factors for outcome of patients 
with enterocutaneous fistulas (ECF), and to define a more 
detailed therapeutic approach including the convalescence 
time before restorative surgery. Therefore data of patients 
with ECF treated according to the SOWATS guideline were 
analyzed. 
Notes SOWATS treatment guideline components: Sepsis, Optimization of nutritional state, Wound care, Anatomy (of the fistula), Timing of surgery, 
and Surgical strategy 
Author’s Conclusion: 
Application of the SOWATS guideline allowed a favorable outcome after a short convalescence period. Abdominal wall defects and preopera-
tive hypoalbuminemia are important prognostic variables. 
Outcome 
measures/resu
lts 
Primary outcome measure: 
time of convalescence prior to 
restorative surgery 
 
secondary outcome measures: 
prognostic factors for fistula 
closure and mortality 
A total of 135 patients were treated at our unit. Overall closure was achieved in 118 patients (87.4%). Re-
storative operations for fistula closure were performed after a median of 53 days (range: 4–270 days). Re-
storative operations were successful in 97/107 patients (90.7%). Thirteen patients (9.6%) died. An abdominal 
wall defect was the most predominant negative prognostic factor for spontaneous closure (odds ratio [OR] = 
0.195, confidence interval [CI] 0.052–0.726, p = 0.015). A strong relation was found between preoperative 
albumin level and surgical closure (p < 0.001) and mortality (p < 0.001). 
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Recommendation 21: 
In CD patients in whom nutritional deprivation has extended over many days, standard precautions and interventions to prevent refeeding syn-
drome are mandatory, particularly with respect to phosphate and thiamine. 
Grade of recommendation B – strong  consensus (100 % agreement) 
 
27. Akobeng AK, Thomas AG. Refeeding syndrome following exclusive enteral nutritional treatment in Crohn disease. J Pediatr Gastroenterol Nutr. 2010 
Sep;51(3):364-6. [177] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
Case report 
3 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
Total no. patients: n=2 
Inclusion criteria: 
Exclusion criteria: 
 
We report 2 children with acute CD who developed the 
refeeding syndrome following treatment with exclusive en-
teral nutrition. 
Notes Author’s Conclusion: 
Malnourished children with CD are at risk for developing the refeeding syndrome when they are provided with enteral nutrition. Clinicians 
caring for these children should be aware of the syndrome to allow the identification and monitoring of patients at risk. 
Outcome 
measures/results 
 
PATIENT 1  
A white boy presented at the age of 10 years with a 7-month history of diarrhoea, abdominal pain, poor appetite, and weight loss. 
Laboratory investigations included haemoglobin, 8.3 g/dL (11.5–14.5); erythrocyte sedimentation rate, 35 mm in the first hour; 
platelet count, 675 × 109/L; albumin, 17 g/L (30–45); and orosomucoid, 4087 mg/L (300–1200). A barium contrast study showed 
terminal ileitis with longitudinal ulceration and bowel wall thickening. At colonoscopic examination, there was a cobblestone ap-
pearance of the mucosa of the caecum. Histological analysis of biopsy specimens showed active chronic inflammation with granu-
lomata. The clinical, radiological, endoscopic, and histological features were consistent with a diagnosis of CD. Following the diag-
nosis, the patient was treated with a 6-week course of exclusive polymeric diet as primary therapy for CD. Within a few days of 
starting the polymeric diet, his serum phosphate concentration, which was normal initially, had dropped to 0.77 mmol/L (1.0–1.8). 
Oral phosphate supplements were commenced, and the serum phosphate concentration normalised within 48 hours to 1.28 
mmol/L.  
Following the initial treatment, he remained reasonably well but required intermittent courses of polymeric diet for acute exacerba-
tions of the disease, without any untoward events. At the age of 13 years, he was readmitted to hospital because of an acute exac-
erbation of disease. He complained of abdominal pain, diarrhoea, and weight loss. His admission weight was 26.5 kg and his 
  132 
height was 148.9 cm. Using sex- and age-related UK growth and height curves , weight-for-height, weight-for-age, and height-for-
age were calculated to be 67%, 60%, and 94%, respectively. His body mass index (BMI), calculated as weight (kg)/height (m2), 
was 12 (<0.4th centile). His z scores for weight, height, and BMI were -2.9, -1.04, and -3.9, respectively.  
He was started on exclusive polymeric diet treatment. Two days after starting the feeds, he developed an acute episode of breath-
lessness and tachycardia. His pulse was 128 beats/minute and blood pressure was 87/50 mmHg. Blood tests revealed hypophos-
phatemia with a serum phosphate level of 0.61 mmol/L (1.0–1.8). Other results included corrected calcium, 2.2 mmol/L (2.2–2.7); 
magnesium, 0.75 mmol/L (0.65–1.00); sodium, 131 mmol/L (135–145); and potassium, 4.1 mmol/L (3.5–5.00). A diagnosis of 
refeeding syndrome was made, and he was initially treated with an intravenous phosphate infusion followed by oral phosphate 
supplements.  
When he was reviewed in the clinic about 6 weeks after commencing exclusive polymeric feeds, he was clinically improved. His 
weight was recorded as 32.65 kg and his height was 149.3 cm. His BMI had improved to 14.7, which was between the 0.4th and 
second centiles. His BMI z score was -1.1. He was put on polymeric diet supplements in addition to unrestricted normal diet.  
  
PATIENT 2  
An Asian girl presented at the age of 11 years with a history of diarrhoea, abdominal pain, erythema nodosum, and weight loss. 
Her admission weight was 18.7 kg and her height was 134.5 cm. Using age-related UK growth and height curves , weight-for-
height, weight-for-age, and height-for-age were calculated to be 62%, 52%, and 93%, respectively. Her BMI, calculated as weight 
(kg)/height (m2), was 10.3 (<0.4th centile). Using age-related UK growth and BMI curves, weight, height, and BMI standard devia-
tion scores (z scores) were calculated. The z scores for weight, height, and BMI were -3.46, -1.45, and -4.23, respectively.  
Initial laboratory investigations included haemoglobin, 8.6 g/dL (11.5–14.5); erythrocyte sedimentation rate, 55 mm in the first hour; 
platelet count, 588 × 109/L; albumin, 21 g/L (30–45); and orosomucoid, 4158 mg/L (300–1200). At colonoscopic examination, there 
was evidence of patchy areas of ulceration throughout the colon. Histological analysis of mucosal biopsy specimens confirmed 
active inflammation throughout the colon and terminal ileum with granulomata. The clinical, endoscopic, and histological features 
were consistent with a diagnosis of CD. Following the diagnosis, the patient was started on a 6-week course of exclusive polymeric 
diet as primary therapy for CD. The aim was to provide her with about 120% of her estimated average requirement (1845 kcal) by 
day 3. She received the feeds orally during the first week but subsequently required a nasogastric tube. Within 4 days of starting 
the polymeric diet her serum phosphate level dropped to 0.63 mmol/L (1.0–1.8). Other investigations included sodium, 133 mmol/L 
(135–145); potassium, 4.6 mmol/L (3.5–5.00); corrected calcium, 2.25 mmol/L (2.2–2.7); and magnesium, 0.65 mmol/L (0.65–
1.00). Oral phosphate supplements were commenced and the serum concentrations had normalised after 24 hours to 1.41 mmol/L 
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Recommendation 29:  
No specific diet needs to be followed during remission phases of IBD.  
Grade of recommendation C – strong consensus (96 % agreement) 
28. Jones VA, Dickinson RJ, Workman E, Wilson AJ, Freeman AH, Hunter JO.  Crohn's disease: maintenance of remission by diet.  Lancet. 1985 Jul 
27;2(8448):177-80. [243] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
RCT 
1- 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
Total no. patients: n=20 
 TPN group n = 13 
 Elemental diet group n=7 
 
Uncontrolled trial n=77 
 
Inclusion criteria: patients with active Crohn’s  
disease (Crohn’s Disease Activity Index [CDAI]  
>150) 
 
Exclusion criteria: 
 
In 20 patients with Crohn’s disease remission was induced 
with TPN or an elemental diet (E028). When patients en-
tered remission (CDAI <150) they were randomly allocated 
to the following diet regimes: 
 
unrefined carbohydrate, fibre-rich diet 
 
 
Exclusion diet 
-patients excluded specific foods to which a patient was 
intolerant; patients introduced a single food each day, start-
ing with those such as chicken and fish, which experience 
has shown to be unlikely to provoke symptoms, leaving until 
later those such as cereals and diary products; food that 
provoked symptoms was subsequently qvoided 
Notes The procedure for the identification of specific food intolerance has been followed by 77 patients. 33 had gone into remission with TPN, 25 
with E028, and 19 with an exclusion diet. 
Author’s Conclusion: 
Outcome 
measures/results 
Length of remission 20 patients with Crohn's disease took part in a controlled trial in which remission was maintained by either an 
unrefined carbohydrate fibre rich diet or a diet which excluded specific foods to which a patient was intoler-
ant. 7 out of the 10 patients on the exclusion diet remained in remission for 6 months compared with none 
out of the 10 on an unrefined carbohydrate fibre rich diet (p less than 0.05, Fisher's exact test). In an uncon-
trolled study an exclusion diet allowed 51 out of 77 patients to remain well on the diet alone for periods of up 
to 51 months, and with an average annual relapse rate of less than 10%. 
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Recommendation 30: 
Supplementation with omega-3 fatty acids should not be advised to support maintenance of remission in patients with IBD.   
Grade of recommendation B – strong  consensus, (100 % agreement) 
29. Richman E, Rhodes JM.  Review article: evidence-based dietary advice for patients with inflammatory bowel disease.  Aliment Pharmacol Ther. 2013 
Nov;38(10):1156-71. [252] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
review article 
2+ 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
Total no. patients:  
Inclusion criteria: 
Exclusion criteria: 
 
The aim of this review was to examine the evidence linking 
diet to IBD causation or activity and to conclude with sug-
gestions of practical dietary advice for people with IBD 
based on the evidence available. Therefore we performed a 
review of the published literature on diet and IBD in combi-
nation with ‘Crohn's disease’ ‘Ulcerative colitis’ ‘diet’ ‘nutri-
tion’ and ‘enteral’ ‘fatty acid’ and ‘food additives’. 
Notes Author’s Conclusion: 
There is little evidence from interventional studies to support specific dietary recommendations. Nevertheless, people with IBD deserve ad-
vice based on ‘best available evidence’ rather than no advice at all, although dietary intake should not be inappropriately restrictive. Further 
interventional studies of dietary manipulation are urgently required. 
Outcome 
measures/results 
Investigated topics: Enteral nutri-
tion, Dietary supplementation with 
Omega 3 fatty acids; Dietary sup-
plementation with curcumin; Die-
tary component modification:Sugar 
and fibre, Nanoparticles, Milk and 
dairy products, Lactose,; Avoid-
ance of various specific dietary 
components; Vitamin and mineral 
supplementation; Prebiotics; Fer-
mentable Oligo-, di-, monosaccha-
rides and polyols;  
 
Investigated topics-evidence from 
experimental studies: ‘Western 
diet’; Emulsifiers and detergents; 
Prebiotics; Soluble plant fibres; 
Enteral nutrition with a formula-defined feed is effective treatment for CD, but approximately 50% of 
patients relapse within 6 months of return to normal diet. There is no direct evidence of benefit from 
any other specific dietary modification in CD, but indirect evidence supports recommendation of a low 
intake of animal fat, insoluble fibre and processed fatty foods containing emulsifiers. Foods tolerated in 
sustained remission may not be tolerated following relapse. Some evidence supports vitamin D sup-
plementation. In ulcerative colitis (UC), evidence is weaker, but high intakes of meat and margarine 
correlate with increased UC incidence and high meat intake also correlates with increased likelihood of 
relapse. 
Dietary guidance 
Taking into account the evidence presented above, noting the caution necessary in extrapolating from 
epidemiological correlations and laboratory studies, we would suggest that the following represents 
reasonable dietary advice for patients with IBD: 
Dietary guidance for patients with CD 
1. In about two-thirds of patients, remission of CD may be achieved, usually over about 3 weeks, 
by stopping all normal food and taking a formula-defined liquid diet (‘enteral nutrition’), with ap-
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effects of dietary components on 
the gut microbiota; Antioxidants, 
curcumin, olive oil and various 
other putative beneficial dietary 
components  
 
 
 
 
 
 
 
 
 
 
 
propriate flavouring, as the sole feed. This is of course fairly tedious and will usually only be the 
first choice treatment for a minority of adults, but may more commonly be first choice treatment 
for children and adolescents. 
2. Unfortunately, about 50% of patients treated by enteral nutrition relapse within 6 months of re-
turn to a normal diet. 
3. The mechanisms by which enteral nutrition benefits CD are unclear and no specific food exclu-
sion or inclusion has yet been proven definitively to benefit patients 
4. The following advice is therefore based on a combination of evidence from interventional stud-
ies together with more indirect (and therefore probably less reliable) evidence based on statis-
tical associations between risk of CD and diets in individuals and across countries. 
This evidence suggests that it may be reasonable to have a diet that – 
Is low in animal fat – guidelines suggest that a low-fat intake is approximately 30% of energy 
requirements, which equates to 90 g fat for someone who has an intake of 2500 kcal/day.Avoids foods 
that are high in insoluble fibre – stringy or fibrous vegetables such as green beans, corn on the cob 
(whole maize), tomato skins, orange pith, potato skins and wheat bran. Avoids processed fatty foods – 
often high in fat and usually contain emulsifiers – these are detergents that alter the behaviour of the 
intestinal lining – exposure to dish-washing detergents should also be minimised by careful 
rinsing.Includes supplementary vitamin D – up to 1200 IU/day.Dairy products if tolerated can be 
consumed to help ensure adequate calcium intakes. 
Dietary guidance for patients with UC 
1. Short-term use of total bowel rest with intravenous feeding has proved ineffective in active UC 
and therefore, the general conclusion has been that diet has little role in causation of UC. 
2. There is, however, evidence from several studies that risk for UC, and risk of relapse in pa-
tients who have UC, is increased in those with a high intake of red meat or margarine. 
3. One small study showed that about one in five patients benefited from exclusion of milk and 
cheese. This study has yet to be repeated and strict avoidance of dairy products is not justified. 
4. Lactose intolerance has probably been overemphasised as a clinical problem. Half the world's 
population does not retain the intestinal enzyme (lactase) necessary for lactose absorption into 
adult life, and a double-blind controlled trial failed to show correlation of symptoms with inges-
tion of 240 mL of lactose-containing milk in people with proven lactase deficiency. 
This evidence suggests that it may be reasonable to have a diet that – 
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Is low in meat – particularly red meat and processed meats, e.g. restricting their intake to no more than 
once per week. Avoids margarine. There is weak evidence that olive oil might be protective. Strict 
avoidance of dairy products and/or lactose is not justified on the basis of current evidence. 
 
 
 
30. Richman E, Rhodes JM.  Review article: evidence-based dietary advice for patients with inflammatory bowel disease.  Aliment Pharmacol Ther. 2013 
Nov;38(10):1156-71. [252] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
review article 
2+ 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
Total no. patients:  
Inclusion criteria: 
Exclusion criteria: 
 
The aim of this review was to examine the evidence linking 
diet to IBD causation or activity and to conclude with sug-
gestions of practical dietary advice for people with IBD 
based on the evidence available. Therefore we performed a 
review of the published literature on diet and IBD in combi-
nation with ‘Crohn's disease’ ‘Ulcerative colitis’ ‘diet’ ‘nutri-
tion’ and ‘enteral’ ‘fatty acid’ and ‘food additives’. 
Notes Author’s Conclusion: 
There is little evidence from interventional studies to support specific dietary recommendations. Nevertheless, people with IBD deserve ad-
vice based on ‘best available evidence’ rather than no advice at all, although dietary intake should not be inappropriately restrictive. Further 
interventional studies of dietary manipulation are urgently required. 
Outcome 
measures/results 
 Enteral nutrition with a formula-defined feed is effective treatment for CD, but approximately 50% of patients 
relapse within 6 months of return to normal diet. There is no direct evidence of benefit from any other specific 
dietary modification in CD, but indirect evidence supports recommendation of a low intake of animal fat, in-
soluble fibre and processed fatty foods containing emulsifiers. Foods tolerated in sustained remission may 
not be tolerated following relapse. Some evidence supports vitamin D supplementation. In ulcerative colitis 
(UC), evidence is weaker, but high intakes of meat and margarine correlate with increased UC incidence and 
high meat intake also correlates with increased likelihood of relapse. 
 
 
31. Cabré E, Mañosa M, Gassull MA.  Omega-3 fatty acids and inflammatory bowel diseases - a systematic review.  Br J Nutr. 2012 Jun;107 Suppl 2:S240-52. 
[253] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
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Systematic review 
1- 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
Total no. patients:  
 
Inclusion criteria: randomised controlled trials 
(RCT) of fish oil or omega-3 PUFA therapy in both 
active and inactive UC or CD; reporting at least one 
of the primary or secondary outcomes; no limitation 
on either the length of therapy or the form it was 
given (capsules, liquid, enteric coated preparation), 
including nutritional supplements and enteral formu-
la diets; Concomitant IBD therapies were allowed if 
they were balanced between the study groups 
 
Exclusion criteria: Studies dealing with conventional 
diets enriched with fish foods; Papers reporting 
pooled results in UC and CD, or in active and inac-
tive patients; Studies reporting only surrogate out-
comes, such as serum/tissue levels of cytokines, 
eicosanoids or other inflammatory markers 
 
We aimed to systematically review the available data on 
the performance of omega-3 PUFA as therapeutic agents 
in patients with UC and CD. Therefore we 
systematically searched for RCT of fish oil or omega-3 
PUFA therapy in both active and inactive ulcerative colitis 
or Crohn's disease, without limitation on either the length 
of therapy or the form it was given, including nutritional 
supplements and enteral formula diets. 
Notes Author’s Conclusion: 
The present systematic review does not allow to make firm recommendations about the usefulness of omega-3 PUFA in inflammatory 
bowel disease. 
Outcome 
measures/results 
Primary outcome measures: 
remission rate (for active patients); relapse 
rate (for patients in remission)  
 
Secondary outcome measures: change in 
disease activity scores (either clinical or 
endoscopic); time to remission; time to first 
relapse; adverse events; hospitalisation 
rate; steroid sparing effect; disease activity 
at the end of follow-up period; quality of life 
A total of 19 RCT were finally selected for this review. Overall, available data do not allow 
to support the use of omega-3 PUFA supplementation for the treatment of both active and 
inactive inflammatory bowel disease. Negative results are quite consistent in trials as-
sessing the use of omega-3 PUFA to maintain disease remission, particularly ulcerative 
colitis, and to a lesser extent Crohn's disease. Trials on their use in active disease do not 
allow to draw firm conclusions mainly because the heterogeneity of design (ulcerative 
colitis) or their short number (Crohn's disease). In most trials, the appropriateness of the 
selected placebo is questionable. 
32. Lev-Tzion R, Griffiths AM, Leder O, Turner D.  Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease.  Cochrane Database Syst Rev. 
2014 Feb 28;2:CD006320. [258] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
Systematic review 
2++ 
Countries: 
Centres: 
Total no. patients: n= 1039 
 Intervention n= 523 
We conducted this study to systematically review 
to examine the efficacy and safety of n-3 for 
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Setting: 
Funding Sources: 
Dropout rates: 
 
Study limitations: 
-clinical heterogeneity among the 
included studies (different prepa-
rations of omega-3 fatty acids, 
with different compositions and 
different delivery systems, differ-
ent placebos, post-operative 
setting, only pediatric patients) 
 Controls=516 
 
Inclusion criteria: Randomized placebo-controlled 
trials of fish oil or n-3 therapy administered for at 
least six months; reporting at least one of the prima-
ry or the secondary outcomes; published in any 
language; Studies published in an abstract form if 
enough data were provided to assess the reported 
outcomes; Crohn's disease patients (diagnosed 
using established criteria) who were in remission at 
the time of recruitment; no age restrictions; Inter-
vention with fish oil or n-3 supplementation given in 
any form (capsule, enteric coated or liquid) but with 
a defined dose; Co-interventions were allowed only 
if they were balanced between the study groups 
 
Exclusion criteria:Studies in which the intervention 
group received diet enriched with fish products were 
excluded; Studies reporting only surrogate out-
comes (e.g. serum or tissue levels of cytokines or 
inflammatory markers) 
maintenance of remission in Crohn's disease 
(CD) and to evaluate the adverse events associ-
ated with fish oil or n-3 for maintaining remission 
in CD. 
Notes Author’s Conclusion: 
Evidence from two large high quality studies suggests that omega 3 fatty acids are probably ineffective for maintenance of remission in CD. 
Omega 3 fatty acids appear to be safe although they may cause diarrhea and upper gastrointestinal tract symptoms. 
Outcome 
measures/results 
Primary outcome measure: 
relapse rate during the observation 
time 
Secondary outcome measures: 
change in disease activity scores; 
time to first relapse; adverse 
events (diarrhea, nausea, vomiting, 
halitosis, heartburn, alterations in 
low density lipoproteins, alterations 
in glucose level, increase in bleed-
ing time and abdominal pain) 
 
recorded, if available: admission 
rate, use of steroids, disease activi-
ty at the end of follow-up period 
Six studies with a total of 1039 patients were eligible for inclusion. The two largest studies were rated 
as low risk of bias for all assessed items. Four studies were rated as unclear risk of bias for randomiza-
tion and allocation concealment. Two studies were rated as high risk of bias for incomplete outcome 
data and selective reporting. There was a marginal significant benefit of n-3 therapy for maintenance of 
remission. Thirty-nine per cent of patients in the n-3 group relapsed at 12 months compared to 47% of 
placebo patients (6 studies, 1039 patients; RR 0.77, 95% CI 0.61 to 0.98). A GRADE analysis rated the 
overall quality of the evidence for the primary outcome (i.e. relapse) as very low due to unexplained 
heterogeneity (I2 = 58%), publication bias, and a high or unknown risk of bias in four studies in the 
pooled analysis. When two large studies at low risk of bias were considered the benefit was no longer 
statistically significant. Thirty-seven per cent of patients in the n-3 group relapsed at 12 months com-
pared to 42% of placebo patients (2 studies, 738 patients; RR 0.88, 95% CI 0.74 to 1.05). No signifi-
cant heterogeneity was identified for this pooled analysis ( I2 = 0%). A GRADE analysis indicated that 
the overall quality of the evidence supporting this outcome was moderate due to sparse data (294 
events). No serious adverse events were recorded in any of the studies but in a pooled analyses there 
was a significantly higher rate of diarrhea (4 studies, 862 patients; RR 1.36 95% CI 1.01 to 1.84) and 
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and quality of life upper gastrointestinal tract symptoms (5 studies, 999 patients; RR 1.65, 95% CI 1.25 to 2.18) in the n-3 
treatment group. 
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Recommendation 32 A: 
Probiotic therapy should be considered for the maintenance of remission in ulcerative colitis.   
Grade of recommendation B – strong consensus (96 % agreement) 
Recommendation 32 B: 
Probiotic therapy should not be used for maintenance of remission in CD. 
Grade of recommendation 0 – strong consensus (100 % agreement) 
33. Fujiya M, Ueno N, Kohgo Y. Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized 
controlled trials. Clin J Gastroenterol 2014;7(1):1-13. [264] 
Study Type/ Evi-
dence Level 
Study details/limitations Patient characteristics Interventions 
Meta-analysis 
1++ 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
 
Study limitations: 
- studies investigating probiotic treat-
ments on the induction and mainte-
nance of remission in UC: variations in 
inclusion and exclusion criteria, the 
treatment and control interventions, 
schedules and concentrations of the 
probiotics, observation intervals, pro-
cedures used to assess the disease 
activity, concomitant medications, the 
ethnicity of the patients and the life-
styles of the enrolled patients  
Total no. patients:n= 1547 (20RCTs) 
 intervention n= 777 
 Controls n=770 
 
Inclusion criteria: randomized controlled studies 
comparing probiotics with standard treatments 
used for IBD or placebo; adult and pediatric 
studies;  IBD patients were diagnosed based on 
the definite diagnostic standards  
 
Exclusion criteria: Reviews, case reports, ab-
stracts, presentations of meetings, uncontrolled 
tests and basic research studies 
 
This systematic review verified the findings of 
high-quality randomized controlled trials 
(RCTs) which investigated the therapeutic 
effects of probiotics on IBD. 
Notes Of these 20 studies three were conducted on the response rate to probiotic treatment, four studies examined the remission induction rate 
and two studies evaluated both the response and remission induction rates of UC patients, five studies focused on the maintenance therapy 
for UC, two studies on the maintenance therapy for an ileal pouch, one study was performed on the remission induction therapy for CD and 
four studies examined the effects of probiotics on the maintenance therapy for CD. 
Author’s Conclusion: 
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In summary, the present study identified 20 high-quality RCTs which investigated the effects of probiotics on the induction or maintenance of 
remission in IBD. From the results of the validation of these RCTs, probiotic treatment is a practical option for UC patients as both remission 
induction and maintenance therapy, but such treatment is not effective in CD patients. Because there were many variations in the conditions 
among the studies, future studies on the value of probiotic treatment in IBD should consider the effects of different probiotics and different 
regimens, together with the specific patient populations which are most likely to benefit from probiotic treatment. 
Outcome 
measures/results 
interventions used for treatment and 
control: disease severities, administra-
tion procedures, number of enrolled 
patients,  observation intervals; articles 
associated with remission induction 
therapy for IBD: remission or response 
rates of the probiotic treatment and 
control groups; articles associated with 
maintenance therapy for IBD: relapse 
rates of the diseases  
After the quality assessment, 20 RCTs which investigated the effects of probiotics on the induction 
or maintenance of remission in IBD were identified. From the results of the validation of these 
RCTs, beneficial effects of probiotic treatments to improve the response rate and remission rate 
on the remission induction therapies [risk ratio (RR) 1.81; 95 % confidence interval (CI) 1.40–2.35 
and RR 1.56; 95 % CI 0.95–2.56, respectively] were verified. Furthermore, probiotic treatments 
exhibited effects equal to mesalazine on the maintenance of remission in UC (RR 1.00; 95 % CI 
0.79–1.26). In contrast, no significant effect of probiotic treatments was shown in either the induc-
tion or maintenance of remission in CD. 
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Recommendation 33 A: 
Colectomized patient with a pouch and pouchitis should be treated with probiotics such as VSL#3, if antibiotic treatment has failed  
Grade of recommendation B – strong consensus (96 % agreement) 
Recommendation 33 B: 
The probiotic mixture VSL#3 may be used for primary and secondary prevention of pouchitis in patients with ulcerative colitis who have under-
gone colectomy and pouch-anal anastomosis  
Grade of recommendation B – strong consensus  (100 % agreement) 
34. Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative 
colitis. Cochrane Database Syst Rev. 2015 Nov 23;11:CD001176. doi: 10.1002/14651858.CD001176.pub3. [280] 
Study Type/ 
Evidence Level 
Study details/limitations Patient characteristics Interventions 
Systematic Re-
view 
1- 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
- the generalizability and external 
validity of these results must be 
questioned (for each comparison, 
with the exception of VSL#3 ver-
sus placebo for chronic pouchitis, 
only one trial was eligible) 
- GRADE analyses indicate that 
the overall quality of evidence 
ranges from low to very low  
-occurrence of risk of bias in the 
included studies and very serious 
imprecision 
 
Total no. patients: n=517 (13RCTs) 
Inclusion criteria: Randomized, controlled trials with parallel 
arm placebo-controlled trials, crossover placebo-controlled 
trials, and trials comparing two active agents; Adult patients 
(age ≥ 18 years) who had undergone IPAA (for chronic ulcer-
ative colitis and were at risk of, or had developed acute or 
chronic pouchitis; eligible interventions: 1. Oral metronidazole 
20 mg/kg/day or 500 mg twice dail2. 2.Oral VSL#3 probiotic 
bacterial formulation containing 300 billion bacteria per gram 
of viable lyophilized bacteria with four strains of Lactobacilli 
(L. acidophilus, L. delbrueckii subspecies Bulgaricus, L. 
plantarum, L. casei), three strains of Bifidobacterium (B. in-
fantis, B. longum, B. breve) and one strain of Streptococcus 
salivarius subspecies Thermophilus; 6 g/day), 3 g/day , 3 g 
twice daily, 3 g once per day; 3. Bismuth carbomer foam 
enemas containing 513 mg bismuth citrate (270 mg metallic 
bismuth) complexed with carbomer (a synthetic high-
molecular weight polymer of acrylic acid cross linked with 
poly alkenyl polyether) administered once nightly; 4. Gluta-
mine suppositories containing 1 g of L-glutamine in a poly-
ethylene glycol base administered twice daily; 5. Butyrate 
suppositories containing 40 mmol sodium butyrate in a poly-
We performed this review to determine 
the efficacy and safety of medical thera-
pies (including antibiotics, probiotics, 
and other agents) for prevention or 
treatment of acute or chronic pouchitis. 
Therefore a databased literature search 
of published RCTs were performed to 
determine which of the currently utilized 
empiric medical therapies for pouchitis 
can be substantiated with valid data 
from controlled trials. 
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ethylene glycol base administered twice daily; 6. Ciprofloxa-
cin 1000 mg daily; 7. Rifaximin 400 mg orally three times 
daily; 8. Lactobacillus GG in two gelatine capsules orally 
twice daily versus microcrystalline cellulose-only gelatine 
placebo capsules ; 9. Budesonide enema 2 mg/100 mL at 
bedtime plus oral placebo tablets; 10. Allopurinol 100 mg 
twice daily; 11. Tinidazole 500mg daily; 12. Bifidobacterium 
longum BB-536 
 
Exclusion criteria: 
 
Notes -Pouchitis was variably defined by 1) solely clinical criteria; 2) clinical criteria in combination with endoscopic and histologic criteria; or 3) 
PDAI. Pouchitis was categorized by disease activity, as active (defined clinically as the presence of mild-to-severe symptoms or by a PDAI ≥ 
7) or in remission (absence of symptoms or by a PDAI < 7), or by disease duration as acute (symptom duration ≤ 4 weeks) or chronic (symp-
tom duration > 4 weeks). 
Author’s Conclusion: 
For acute pouchitis, very low quality evidence suggests that ciprofloxacin may be more effective than metronidazole. For chronic pouchitis, 
low quality evidence suggests that VSL#3 may be more effective than placebo for maintenance of remission. For the prevention of pouchitis, 
low quality evidence suggests that VSL#3 may be more effective than placebo. Well designed, adequately powered studies are needed to 
determine the optimal therapy for the treatment and prevention of pouchitis. 
Outcome 
measures/result
s 
Primary outcome measures: 
proportion of patients with 
clinical improvement or re-
mission of pouchitis in pa-
tients with acute or chronic 
pouchitis (treatment of 
pouchitis); the proportion of 
patients with no episodes of 
pouchitis after IPAA (preven-
tion of pouchitis) 
 
secondary outcome measure: 
proportion of patients who 
developed at least one ad-
verse event 
Thirteen studies (517 participants) were included in the review. Four studies assessed treatment of acute 
pouchitis. One study (16 participants) compared ciprofloxacin and metronidazole; another (26 participants) 
compared metronidazole to budesonide enemas; another (18 participants) compared rifaximin to placebo; 
and the fourth study (20 participants) compared Lactobacillus GG to placebo. Four studies assessed treat-
ment of chronic pouchitis. One study (19 participants) compared glutamine to butyrate suppositories; another 
(40 participants) compared bismuth enemas to placebo; and two studies (76 participants) compared VSL#3 
to placebo. Five studies assessed prevention of pouchitis. One study (40 participants) compared VSL#3 to 
placebo; another (28 participants) compared VLS#3 to no treatment; one study (184 participants) compared 
allopurinol to placebo; another (12 participants) compared the probiotic Bifidobacterium longum to placebo; 
and one study (38 participants) compared tinidazole to placebo. Three studies were judged to be of high 
quality. Two studies were judged to be low quality and the quality of the other studies was unclear. 
Treatment of acute pouchitis: The results of one small study (16 participants) suggest that ciprofloxacin 
may be more effective than metronidazole for the treatment of acute pouchitis. One hundred per cent (7/7) of 
ciprofloxacin patients achieved remission at two weeks compared to 33% (3/9) of metronidazole patients. A 
GRADE analysis indicated that the overall quality of the evidence supporting this outcome was very low due 
to high risk of bias (no blinding) and very sparse data (10 events). There was no difference in the proportion 
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of patients who had at least one adverse event (RR 0.18, 95% CI 0.01 to 2.98). Adverse events included 
vomiting, dysgeusia or transient peripheral neuropathy. There were no differences between metronidazole 
and budesonide enemas in terms of clinical remission, clinical improvement or adverse events. Adverse 
events included anorexia, nausea, headache, asthenia, metallic taste, vomiting, paraesthesia, and depres-
sion. There were no differences between rifaximin and placebo in terms of clinical remission, clinical im-
provement, or adverse events. Adverse events included diarrhea, flatulence, nausea, proctalgia, vomiting, 
thirst, candida, upper respiratory tract infection, increased hepatic enzyme, and cluster headache. There was 
no difference in clinical improvement between Lactobacillus GG and placebo. The results of these studies 
are uncertain due to very low quality evidence. 
Treatment of chronic pouchitis: A pooled analysis of two studies (76 participants) suggests that VSL#3 
may be more effective than placebo for maintenance of remission. Eighty-five per cent (34/40) of VLS#3 pa-
tients maintained remission at 9 to 12 months compared to 3% (1/36) of placebo patients (RR 20.24, 95% CI 
4.28 to 95.81). A GRADE analysis indicated that the quality of evidence supporting this outcome was low due 
to very sparse data (35 events). Adverse events included abdominal cramps, vomiting and diarrhea. There 
was no difference in effectiveness between glutamine and butyrate suppositories for maintenance of remis-
sion. There was no difference in clinical improvement or adverse event rates between bismuth carbomer 
foam enemas and placebo. Adverse events included diarrhea, worsening symptoms, cramping, sinusitis, and 
abdominal pain. The results of these studies are uncertain due to very low quality evidence. 
Prevention of pouchitis: The results of one small study (40 participants) suggest that VSL#3 may be more 
effective than placebo for prevention of pouchitis. Ninety per cent (18/20) of VSL#3 patients had no episodes 
of acute pouchitis during the 12 month study compared to 60% (12/20) of placebo patients (RR 1.50, 95% CI 
1.02 to 2.21). A GRADE analysis indicated that the quality of evidence supporting this outcome was low due 
to very sparse data (30 events). Another small study (28 participants) found that VLS#3 was not more effec-
tive than no treatment for prevention of pouchitis. Bifidobacterium longum, allopurinol and tinidazole were not 
more effective than placebo for prevention of pouchitis. The results of these studies are uncertain due to very 
low quality evidence. 
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Recommendation 36: 
When more than 20 cm of distal ileum, whether or not in combination with the ileo-caecal valve, is resected, vitamin B12 shall be administered to 
patients with CD.  
Grade of recommendation A – strong consensus (100 % agreement) 
35. Battat R, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, Bessissow T, Seidman E, Bitton A. Vitamin B12 deficiency in inflammatory bowel dis-
ease: prevalence, risk factors, evaluation, and management. Inflamm Bowel Dis. 2014 Jun;20(6):1120-8. [296] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
Systematic review 
2++ 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
Total no. patients: n= 3732 (42 articles) 
 
Inclusion criteria: 
 
Exclusion criteria: Articles not pertaining to the inves-
tigated topic; Case studies, letters, comments, re-
view articles, and studies analyzing patients nil per 
os or on total parenteral nutrition; Publications identi-
fied as duplicates 
This systematic review examines whether IBD predisposes 
to vitamin B12 (cobalamin, Cbl) deficiency. We provide an 
approach to the management of abnormal Cbl values in IBD 
based on current literature and consensus-based guide-
lines. 
Notes This systematic review of Cbl deficiency in CD and UC included studies analyzing both serum Cbl levels and absorption tests. 
No mention of eligibility criteria for included studies. 
Author’s Conclusion: 
This literature does not support an association of Crohn's disease in general, regardless of ileal involvement, with Cbl deficiency. Only ileal 
resections greater than 20 cm in Crohn's disease predispose to deficiency and warrant treatment. Based on these findings, we suggest a 
diagnostic and therapeutic algorithm. All findings and recommendations require verification in further studies using confirmatory biomarkers 
as per diagnostic guidelines for Cbl deficiency. Serum Cbl levels alone are likely insufficient to diagnose deficiency in asymptomatic patients. 
Outcome 
measures/results 
prevalence, risk factors, 
clinical significance, evalua-
tion, and management of Cbl 
deficiency in IBD 
Crohn's disease without ileal resection, regardless of disease location in the ileum, did not increase the risk 
for Cbl deficiency. Ileal resections greater than 30 cm were associated with Cbl deficiency in Crohn's dis-
ease, whereas those less than 20 cm were not. The effects of 20 to 30 cm resections were inconsistent. Ul-
cerative colitis did not predispose to deficiency. All studies failed to use confirmatory biomarker testing as 
stipulated by diagnostic guidelines for Cbl deficiency. 
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Recommendation 37: 
Selected IBD patients, e.g. those treated with sulphasalazine and methotrexate should be supplemented with vitamin B9 / folic acid. 
Grade of recommendation B – strong consensus (100 % agreement) 
36. Pironi L, Cornia GL, Ursitti MA, Dallasta MA, Miniero R, Fasano F, Miglioli M, Barbara L. Evaluation of oral administration of folic and folinic acid to prevent 
folate deficiency in patients with inflammatory bowel disease treated with salicylazosulfapyridine. Int J Clin Pharmacol Res. 1988;8(2):143-8. [306] 
Study Type/ Evi-
dence Level 
Study de-
tails/limitations 
Patient characteristics Interventions 
controlled trial 
2++ 
Countries: 
Centres: 
Setting: 
Funding Sources: 
Dropout rates: 
Study limitations: 
Total no. patients: n= 30 
 Folinic acid group n= 15*  
 Folic group n=15* 
(* ten patients affected by Crohn's disease and five 
patients affected by ulcerative colitis in each group) 
 
Inclusion criteria: patients with inflammatory bowel 
disease (IBD) 
 
Exclusion criteria: 
 
Folinic acid group 
- treatment with salicylazosulfapyridine (SASP) (1g twice 
daily at meal times); intake of 15 mg/day of folinic acid for 
one month 
 
Folic group 
- treatment with salicylazosulfapyridine (SASP) (1g twice 
daily at meal times);intake of 15 mg/day of folic for one 
month 
 
Notes Author’s Conclusion: 
It was concluded that: a) both folic and folinic acid could restore and enlarge the body stores of folate in patients with IBD treated with SASP, 
when administered at the dose of 15 mg daily for one month; b) folinic acid seems to be more efficient in enlarging the body stores of the 
vitamin than folic acid. 
Outcome 
measures/results 
plasma folate concentration, 
red blood cell (RBC) folate 
concentrations 
After one month the mean increase in RBC folate concentration was significantly greater after folinic therapy 
then after folic acid therapy (910 +/- 383 versus 570 +/- 212 ng/ml; p less than 0.01), while no difference was 
observed in the mean increase of plasma folate level (19.8 +/- 6.6 versus 18.5 +/- 5.0 ng/ml). 
 
 
 
